var title_f0_50_800="Persistent perforation";
var content_f0_50_800=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F65036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F65036&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Persistent perforation after tube extrusion",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 396px; height: 388px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Persistent perforation after tube extrusion, as depicted above, is a potential complication of tympanostomy tube placement.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Courtesy of Glenn C Isaacson, MD.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_800=[""].join("\n");
var outline_f0_50_800=null;
var title_f0_50_801="Latex food cross rxn";
var content_f0_50_801=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F60713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F60713&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 548px\">",
"   <div class=\"ttl\">",
"    Patterns of allergic cross-reactivity between latex and food",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 528px; height: 318px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    The numeric risks cited here are based upon findings in limited series of patients and may not be generalizable to all populations.",
"    <div class=\"footnotes\">",
"     * Rodriguez, J, Crespo, JF, Lopez-Rubio, et al. Clinical cross-reactivity among foods of the Rosaceae family. J Allergy Clin Immunol 2000; 106:183.",
"     <br>",
"      &bull; Garcia Ortiz, JC, Moyano, JC, Alvarez, M. et al. Latex allergy in fruit-allergic patients. Allergy 1998; 53:532.",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_801=[""].join("\n");
var outline_f0_50_801=null;
var title_f0_50_802="Nasal dermoid with intracranial extension";
var content_f0_50_802=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F57665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F57665&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Nasal dermoid with intracranial extension",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 432px; height: 321px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_802=[""].join("\n");
var outline_f0_50_802=null;
var title_f0_50_803="Gastric volvulus on computed tomography";
var content_f0_50_803=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=RADIOL%2F83733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=RADIOL%2F83733&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Gastric volvulus on computed tomography",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 394px; height: 363px; background-image: url(data:image/jpeg;base64,/9j/4AAQSkZJRgABAQAAAQABAAD/2wBDAAYEBQYFBAYGBQYHBwYIChAKCgkJChQODwwQFxQYGBcUFhYaHSUfGhsjHBYWICwgIyYnKSopGR8tMC0oMCUoKSj/2wBDAQcHBwoIChMKChMoGhYaKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCgoKCj/wAARCAFrAYoDASIAAhEBAxEB/8QAHwAAAQUBAQEBAQEAAAAAAAAAAAECAwQFBgcICQoL/8QAtRAAAgEDAwIEAwUFBAQAAAF9AQIDAAQRBRIhMUEGE1FhByJxFDKBkaEII0KxwRVS0fAkM2JyggkKFhcYGRolJicoKSo0NTY3ODk6Q0RFRkdISUpTVFVWV1hZWmNkZWZnaGlqc3R1dnd4eXqDhIWGh4iJipKTlJWWl5iZmqKjpKWmp6ipqrKztLW2t7i5usLDxMXGx8jJytLT1NXW19jZ2uHi4+Tl5ufo6erx8vP09fb3+Pn6/8QAHwEAAwEBAQEBAQEBAQAAAAAAAAECAwQFBgcICQoL/8QAtREAAgECBAQDBAcFBAQAAQJ3AAECAxEEBSExBhJBUQdhcRMiMoEIFEKRobHBCSMzUvAVYnLRChYkNOEl8RcYGRomJygpKjU2Nzg5OkNERUZHSElKU1RVVldYWVpjZGVmZ2hpanN0dXZ3eHl6goOEhYaHiImKkpOUlZaXmJmaoqOkpaanqKmqsrO0tba3uLm6wsPExcbHyMnK0tPU1dbX2Nna4uPk5ebn6Onq8vP09fb3+Pn6/9oADAMBAAIRAxEAPwD5UooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKntbS4u3K2sEszDGQilsfWgCCity38NXsgYzPbwbeoeTJx9FzWha+FIZN5kvnKp12Q4z9CTQBydFdhL4Ys02BWu2LDPVRj9KefC9ltwGvN//AAEj+VAHGUV01x4ZRJNq3EgGM8xg/wBabJ4YG9VivQxIz80RXH6mgDm6K6CXwtdK2EubVxjOQW/+Jpi+GL5yux7dt3P38cevIoAwqK2W8OagoJKxcdf3gqU+F78Lktb49nJx+QoAwaK3k8M3RlKGaHj+7uP9Ku/8IdJ5aN9rGG9Iif60AcpRXVyeDLkRbkuod2fuyKy/41nXPhrU4V3CATLjOYmDHH06/pQBi0U+WKSGQpKjRuOqsMEfhTKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKK2dK8O3t/AbkqLeyHWeXgH/AHR1P8vegDGrb07w3qF5F5zILa2xu82bjI9h1P5V1mjaVZWcoFlb+fKORcTDcT/ujoP511GmeGbq+QyyNIZGwdrc8UAcVp2h6fbsu2B7+bON0vyoD7KOv4k11CRXU0SwpEIbdFG1I1CKK73TPBrwHfgI55DtyQe/HSra+EYLgZuLp2LcHA2kGgDzmHQo45VR1wxHI7n1r1P4f/DGPXQsUzrBGqb2fbnHI4xTLDwzpVnuuN8kkqHBaQ5P0rpvCfiqPRr4vFh0TKyIeNw9AaALuufCC00vTZLuzuxMYcEpJEBx065/SvO77RbKOY2ssQSQ8gZxj6V634j8e2N5oMtnZwyQySf6xWI+UdcD615Jq2sWs0puZJ0MhG0HP3QB0zQBzsugafdzyrBLsmXkg84AqlFpEEk3kRAszfek/hGKfb6msslwqRo2/ktnOBSRa4q38QIj+zR84HGfegCnd6SbVSoO5mbg7egPY1BJpgZn8s5kwM9to9K6HVPFtgkBFnZDeeshGfxrj49XkWZjn5R3BOf/ANdAEw02aL5m6EY+9nnNWrfRbgycY3+mPXv9aqjX5Bt3LsRBneDnPsavLrtrNGj3TlGHLYOO/AoA0rHQAu3z5DkNggjqK6TRtJtpLmWCKNd+eSf4RXLw34M0c0cx3D7yk5yK0tHu54dbaaGdRE3LL259aAO6Ghae4KNGGXoxxzmuN8T+HtOgvGhadYCchVH9a3tT8X2lkoEkJMjchgcj6159c6xFq2tQT3ILRrIDsB6jPWgCleaI06uMx3MPTawDZAHB55FcxqHhSzfAhke0m6bSC6H8+R+te/X3h7TdYWO58Nu0G9QFV2zg965HxB4evNPmZb2yaMOcLMAQSPXj1oA8K1PQr/TlLzQl4B/y2i+ZPxPb8cVl17a9nJasHjLBVPQdT9axr3w7puryP9vQaZdnLfaIVyrH3TgfUjBoA8ror1Gy+CniPUrOWbSLjTb6QH93DHNteQf8CAAPTgn8aqp8EviM9lc3Q8K3vlW5ZXUvGJDtGTsQtuf2Kg57ZoA84oqzqFldadeS2eoW09rdwttkhnjMbofQqeQfrVagAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKntLaa8uEgtYmllc4VVHJqXS9PuNTvUtrRN0jckngKO5J7CvR9ItrTRLCSGwxLcNhJpyvzMfQei+1AGJY6BaaU6fbtl5fnP7rGYoz7/wB4/p9a6zTdOudVkIkbIVhy/AH0q14f8Py6pNGVQMNxyx4J75r0ew0aKzhjkcDCKNye2aAOZsfDqR4TAUjGZO+e4r0PStPj06xAAV2MZOf4hmuRn8S2Ni0kYbbKhOd31rm5/FupXNx5cMoZHzsKcEZNAHrLtFBtd5AMAYO71xzWRe6xbw3pjRjMVGCE6A1yFvb3F6vmTSTsBxitSysjNCViVkdNx6d88UAVdV1wi3nkvFeO1thvynGAATz61S0XU01WxuJdNRi6NzvQrh8Z5BHpim+P7OW08LTm4xuuGSFQP9pgG/TdTvh/os03hxJg7xi6llnJHpnYp/EIDXSqC+rOu3rzJL7m392n3mfP7/J5HM6zqOrTXTQXMrRnHIHFVhpF7OisqtMpGT9egA969iTwraGYSXKmRhwhYcMQM81rwWFrDIzLGqhsDgDavvXMaHklnoGpR25W3tXDsBuHQ5NMXwNrEkmBGmcDcPT2FezAAsWOI2zv+UcYxU8JK7g3DYGQO5oA8bHw61d3OJERY8AjHA9qJvhtfeXORhpXHAzgY9a9kjThcnaTgEep9MetPAELOXDfISMk8E9cCgDwi6+HWrxw5CqcHOc8Y9T61k6j4R1S0VWa23AnIYjrX0WEUsVViN/yjdyBn+lNkSJmO5Ay/d2sOnuKAPmBLea0dYplkRmO4s31rTkl1G3KNDkpjKgHPHcmvcNZ8N2WpJIJYF35OGC4JI75rgNR8NzaNLwzyWnXafX6/wBKAOdsdftZwY9WtUx0V0479TVmO30K8ctaXggmxnnoPwqnrOkebCz26ASkcoo/WuRkjaJvJBGVODnpn14oA9m8A+IrrwZrcF3cW4vLAgh9h554DD0r1PXPEkPia0hli8qWIncqgDcg9Gr5Qt9SvLRozDIykgck9vYV0eieNr/T5A7BXXJLJ/eHvigD2O90azutzPEqMQSrgcE/SuP1nwrIYlllGFU8ugzXVaF4n03XLFX4E5AzHnBB9vStSUF2Y48xTjEa/d/GgDyaDWLzw5L5mnlgikD5ehPvXp/gf46SidbbxJCGRiFUxgBk/E8N9P1rE13wxEY5ZLeJUdzu27s155f6Egd54uZU/wCWTHHJ7igD2n9oLw1oXxJ+H02u6BEt54k05FNqYCFmkj3jfE6nlgFLMB1DD5T8zBvimWN4ZXilRo5EJVkYYKkdQR2Ne6aT4h1XRGMcRkKRqdykYx9KwviIH8f3EGo6eluuqQReVPCQEknx0bP8TDpzQB5LRUk8MkErxTxvHKhwyOpUg+hBqOgAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACpIIpJ5o4YULyOwVVHUk1HXb+CdMFvaHVJcC4kylsrDtjlx/IfjQBp6Zp0Wk2RtEb/AEnP+lSrzuP90ewrvPCHhiScebOv7ocgegPes7wNpCarqsKOpYKd75Gc19E6B4JMF1BiydbHI8w7hhl6+ucUAcjpGlosUdvYxqN7YDegzWX47dtGsrgSMQVYgDrn6V9BvBYaeqQw2UIRULYSMDaAOvSvlb4xaudT1OSGzGYQclQeMZ7UAef3jbr2fzXZklwORj5q0NNsmi2tGxOwEg55I61Us7B1uAzLvKEFo8j09a9F8P6cYYWDRrl1DZODnNAGv4ci+02ayrhgcBgB3+ldDaWsQY7EYZ5OBzjHUVDpdsIooVjAVWz0P5CrxBfzA5K5THP06fnQB5f8bdRItNJtlJYgy3RXv8i7VyPfzD+Veh6Bp6aVodhYhGSS3t0iLdjtUAn8TmvLfG//ABOvinZ6em0pE9vbkDuBmZ/zQj8q9h3vGFdhu6MwIyDzXoYr3MNRpeTl97t+UUY09Zyl6L7v+HI2BWNmBxt4Awcn6e1T2bbfmH3V6qe5PQVHLJFJII9rLuAPB6Ur7lLLGx2pxuIyCD1xXnmw6PCM2G+SRsgH0+tLFJh1ypIVuQO5qaOI7EZFYopwSVyOfQ1EYvLVd2fvFsAdaAJnyx2pvkYnLcdD6mmxsWSYbN0agEf/AF6R2JV1xjcCSR0FLC4SMjaXj3ZyepPp9M0AMiZhmMlgrknrk/8A6qsoWdCioNygbcDgDvTZ0Vfv4D7tyqPU9fqMVAF8t/MUAYbIBPLf0oAkYxjZuLmQLkIONp9qq6jaR3iGKWEg84LLnmrJOWXkbs5YjnaTSyruDZBcDBJI7/0oA831jRXtbndGimMkllJwTXL65okEsf2mEKjPgqmT8vrXr+p24nJFxnLEALgHp71wGs2ZENwjudgBIHTjNAHll1Eyo8aqoZcLubknn9KiuUjiEY3ksQDgH7tWtWgbz5FgbcQwxxgYHtVD7DLdS7dzCYDnJ4+nvQBPGzRyAwyFWXGQhIJ9q63SfE+p20MeySVgv3i545rFsdCMbt98SgjA6CrktpJHEBszgbh3I57UAemWXilNRstjssd04wiqcc9Me31rnp5oJ70xBhBMDgsOp+ua4dbx4LpGiLbwRnI6H6Vs+IJbiWwttVAG/cVlIHHHegDp5rSC4iUyISSMB+uT65ri9b0OexuvtEB8wKc71PQV1Hg3VvtKCG6VdjLhN45/AV1N54UivLR2s5GUsMnIyD7UAeN6jFa65bY1VCGRdsdwgw6fX+8PY/pXA63pFzpFysdwMxuN0Uq/dkX1H9RXvV98OdTt7Ca88rESsMMMY/AVwmpQF1ey1KMz25PIJwyH+8p7UAeXUVpa5pb6XdBCwkgkG6KUdGH+I7is2gAooooAKKKKACiiigAooooAKKKKACiiigAooooA0vD2mNq+qw2ikqjHdI/9xB1P+e5FekzZe5AiVo7eFRHGq9AoGAKy/DWntpfhgSlf9L1Egt6pCPu/n1/Kuk0qCS4v4oWwYzhnx0ABoA9E+Ful3FvBcXSxYaOEy9fyr2jwp4ymvvD8s09mkCWUeJbqaXbFwOvTP4V5z4cKW9lL5ziG2YBZTu+7GO1ea/FLx6+uxQ6Now+z6RasyBIz/riOrH1oA7zx18aoorW9tNAme7ml+RrpxtUA/wAKD0rxyLULjVGaacBEAYkhuhB5/OsG1jB4Jw5Yfof8K2WsG/couTDI2d2eg/8A10AbuiwC4niWNQYi3O4c5PvXo2kW+ITC6c7irbew7V5xoYurHWViK7h0bCkcDvXrOmRvPbRmGNfMf5jkg55oAu20ZS1w38LAbSu7j1qYDMG9lB25259veos7ZScYLYUdevc15n408Q6r4e8YXiWMxa3ubZJUhkYlFYqyZU9VOUzgcc9O9dOEwlTGVVRoq8ney72VzOpUjSjzS2M3wAF1r4j32oyKHjXz7hMH+84SMZ/65hvyr2FWjkiViFVTzhTzj+teF+AvEEfhVLsJp8l5dzmGGFVfaGCggKOpyWcjGPSvb7czfYInnSOGdk3SIH3qv+yGwM898Cu7OsPVw+I5Kiskkl5qKSv82vmZYWcZwun/AE9SeQ5SXYvychQB8wP19KbHzHtjcszdC2cHuaHYQoZCcMFww2kjcfanRuWKEjy9o5LHO7ntXkHSWfOBkRF+RQuflPVsVXYsFRZMEDkYyevr7URII2Pmoz4bO3puz7ilLBUYo4UBwAAuSB+FAAM43Kobb1II596coU7HU7ctjceST16etOWMRyEBS24k8dGGeKZ5qiN5GYiUtuWMLknt1oAcg3Zdwypu+U5yeP5U5JNzbtqsm3KqR2xTFATbEsRLk7uTznrzUtykZljcZyByM4NAEeAtsu05YdSx+7n2p6RbVKuwTC4XHVvXinuYh5m1Nrg8r2b0OfaoPLEksZikEjFyX5wce5/pQBFIgaQnGQo+bJHTsa5fxFY+bbM6qVXlSAOiiuulPmMCAAFyMEfMR6AVl38BnSVZgNgGCSx9evH8qAPEtatxEwUKCqv0bkmsy3tZI5flJfHI+leqa1oUcxlVFG8g4dgMEeornH8NXEQzATIQc9RgrQBJpEcZKSO3G0AjOM+9ah0mORtgdM5yCTzjtmsmzE0bESwhcHawYbsc1uWepN5flLjcoHDADJoA5XXNCuLQyMY/MXcWyq45qPUozdaTb28II2xglQc7jXZXV/8A6M7y4ZSDl+n4Vw0d/Bb61BHJl4W3bi2cEGgDKtrtraSHydqshwQD2zzXu3g7UodWsoIrd1kmAC7e5+grwDXnQO5h2eX5hC+3+TXQfDbxs3hfU453hYgja54G0H+IUAfTni2D+yfhkbm8AimtCJgm7O8lsbT9Qf0rxHxLo0HifQn1jRBteE/vohgGNv8ACuo8STXniTRpbvTNWn1DRtvmtB5hbymHYr+Nct4FvvsmseTcswtrseRIjD5QD0OBQB5RPaxSQva365t5CASDkxuOAw/OuG1bTrjS76S1ulw68q3Z17MPY17j8QdB/s/UJQFwuSrIoxj3+hrg9QsYtUsRazMFuFP+jTtjAP8Adb2P6HmgDz2ipbm3ltbiSC4jaOWM7WVuoNRUAFFFFABRRRQAUUUUAFFFFABRRRQAVveDdH/tfV1EwAs7cebcMem0fw/U9Pz9Kw0VndURSzMcAAZJNem6VbDRNOGmRoGupPnvGA79lz7A/nmgC/cXTy33mMmUlztAHYV0/h62W00+Sa4zu75HOO4rG0mzMl4AQoDDCs3OF/xrp9SdLbSCZMiNscZxx3/HNAHP+JddnezNpbzMm5iS2e1eaave3CYS3XKZ5wc9D1FbuqymeeVnLB2cEKG6/wCRUmn6FPcMGiU4x8jYxQBS0gzSRKXRiT8gJOAfWu68K2rtKI5t3lnBAIzkY/lVGw0K8YFJV27GwMLzk8V3nh7T2itY0lUnauwHuaANG00+3kPmsqmTPlgtwQO38q6OyQYTy3C4bAPtj/Gq8MKxMm4tlgoGB3x61fgKK8UeSxPAzxmgBxeRkk2gk7tuB0BH+e1eY/Ga18u60W5VGXMckDkkHJ4ZRx6Yf869QUjeRg4BL5LZIbPSuU8fWmmazJpGjXz3Mc0t0JgsY3bgoKkZ/hBDEZrty7F/UsVTxFr8r/Dr+BlXp+1puHc5j4V+HvMk/t+9T5VBFkhGc9jIR78gexJ7ivVFKMx3KAoJZWABzx09KSOCO3YRQJGEjCxhAuAFA6CkZVSIkbkZV+X3J68dqnHYypja8q9V6v8ADy+Q6VKNKChHoO2kYONwxnrgkg8DH40yVvNdwE2KCQAOmfUnsae3mNCNyESPgb+/HUcdOKS2XeCqqkibgCM9O+a5DQewkDRMQGJX5k6k+vtSAQlHZVkJzkqDjn/61TOqrHH5jsgB9cZ/CocM4Kpl43ySytk/l7Y7UAMd5NzFQkYycjG7A+uevtT1RQXVgx7jP8P+FR4QKA+CpHHHJPufwp5lbaGSJsH724fdoAsidBHFIiI3PXZlsd800Eu29dsm8c4HbPH41W89FXKnYDjayjJI9/xpUMkTBGR9xBJLHBGfpQA4FpMyODEqsFBx+tLISHKD5WfBKjHPvjvSMg3M+WY/dGecZ7VG5OArAqo+82eSfTNAEkoJ2oSySE5DLg5qN3/eP8u0hcEBvve47UsSeapZMpxw6dfyqKbEO0Nxnnb7+tAFC7tWZAWCrlj5ZBzgGqOwkyK2GRTjJ4H0q/fSBYRMgbG8DA+bP+FZxbJD7gXA6NyVGaAKt/a21ynzKFkK5LDg+3vXJmJba7V/MkCqPuHozeua7G7keIhhluMNn5SQa4zXbe4lllmiJWKLL4UZyT296AGTzXl+JLe2hy6Lknrn29qq2/hsapfTQCfbIsJJYcgfQ1T8Fz3Ol6rdTyM0iyLgj2596snXfKjaJI3j3sSxAwcZ/OgDlNWsU0yE20YLANnexz36kms63BcHe6l8dD3re1NX1S8ZEAWNVGAF7fj3qKTT4reFXkbI6Y24K+9AD/DPiHU/DOoiXS5Nmz7yByVf1DDvXqtpJpfjG2F7pB+xapjfNak4Unuyn39K8VKiUuyh1IG7k54qzpl/c6bcRXFu5jdOjKT19KAPa/GEL30Vosqxm4lh2zZOcsOAa8q1DRpLW4bdExiJ6lev09K6ix8QnWo1k3kXqkfKxwPU471qXcS6pZNkr5ijlQMYPvQB5H4k0savEhRNmpxDC5/5br6EnuOx/D6cAylGKsCrA4IIwQa9n1HR3SQsqvEVOAxOfyrkvE+hC/ie6tm3ahGMyRqv+uHqP9rH50AcHRS0lABRRRQAUUUUAFFFFABRRV/RNPbU9Rit1O1D80j4+4g6n/PfFAG/4K05UDapcAFkO22jI+8/Td9B/P6V1mm2xnujI7Frnfh2P8XNRpGDLF5SmO3iQRxpj+EV6J4M8E3Kouraw/2WycfKWONw9BmgCGxtFtLRsYPzEhj09/wrj/EviKLVbldOsJo5ynVU55B/xrT+OOsjR4Lax0xjCbqPI2nBEfQn6n/GvEdOvJdPvoLu3OJYmDD/AAoA9m8N+FpLh1nu4syPgFNvQ5r0yy0SGK1T9xGCvQdOc1U8NalBqVvFeQFGjYBgUOc4A4NdIh4iABGM7g2DjPTFAFU6VC6uwzvUkKRz06UkUDRfKpYD0UdyccVoJEPKChugw2TjOaRQzebknhQFJ/z0FACQq2+T5ZQdn0B7VJLhvKQsCxYdcfz9RTd7Hy/MlTAUrjHUjqaPkVk3RZHmH1yD0z9KAJFIYysJAVJ25xxxz0FEoWW6gnMayMinDY6H0psJAljJwiSPuJA+72A+pqS2cBZdpG0Env1BznFAD3je4hQRuVZH3HHOfwoP7pkUZw/ZBxx3NK+ULeU+WOSGJ/h9cevWo7eZJS5YnfGpUMM9z6UAXbe4Ks5DnB54XPXvmktIf3srbC0XG0ggAEeo/OqZ+Qxs4H7wcFvbgfhUzt5Lurj5d3POM0AT3v7x4xklnJ+Z+cY6cDpxSM0VlGpSYlhlnc/TsBWc+oSSM8cJXYDwxHzHPUCmRSswYSOVw2DJnk+2KAHuI3mMoKs24bQRjPHXjvVsCaRm2NsHHyMcc/WqqlJd5WIjD7CepzT5HJiVSNnOAp+8fSgCaN/7ixbVyGc54zxwP60RyiFlMbq0gbCpjJA7nnr+NQPKkXzEuocbWU8Z5pROiSqdnlhuhznOemfSgB7XJYkbCJHJ+YsMNn+X0pqyrCqvuDbSQULfd9QPeqrSebI8ibVxncS2cHpTJCVkYsE3joytg/8A16ALQuUAY71XeMKQevtURJZkaMtIrdsZA7HJqqGbDnJII5+XIPv70xZJgHaN2jOR2wCvt6UAPniwA0bNsXpg4NZz7hgZKFxnbn35wavXkwafAQZKjJVsiqxkhkbbOhRVycDv6YzQBVmJkcmPc74G4ntisq5tpFkYIcKfVeDXREqpV3bYmOHbqy+xNVL+UtHtjQJG2fmJBYe4xQBgXFrFFDJtXY+PmZcgfhXH3FgZbiQPLnHXJJrrLgF8jY3OWJY5Bx7VhTQM87smVXHAXkigCL7DDFCMYUNx8vOeKyb+UTGSJAHXHRDzjFdS9nNNAgtj1G0oo/z+dPsvDwULPPGHfGCCf5UAcfomnXQZmYAKRj5v7v19a1X0E/ZwdxYMcHB4z9a5nx/4wuYr+bTbBBCsXyvIAAWPtiuasPE+pfarSP7RIY1fG3OM5PX60Ad/d6bdabOstnuAHJfOQPauk0DX2vGFvOoikx145PpWN4h8caVpKw2jh7252bpREQVVvQnPWqmn6tomtTLJZS/ZrtcbUY7aAPQbfRZtUSZoRJNIi7gCo2j/AOvXIavpDRqHRTDIpPzbcEN6GvSvhhJd3J1LS4CReTW++Dc2C5XnH5VqaVp+k+LZJND1kfYtXbcIbhBxvHOCD1NAHzD4w0XzUl1G2jCTIc3Majr/ANNAP5/n61xVe+eM9AvPDmtz2t0i/aIH2E5wsgx1x6Ec/jXjvinSxpt+GgH+izjfF7eq/gf0xQBi0UUUAFFFFABRRRQAV3fhe1aw0cyjInuxuYYwRGPu/n1/KuP0myfUNStrSMEmVwvHUDufwGTXomoSqbgSRoEW3+RQPToPwxQB6N8E/CUfiTxVBFfMZLK1BmcE9cdvxOBXp+tQy+P/AIhJpVsdmh2I2MFGFCr3GPU8D8K87+EU81vpmoNblknaAqSMZYH0rS+Kfju38B/C9dF0uQDxVriMLiWMYaCHOGYnqCRwv1J7DIB4D8YNdj1/4havPaMG062lNnZ4OR5MZKqR9cFv+BVxdFKATjAJycD3oA9Y+CusGJJ7CSTjfuRQMkZ617jayiRSQcckE44zivnj4Y6RfwagL4oUjZcDPUjua90sN8cZRWLKAHz6k96AN0yfeLA5Dngd/wDCpQoMkql03feOfyJqsC0y/KFj8wiRSTySeOnpUqZDkgAnbsJJ5PPNAEsn7xWjjIDsD1HTvSFnCBYyGw+M9+cHk0RE4UEbpDg7s9qYp4eMglZD8zL/AA/jQBdEZnmVSQi7yyhTgZFVSSq4LoGHXA6kipGIKxrKAsZyAB3A/wAk00Ov7sIH67hxwQOhPvQBYhKxMS6MC6eWqjsQeR6mqykqu0yYYll+QDBHv70oZT8zNuYc7S3f2pdsQfzIQu5GAI78mgBZNyxq6A4C7MscngcEAdqyb55JY0j3FpG+ZmC8r2HNasC7SNgZSMjK8ZFZkseLgZZguc7zyP8A9dADT9pggTLSMM78YGTiq0t20c2WUsGODuAwPzrZkRYrNVUowXGMDPXgk561nahulkSDZHmPqW7+/HagBRdyyqzDDMDnC8ZOQP5VY1OaOwkAeZBJjd6En0rmJbiWKZ2iKFgxUbm4GB2qneS+Y7S3E3mSEcl2xx3oA0ZNYl4MkqlQ2BjHH40xdTmVAZJAkRG0g8En1NYEl/FArrabGHGWIyBzTUu3kGVGwbsMNowT1zzQB1kmorJEy3Hl4VcY3bs+lZV3rM0MitJvmiA+6BkVgzCVmPkylhjDDIPPc+lR+T9p27sh1wckkDk9hQB0lrrzEbg7ALkkIc4HpzV9b5JbcBCGVs5IPzDnPOa5OLTp4ZCxXchbHHzL+Qq59qaDYLhcDJHmKeuegI7igDsba5jvLd2mcR+Ty2Rgt7CoZtRV2K2iIgjUfMRlyM8nmqenyJLo87KxyvzMhPzdOv8A9aqMO/JVlDMQDlsD8A1AGq0iYKu4dFUEsSCP/rVUnnh2BfuyDgckqf8A61VXOXJhR42BAMTkEtgdR2NOmkVBI/zRhhtbyx7d896AJWhjlxsDMSRlW/pTvsyvbMskYlOd2TgYH0qhp9+088gLO8aqWZwPmAHc+9Ydt4khvPEMWnsHwzYUpyWHU59KAOoWVFHlwqq5438Dae1c34z8Zw+GIPLVVbU2BCxKQy49W9K46+vZtGn1HxBdTySNPI0VjA7HoP4se1eZ3t1Ne3UlxcyGSaQ5ZjQA7UbyS/vZrqfHmSsWIUYA+lVqKKAClBIIIOCOhFJUkErQzRyJjcjBhkZ5FAH0N8PPEmoaY+kalPGf3SLKc4BOBjB78jj8a9e8fWsc6ad4y8NbpHlYM6g/6p+ufY56+/NfImk+Nr+1vlN2xurMn5o36gZ6g+tfQvg7xHNY2PkwyrLZ3Sh2Ucgg+goAv/F64TXNM0nWhGqXckPkXIGMFlP/ANevC9a057+1msD80h/eQknADjt+IyPxr17xpqEd3o6rZDbFGScYyB6ivNNbDRQxyR/wYIYDkD6GgDyAgqSCCCOxpK6DxhYmC8jvUCiK8BfA7P8AxDHbrn8a5+gAooooAKKKKAOp8AwAajPfyMVS1jIVh/ffIA/LdW3dfvVVlUrvk5YnIb2qLRIn0/RorcEB5j5swxznsPwHb61saZp73ca2xVw0hBOf4cHg/WgDrPCl/JpmnxyrhXY7MDkj3HrXj3j/AFa41nxVe3N1N5rKRGp9FHb88169bWUsCwpO22KMHBzyT0rwzWZFm1a8eNQiGVsAemaANnwLokOuam8FwpZVUHAYjv6ivc9L8HaZaWhQWyqiYIXBPzf/AF6434NX2nXAMCWax3a4EhU/e9x9f6V7LGdg3SfxDkE9+1AGV/YqWwRbdAsCjgY5+lWI7aVCIlBCIOw6fWtQkCUnKjdgYHJHFDLvIVsDeOBn05GfxoArxosaxphyFOC2eUGePxqcxnaI8HemBkHPfrSttkQlYwcgkqOBnHX8KIWDRAnaMDBPfjvmgCQxl5CygBs447g8ZFLHHukSOLADfNuboSAQMD3pvyiEynzDIRhB0HXrUoKIdqbuBu4HP4GgBjlZXR1TIwBz/Ae4qwmVjRy5G8kADnGB2qCEsFchFLDjYo4O7v8AWnx+cIjvk4Q/NyM/UY9qABGYMxLKoIU5UZJ55/WpgPNWRdgUtxw2CT2/DNNZhJErJuLscqoGAR6VmreXj3O/GYwu0HAxgH+YoAvpIiyBGQ7gQFPbPcD1NJIu+VflyXYFNwyo49KFdGcNOzI29icZJbA9e2KVVZyz7yxVl2jIA2/0470AR3UBjJUMpjYfMc4P0xWRfSSQ2czzIokc8FsDOP5VtXep2UMxxIrFVYDbg+vGa4XxLrx1OZo4n2IVGO5BHGKAOb1i/kkuGgt3Zyz4OBwv5VcstLL26teMzKwOAn3s+me1W9MsIba2YyGOJBhy7c49Sf8ACuC8W/E0RLJZeG1B5w13IuRn/YXp+J/LvQB372lta6c9zKI47SI5Mk2NoFeda38QbSBWj0tGuZGPzSY2LjPTkZNeeahq+o6ju+3XtxOrHdtdyVz7DoKoUAegWPxA+bF1aFCcfPEQf0Ir1rQL7SdV0T7RY36TyqpGwYDDODgjqK+Zamtbma0uEntZXhmQ5V0bBH40AfS1ndxHBii2FWG6ReRn0YVbvDDIrZjRGOQ2D8p+gryvwp8TEAFv4oiMi7lxdW8ahsD++oxn6jn2Ndwut2Wrvv0iZZbJeS38XPbHqPQ0AaUmbNW2t+7kXBwnINU7aeRQoVGZGb17+pFVrm+RI9rfM8nAG3AY/Xsao3NzLGfLtG+UH5RG2dvrmgDpmj/ejfDt+UshDZXp6GlhDtaESmNTn14J9uaytL1DYnk3ancW+6RyoHXHpWneSRysPIQBSSc7cZHrQBh+Lmg0PRLgW8rQSTcmQHBTPavP/hLbtN4juLq6jBiSB8PIeFY9x+tdv4rtI9QhUXO8RqBhW+YHmoPDFtZ6ZYajb2oEc8sDKhboCe3tQB57491Jdc16Oz0/LQ2wEMSg8MxIBwPrT/EfhOHw9osM2oSk38i4ESHgN7+oFaPgu2Hh2G71fXbclbR/3cTL8xkI+VvXFcf4i1q513UXu7xvmPCqOgFAGWoLEBQST2FJTlYqwKkgjuDSYz0oASiiigB7u0jZYknpXr3geK907SrFronBLMmGBwlea+HNTtdKuZLi5sEvZNuIhI2FQ+uO5rQfxjq91qMM0twFjVh+6RQqgen5UAe+3dkj6aCwwpfPOe9cRqaJNc3VttEiq3EgOCPz612tjcLc6JA5ldVZAWGc4/GsTXNOjngaWMEz8PuHfHr60Aea3lqt3azaa3yyZ3xu/wDfHT6Z5H41wZBUkMCCOCDXp+pw+Y4nAKkdyvB/GuK8UWyJeC5h+5Py4/uv3/Pr+dAGJRRRQAVq6FZ+dMbiRT5MJz9W7D+tZVdjbWDxW8NlGAJBgyMD1Y+36UAbWn2bXKC5djsHLe/vWlbXkl9qcEED7AnUqOCPeqV1KLC2jtEILtyVB71a0TS5XKXCtiV/lwBQB2s0qRHdKPkKHIzuIr5zmKtK7JnaWJGeuPevepdN1ZfCGs6ltKpZ28jZYdeO9eBUAd98GrwW/ihoWUsJo+g745r6KV9r7C+7J4546V8meGL86br9ldAkBJBkj0PFfU1jMHtY5Fw2BnI4DEigDTRi4VnV92N20fwj3NPG9xsbhlUgccEHkc1BG5+UqwCE5z9RyPpUkj/ugC3ltnJXPA7fjQBYbKrw67wMqVPJXvUShJC4jBYvk4AwB0GPrVWMqqZKhd2dydT6j6VauJMquzo0eQT2PUA+9AD1Xe0iYzuweW6AdM09ZDIrBGw5OEKjggdqigAdpUddp3Yds88dBSH5gYSp5+6yn7uefwzQBYQhVyGxGFztGe/Y+9Q+fGRGIuSV3MGbGPpTGmCENtXK4VmPft/k1hajKRfqUYlk+bg9Tn+VAHaQQxsBKCG38AdMjHXHan3TwJZfZ7YI24GVmGMA+grhLbVvOSeOaVk+bdHg4H1qe3ub6dpVDCNFO5kU4zkcY9jQBu3ckcVofPlXjPU5Jx1571yWr66I4wsb4jc8KDzz6+3tVK7uNQnkl8u3Max/Mzv91MDAP41zN5r/AIe0eTbqVzJPOcSYVS3bjH40Aaha7vnc2qkKw2sXPHH8qsi+8N6Mks+r61aGdSG8pGy4B7BVyf0rxnxd4wvNameG3llg04ZCxKdu4erY61ytAHonxH8dw6yH0/Qo5IdODfNI3ytLx0x2H8687oooAKKKKACiiigArR0XV7vRroz2TgMRhlYZU+mRWdRQB6HofjkzzLDqShNw2716H6+ld+trFLEkVpIgldAzHI2qP618+1raf4g1Kwt5Yba5YJIMHPJH0z0oA9ni1vQdPvJU1DUIvMi6oxGSehX2rX07xP4OuiA2qQQoBz5rgEe3/wCqvm1mLMWYksTkk96bQB9QapDot5ZLJp2pQ3CFecHdg9RtxXHTu8RlitjGQ43hScd+1ePaRql3pN0s9lM0bA8gHhvrXpmk63Y6vC0S3IE8g3GKT5SD6A0AO1fTH8R6E1raMy3qSh1SRvvn0z9OlcnaeEp9PM154oheztIFLbON0jZ4UD0PrXZTiSAKGTaqZIboSP8AGqXiaS48VaMLfeGuoX3xFm++MdKAPLiPOnIiTG9vlUHpk8CtXUPDWqWFv59xb4hxkuGGBWlp3g+T5H1y9t9KhcZQzuMv9BVnxTremrpY0nSJbq7Ib97eTNjdjso9KAONYliSetNoooAKKK9C8CeDLDXLVLu5nuGCn5kRQq59M96APU/gpZnxTpWkWGXUOSjnPJCg5PvwK6r4i+ENQ8PTCeKEy2TAopROAexY103wC0O0s9QungjULaQhI+MEFj1/IEfia9pu7aG8tpLe6jWWGQbXRxkEUAfB+qWcsFsyzFWY5bjIH/165W+hjvbCeFmYShS6EngsOmPc8j8a+h/i/wCGbfQ9Xe1twPs1xF50Y6leTx+BFeDR5W+dHIiCNnkZ4zQB57RVzWIFttWvIUAVEmdVA9M8fpVOgC9olt9s1W2hJADPk59Byf5V6B4eSOa5lmumWPZkgNyCa4nwuP8AiYvIG2mKF2H5Y/rW3HLIbtI3ICP94IMD8qAN0WgvtUj4JVjnpwa9p+C3hZNV1947uIi1tV8xhkYbsB+tee6LYrHYo6g5CgheuBXunwMmjsrPWriQbVRFY7uvGf50AcZ8dx/YHw48RtYsIba6vl0+Jeu8A5f9ARXyPX1T+1pKNM+HfhHRTzNNcveSEeoU9fxkP5V8rqpY4UEn2oAK+jPh9qMj6HbxTSB5CoUM3PYcmvG/CnhS61WZZZkMduG6MOXP09K9q0i2SxiRLdfKYAIUPGfXFAHXRsjyDZl9q42Zz06iplffFtUBm5DMTyo6YrDsXUSbkJV1+UFumCa1IZRJkKGBIwzDnFAFlkUExnkqxGW4PA6U+2dm81SBkLuVemfQCo8x4TzCOc/P79OfehXYOvUOPkJHc/1zQA5JirCRmOAcFSevb9KbJI0ElwVJMbEFfTp0+tMlUPGWcqJQ5RgvJGOf6Vl396CkZLFon5YgdOx49aAF1O+TyfMxg4Crk7sEHlq4zxH4usdF3C6m3zlgfLQfMR6+341otqEH2hUlkVEd/Li3HGef514j4/Jbxjqm4kkS459gBQB0T/EqZZg0ViCB0LyYz+GK3tM+K9pMbiXU7FoLgIPLaJt4bH8PQYzXj1FAHYeIPiFrmrtKiTCztpBtMUPUj3Y8/liuRYliSxJJ5JPem0UAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAFFFFABT43aN1dCVZTkEUyigD0vw5rB1rTGinCG4gwCC3DDsana2VLkSxPlchgR95fUmuB8OXostVidz+6c7H+hr0a5jS28tlA8huCwPT0560Act420zUbrUTdxI1zBsCjy8tsx7VR0zwjqV3IvnqlpF1Z5mAIHrjvXobW0t5pEkaYSSQERyA9c9x6V5NqtpNZXbwzszFTgE/rQBp+ItJ07SJ/Iiv3u5DzuRAFUf1rCQqsqkjcgIJB7ipbWFWuUW4DrF1Yr1A9aty6ehiea3YmE8x7+GPt9aAC2tYtQ1Tbbq0NszcBucD0r3Tw3cWGmaRFFGBHHGAN64Pbpx/WvAILqW3UrE2ATk8VdbW74H93OygDAwOAPT3/GgD6L+FvxGbSfH8drJdJJZXciwO2OACf0I619Z1+XkF9doDPFKUeIgh0GCDnrkV93eBvG/9sfDNPEN1KxnSwEY5zmQjBP13AflQByvxP1ePXfEG+1Ikt4Y/Ki3LtOe5H1r531+MRaxdGQsmTkbhj8q9kZC8J+YIDncxO4ivK/Fu1LuZeZNvrz+RPSgDgPGsZTxDO+BtlRJFI6EFBz+eawq6Txzk31lIf4rVf0ZhXN0Ab3hWPL30mAVSDBBOOrD/AArc0e3kk1RVYAheSCOg9vWsPQP3em3sh6M8acdf4if6V0fhcSXN9KH5X1PB/CgD0/TI02qFBO0Dg9q774b6klrqV3b3GBbzRlWLHuOea840q4EksflbgeQQPpSXt5PbP5sb4kMgUqvDc+vrQBp/FBrXx94k+yahcEtYDbEivxj69qz9A8HabpbgQQqJBwxf5gT75rxvxRqN3a+NLy7gmeO4Rxhgf9kcfT2r2nwL4kXxHoaXIURXMWIZ489SMHcM9ByDQBvf2ckYQmJFIIyexPXI/CnT2ZZlmY7mB3Z6ge9XoSjYIJcKMkMOAcelOwFZSRtMhwVblcexoAzkCjLlC7K2AoHL55zVyyjZMOx2+YTmPtn0B7VYkEQCmbCyMCAcdieop00blCBh0C7kGfm/CgBuwGN4myHUF9p4Gep+tIXJiXaflKli3TGR0pxdiGkfcVCgA44bjPSoHb9yGTDqeoIwwPHA/CgCN52hZZGRkk2kuAM9+D+Vcnq9wPtDmBg0aHdtU/eJ7CtfU7oi3xGd4kUnGcZ/2c+1YOk7JZPMyNvlthv9peMflQB5X8Q9Ukm1dII5yVhAc44Kv/iOK5a8uZby6luLht80rF2b1JpdQlee+uJZAQ7yMxB6g56VXoAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACiiigAooooAKKKKACvUvDVx/a/h5QyEmNtsg9SOhA9K8trY8MatcaXqkDwTmJGYKx6gA98UAd/D9otpcs/7sHCgH5APp61S13ThqSZ8xHkKn5RzzVzWiZXDr8oAyFB59/rzWXZb4JMSS7gDlBjAH+FAGhpPgq1ihhu9Rv4nhReA5wB6j3rndetbOe/jjtrlfJYnywBgg+3bFdBfPNdQeVHiNe6k8dO1Z9p4ea8ZvtgYGMFlYE/u/bigDkHisba/McxmliQkNsIGfxrTsj4dmmjiNpqBdztGZBjP4VLeeGZTKTG2HYE7XBx9Sa0PDWiLot8mp6xJGIIQWCgbiTQBF49trXTLSxsbS3eHeDMxbv2A/WvVfh1qlxb+B9I0uFswyoZHDHuSegrwbXdTl1fVJ7uZnO9jsDHO1ewr2nwK0a6RpURV42ECuXxnIIH+NAHZTbBvY7pHPpwTXmPjNVGoSiBgQQAw6D6YNekySmPd5ih4sZzn5T+HXNeWeKip1KWaP50BG09SD6Z7UAc145g8u00h8EbkkXB9iP8a5Gux8bSSXOlaXPIyEo8qYAxj7pH16Vx1AHQ6EQulys3AEw5/Cuv8ABcTHVXO0eWRwWGD+FcXoTZ0+7RkDKHjb3H3s/wAhXbeCyReK4YkldwGfu0AdhPGLS4BSNyCQRkjnPf6VJrsxgt2cqGCkNt6/U1NesLjTWO4bV7459cfnVXU5Fn0nDr/DyO2760AeTfEeNE8SM0ZGJIUc47Hp/Sk8JeK5/D8Rht0XEswaV2/u8DH86t/EmFRcadcbWDyQlWJ77T2/OuMoA+qfDOoLqenLcxY+YAkfw+5ArbRwY9k4IAOcOM/TmvGfhB4ib7N/Z0k5V0YbAf7vr+FezJPl8TAYYEgdN3B70ASXBV5It21kC7ic8k56D0FRSZ28YKg5weNwB6e9D7l2uNrDgNF3HHb1FShYy4cgYz8oPWL2/nQBD92BFYYViSRnk57fSqz7iZGADjdn72GU4q0yNHMyvuLEkKQeP896z9QkESys4Zoyfmx16ccdxQBz+sKUlTa33MFlK4YHrmuR8aeJbfw3JbQWISa+3+ZPGeFwRkHI9c12dokt9qTojpIjyZ+U44xnoa8f+K2i3GmeIZ7i6kUvcPxGF+4ABgZ+lAGVqup6Pq0Fzcz2Vxa6qxyn2dlMT5PJcHnPXpXOUU5m3Kq4UbRjgcn60ANoop4fbGybVO4j5scjHpQAytfXItJig07+yZJ3la3D3XmsCFkPVVwBwKylbbngHIxyM06CTypVcqrhTnawyDQBHRVm5njmjQJbrE65yynhh7j1qvQAlOJz0AH0p6wyNKIwjeYeikYNR44z2oASiiigApw27DnO/Ix6Y7/0ptFABT4grSosjbEJAZsZ2j1xTc8YpKALcK2QE4nlnJHERjQYb3OTxVbI2EY+bIwfSkwaldI3Ma2wlZio3Aj+LvjHagCGiiigAoqWIq0ymYkqWG459+a1fFa6UmphNEjZbdY13EybwWIycGgDFrrfAnh/T9cvlW61BonjIYwBMM/PZicVyVdT4HuYbfxBZqjDDMhJcAEP3wfSgD0LxPpQtPkgEjkAADPJ+tc0sdzBIQ4Vlz0AyEz6+tem+J9MuC7ymQFXGMx84HYZ71xfkbYy42qDkc/xfQev1oAitmIjQhyzKQeQOPb/AAqxJqHkyddyNnftPX6ipbHSjNavgADqezY9an/sgRgguu6TpIwzj60AUnuS8ZMexEPRvr6elcV43v2dobRZg6L8zAH+frWr4lv4tKikgSYyXLA8Z3KPp7e1cBI7SOWdizHqTQAgGTgcn0r6EskNnbQRIMqY0VmB+XAHqOhrxDwvZNf69ZwqpIEgdsDPyryf5V7bNPm4bkkKMqsfQ+ooA1pZXht2Y5kjc4K9Dj29a8w8QhotUnCn5C5yRwce4613r3buYoY4/LRMs+Tg4+hrzvV9kurZ3Fgz7dwzxn1oAqeMIlTwppzgDLTsQfUbf/rVw9dd8QtRSW8t9NgOYrJNrt/ecjn8un51yNAG34dYNDfwgkO0auuPZv8A69dh4SlP2+ASYxgjg4FcT4cdvt7QIPmnjaMc4weo/lj8a6jw7KEuYxwZEcoSR0oA7iwvj9ovLN2+bqit3zT7i4zp5jGCysU2+4//AF1z+su1lrEF3GNwZcFgfarWi3S3V7JCrkq8g6+57UAY3xPsLiPQdIu50IUO0YPUDIzjP4V5tX138bfAMlr8JtXO8FtLFvdLuXkhm2tg+2W/KvkSgC9pGoz6ZepcW7FSD82O4r37wZ4pj1W3jkjlBKLhgR3HoK+c6vaXqd3pkxks5mjJxuAPWgD6uhuoikjuQykcMDyM1c3gx5xmYnJdGzgHjFeIeHfiGEssXU+yXowYcf8A1xXT2/jG1u2VlnQOOdyNjd74+tAHoDXDSFn8syQf89F52fhWJf3UcgzGwIzvjGeoH93+dGn3pazMgnUMTuLoD8wPrWVq8mJBh8Z5AA+UHHOPTigBtpeC21VSGHc54+8emR6dad4o8NjxPp1wdUeKWSPDwzR/Kyj05rMnRZbuBwd2xfu9GGOa63Qri2ez8oxzsjp8zsc4xQB41feCY9MQsTK0TN5cnmqMoMcEceuK4d7GSS8eGySSdQxVWCEZr6b1LTrbVYx9rj82NSdoDEFQDweOoqG10W2t44xDGvlD7ysoPOD/ABCgD5vfRNTU4+wXLdsohYfmKsah4bv9PsoLm5QYm5RE+Zh65x0r6Oj0wWbuUUTsw+VdvGD0Bqv4esr5Lu+/teyhhkE/mW3ldBHjuPWgD52l8O6tDp8d9LYzC2k+62OTxnp1pmm6FqWpRzvZ2ryCFSzjvge3WvpSPRVRQkcjNEzk7ZhwS3cHtVtdKtrJR9ntokYeow3rwe+aAPljToI7icxT5RQCxcHBAAyc5rT0nSrLUY4vInnNyHPmRGLKhOxyOnpX0VN4c0yYyvNYQl5Vyy7eCc+3WrGm6JpdiJFtLKG0nkyZAkYXI9aAPDZ/CWpX2ji5MTW7q+20tVXBY9/5da5iN7GxRBNaPNeRMRIkuVU/XB7c19RPZoCytGW8sZDAg7ie4p0FnaPGPMht2V1GQYw2G9G9qAPn/QfBF/eqboGM2ksgUooYkDOckHnArt9P8EaLdzXFte2aRqpUxmPMbP8AQ9a9MS22OiyLB5b/ACD1Q9qV7dTKkyoEPGWBGcd6APC/G/gjT9Bu4UihujbSS+X5hlG4cZ44x+Bqv4h+Gt3BDa3GgiW+tplDMz4BTPT69817Zq/h/TtcjQamjS+WRIh5UqwPXg1Yt7Jo0KpMVjKbdu7JGPQenvQB87694NGiW0Mt7fqokcKWMRAHGSO5JH0rpf8AhW9lqWlJdaFdu8UgEiyyjJH+zgAV65qnh3T9Ut1TUrdrkxOHRZQHAPTp369atabawaemyMbWUeWgzj2IAFAHht18KteNvFILy1eBFIAdmDLjqAMH+dc4fD+o6TIHNpdS3LA+Q8CkhWHfp+lfT/2dXhBJLFSSEIxgn3/xrH1m2vbox/2ZLFakcSPjOT9aAPl+e3vJ710eCd7xiWkTyiGznngVE9tcRJIXidQp2PkfdPofTpX0OvhO20m9fUrSCVtVlXFwwy4UEglgD610g0PT5oAywK7kgyfKAWI7mgD5St7eW4lSOGN3ZugVSa0xo1zC7s1lcXVtggSxKQOOpHHUehr6am0949NuV0+Ex/IQqABCD2IP+FVND0vytJjivUlTzfmmYhcqx4zkUAfL1zFJGwEiyIMkKsgwQP8AJq6mNMiSeM29w0ysgOSfLOBnj15r6GvfBlhrTPb6mkbKMGMo37xhj1x1rPsfhlolnFKFi+0RuclLl87cemB1oA8m8NeL9WgmtraSeWa0H7tlJJGD0z9K7W4V5CXj9d2UXqK9Ah0TTNKsWjsrOGMAZJiiB56ZOf51xmoxYn2IzsMnCqPlH5dvagDI17Vv7H07z0UvJkKEkbp9MdeK5WXxrO2nlFH+kEbQOy+/1p3j3Uoiy6dFBtkQ7pGJ49gBXF0ASTSyTytJM5d2OSSetR0UUAdl8K7Wa68TlYEc4hbcQDhQSBye1ei2FrcLq9xbyA+XCc5Y8Z9qtfs06K66FruuCLeZLmGwiJ42kDe/P0Za6zxfp0WiazqG/AY8ke+M4Pp2oA4WNDPd6lcOSfL+UOeSPrXEx3O67muZA0n2dHlKrxnaCcHP0rqw/k6BNOVYGQk7i3BHvXC3E6Wun6hIUIaRPKQ5wMt14+maAOVnleeeSaU5kkYux9STk1HRRQA5GZHVkJVlOQR2Ndpavm6guIyAlxGsjqpyAe4/OuJrqNDAuNLiZctJbyFGUddrcg/z/KgDs/ESifRopbdSShzwM455zWdoM5ttQhuUJIA3Ebec564rc0OVLrTJ7Jt7Y4AYZH1p+h6dA1tGuS0isysQc4FAH134ssl8W/DDVoo41Muq6O4jyOAzREp+TMDX5t1+gfwY8TJP4K0ywmcG6tJ/sUinlgpBKH/0EV8I+K9IfQPE+raRLnfY3ctsSe+xyufxxmgDKooooAKeqnDMCBt564P4UyigD0Dwp49/s+3js7uIiPAUzKcn8RXcwXAmWOSJnMEoOMAHbxXg1ek/C/VvOEmm3DZMal4sjnb6Z9if1oA7zy2lYMgDgpkDIz05x+Paun0ayMccMkhe2jJwGZMZJx1Ncnp10I1kdl3EbgNqjJxjipNG13WPEGtRWMdvs09F8zfJkEqOox65HFAHePFJJLI0KnHzEMACMj6djSIBJbglCHbAyDx9DT4IVjSNod6hSd4PBxUkZEkDbBkDIUNgEd6AICgWeNWKYxtY5IIHOM+tOMMgAJk8yM4VA55UY6ZH9akULJt3sWDbg8bLnIA6/mKW1O3aJHDq+QMZH0oAYyJFIyEyJn+FgOOOo9qVQqOsbAsC4IUjj6qakQFQcFCmCR5jfcJP5ihXeCMQSSFVBL/Mm7av9RQBGSqqhZ3BPzhgOT2I/Sh8kFJG3MTkYHOD0zUwheJVZmXYcneD8vToPehomUM3l4BIO0dgRx9RQAQPGC8ciAy55J+Ug9/oKRirSMGkBkI7pgFT/WpY4G3zxuskceCQFH3vz7Uv2fzF8vYQEwQVOMAeo60AV5ItoHmqIie/JVuP0NSxlltW2YZwT8q9iexNJfXcMXmqz/uoxu37Mlcc49657UNV+2xabc6VctBC02+RwuNyjsQeaAOmhjL4mkUogX5gOx/CkaBE2SBDkHG/oW/+uKqRyl1SaGcNG38ZOVJ+g6Uec3mYCxylwQNsmNp9B6GgCaeRzLENoljb5kJOc+o9qczlYkMezzcjDEcA9eAe9EO3bKZhjaoJXoD9P9qqeoyfZLdiAzyB0K7hwBnjJoAtG482eRVbe27O8defbt9KS8jHktIWVXzjcwxk9wfSqcj24vEa4fyru6yUjByGwOdtT3amLeLdZJmkzuic7tzcY9s0ASRsFZEWAKpX72Dj35/lUImzdPIHG4kgksTnHalleSC28y7d4yjBZYz0TPbiqNzZrfySx2s2dzb5Sj8A9vofpQBpoDNa+bCw2RsQQ3Y59D2qvBcRT3DpcQzIoXO5lADHvtPpT7eSWzKvbs8j7cGIrkEH61Je2sckeLqByWH3ScN+YoAhs7q1vo3FtLHKqMVYq2dvHt0Ip4QZdSBtGfmWsywsIdKQ3Om2/wBlWR8zjByT0yB0rQkkeaXy96GU5IXoCvr70AQamyLbs24oy8YzlmFeY+Kr2PS9NnuxkNGcRrnAZu3v3/Sup8davF4W0l57gq8rsVjjC4Lkjsa8D1/xDe62wF0Y1iB3CNFwM88k9SeaAMqeWSeZ5ZnLyOdzMepNR0UUAFFFWNPs59Qv7aytE33FzKsMSf3mYgAfmaAPsj4GaQNM+GHgSyHE2rX8upzIVyGVcgf+OBK4H406+17431aytpEMYuDEXU4PBxjivdLWO28NTqspUWXhPQ47ZJWzjzNgH6qAPxr5PjuZ9S1+S7Z48tLvLEcHnPegDR8Wq1ro1tAnzqUw3Nec+JHaPT7CAONrbpCo/IE9/Wu38Zzzy30cIkUMRkqMYYHtXnniWUyaxMvO2LEQB7YHI/PNAGVRRRQAVteFp3W/a2HMdwpVh6EAkH9P1rFq5pNz9j1O2n4ARxuz6dD+maAPQ9Du/Ju1I5DrjGeldBbJ5GtmGEPiceZ8pB29jXNDbFcqPlPly7cD09TWrrZaN7K/tAUmXIb1IzQB6b4G1ZdE8Qv50gS0vQse/P3ZF5Brxb47QyN8Q9Q1ByGF8RIXXoWAAb+QP412sd6moaeLhZANg+bH8JFYfjCBNe8HeagWS9tD5isOrL/F+n8hQB5HRRRQAUUUUAFdJ8PJUg8Yac8jhRuZQCcbiVIA/M1zddX8NNJXVvFMEbSBWgH2hQf4ipHFAHsUel5uWt0mMSzPlk4PIGeDWl4M0abSXeC5l8wK5MeeSqk5AJ/Gq+rK1tr1ncK37tlKKwORnriupmhj4nUgKyj5t/8AMd6AFxJHDcIFkYA8c9ATjNWSIcEFMFTjP3T1/wA81StJI5Y5ShZyqbeO2eRVlw/2V/Njd9p52t29j/SgB/mEMfMI+82Ax5PPXNIzIx8oDP8AGu4kdO+aqieYw7rNIGO0kpKD84+n9atu0kaxSPbLE4BXaPmBHcfTmgBViindEBCs+SVOeR9R9KckTzjzCN0Hl7H3deOMjvmqyGKSySaWTylXGznjPqD2pusX0lnbiJ83G9dwZOCE9f8A9VAEeqam6ThbUjbERxGOWHuKYusEhVt7hUeVTHg9GP49KxryeGODzTK0iyjAkHP4ZrHa6kmaOKJA8rMNq7c7j2yev40Adhca1sjT935ZPHmKM5JHOfapH1ua6tohHAs7KMAxjDD8e4rsPCvw1SPTGvfE90scboHQBsbD2Jz9azvEa6ZoixQ+HAl55rFC0kuyGE92+VWc5PGFU/gMmlKSinJ9AOIk02U3FxI0ZjM2NzB8EYPXHqK5nV/C7xWax6VevA7yl7l2O/Kt3wTwfpXuVr4Vm1uzSW71SwS1lGVGk2y/MO/7yQvnp1VVP0rkfFfhbw6/iC20i2gZWtQLi51C4d52WYj91HvcnZwS5246J2JrwMPxJhMXilhMMnOXV2sklve9n+G5q6Mox5pHCaZrGuW2qPDqmnLLp8IEds1udpY5xux+ddrdQ3c9693bLNDDEFK/dHmlh09sVR1K0udMuxHOqB2zi53ZQkd1xxn+dTRat58ckV9t3b1YPu6cdCK+gMiw1hHd6bJbtJ51w/7t2jbDHnPzY7j1FMmsL1Yons3DlGETpJyoUHnJ7msAgWOtpPp7MYipWVSM7snrwa1JvExFqRHA8LqTGrE78543EGgDbbTrW58lJIyzxYxjOVbvip5LeGOaaQsRHgYcg7s+jZ9PSsXRNW+3WskUTRSXVs488LkHnv71pSXk7CJof3xH31z3+hzQBKstzPJcK0TeShGxieCOzD/Cq0L2dpdCzeJzLISfMWHKjJ7sP60xtRdVVkJSXoYnHHHfNVbm+aW2l/0aRtzhjGnJx3P5c0Aa135zTRW9qgYJkuenH9frVG8jlguGaK5dJFwHBG4/SrrNA1ogt5WmQDOHPPUdCORVee6s4nO5WYyNtKx8sW/2ie1AEuJkYEN8xJ6sckDpisvVNQj0hJLq+McdvtZizsAyD0B71V8VeK9N8P24kurgRg42xr8zEAfdFfP/AI98Z3fiu+JKtBZIcxw7s/ifegCv498SyeJ9flu8yC1X5YI3P3V7/mf6VzdFFABRRRQAV6P+z7po1D4qaNNIm6Cwc3j/AFQZT/x/bXnFfQH7P1lb+HrC61zU5FhaRRIoY/wD7v5k/wAqAPSPjtryaP4UGlRur3+tS/argk8hB0Xj868U8LWSXC3ayuAAvXfgj3x3p3jnX5fEHiCW9nRtithABkqvsK0tPEWnaBIzxgTOOGcY4P1oA5e7eN9WYyMohiOfnbG1R3/SvOppXnleWVi0jsWZj3J612F1crFpGozlV8xl8kAjHLHBx+Ga4ugAooooAKKKKAO5aUXEEN2smN8ayMVH3WH3v1zXb6Xarq2lxurbnj4AzyQa858OSNc6TJACD5DnK/7Lf/XBrtPBd+sTpDhgM7PwFAFJZP7L1OeNgTavkMuM0zQpUF9NbB/3b87Q3De1XtchS8muBGhVo/3g55xXIxzTWt6J1k+65C8Y2g0AY/iXS30rVJIipETEtGexXPT8Kya9X1rRv+Eh8P8Amwqv2qL5kOc5PcfQ15U6NG7JIpV1OGUjBB9DQA2iinLtLDeSFzyQMmgBtdF4B1iPRPE9rdXH+oOY5D/dDd/wOK52igD6q12zabS43gHEOJPLPPP+NP0O9ivkMP7tHUcIflJOeuax9L8b6ULPR9La5SS4uoUAmLcdBwfT05rO123n0fVPtdr89nNluOQMf3TQB35VBcyIYkVZCu506E+uKnkl/s0Swi3e4SZweDyvuR7VwVr46nsWT7XAJ7bHzHuvoTWuvxH0opGVgKyuNvAyc5zQB1M0WLUYQsRkCQHBGf6UkEyoz58xVxnyyM4wPm59K5DVfH8ZciCBwhIACr8uf722qFx4gvrq2UCWFixJxkgoSOePf0oA7DU7qwtzLGse+NUEiIOnHqK5We9lfbOsjBmGV2chQeo9u1VZJ4zbwFHMzsu4spxz6Y61m3l8st5HHH5gcnPyYHHXFAEtzcGGHzhsR5TgnOFYnoQvqa9P+AfhCeXU11y6aJ4FB3RMMtkjj27V43rbSSJHKJd6RyDaS33Rjoc1738B/FthY+CryTVpYrK3gckSEkq2OMKe55GAOSTgUAel+NJImtRDcW80kYHmbkcKFI7nvxXz5qOm21zfSapHq9xa+HjJte6KiR7qQ/8ALK1TB8xuPvgYHbdg7ew8Y63Lr+oJHqlvMlvc7XtfD8sgR5B0868cD9zD6x8k45BOUGzonh2aOa/1DW7u3vNSjj8mFoEUwRR8Hy4Eb7i8DJHzHHJ4AHkSxNXHN08I7Q6z/SHf/Fsul3tpZR1lv2OT8KeLm0CK7LabHp2hrCVsrFfmme4LDaJJD96WTJz2GOp5Jj0/TL64ge31NolvLyRrqa4LFUlduv1UcADsAB2rWS0dJpPMEM6oxcKzggdQDnHBAJ5rMli+zz3EF89xcoIw0BU7lRs/xD1x2FXgsow2BrTr0V70rJ9dvPe73b6sUqjkkmWLOGCO3Onzt5lncZhYsdwhkxgMPSuB1uNtE1k6feujMGKecp3Dd25/xrrdU1CCHRERYMTmRVDoxyO/5e1UvHNlb6nqseptcpZ7rNDcBRlWb1K9vrXqEGDI0aBFlbfuGMM+3B9h1NPgvA5WFMEcEqU6f7XvXH6jdz2l20d1McDJicDK5x2PpW34DvH1DVI4blPLY4K7CSSfWgD03wl4fkCtNKp8oYZv3e5SM4JDD+VdVFodsGKYVTgfvFPTPtV7S4X0+0S2x5ZXB+dCFP5e/rWhGrXD+VLCwk+8rlsHHpxQByl/4VZ1IgcbHzjJDKzH+VcpqVtJp8rRyoVmHCYPXmvV9yxLhWHkjIZen0OfasvxJp0Gp2RWVlW5xtGRySB1B6UAeQPfxQTSeYfLkDFXQDjPYisDxh4oXQdPF4+HuGwIlH8bep9Mc1raxZ+VdtblpBNG+V3DcD9favMfijO91YQyFkKW1x5YwmPmIzjB/GgDgNa1KfVtTnvbpiZJWJxnO0dgPpVGlJJOTyTSUAFFFOwNpORkHp3NADaKKWgDa8I6OdZ1iOJwfs0WJJyB/CD0Huelej+KtWE7/ZUQWsL42o3cDjBqtoWhf8I/4d826VlvJsO+MZHHC5HIx/MmsRXmubt2kmY/3TIQ2B3FAGz4f01rq5ygfyU5bZwD6DmrHim4MZ8gSMQRlg3GKt6XeQ2OneVGW8wLvL8rk9uDXNPdG5vri5uXEkEKGaQYzwO3PrQBg+MLkJDZ2KgghRNLznLHhf05/GuYqxfXMl5eS3E2N8jFiB0HsPYdKr0AFFFFABRRRQBteFLtLfVBFOxWC5UwufQnofzx+ddNp7HS7zB3EFiCPSvP67KxmOpaJFMXLXFs4jlz1Knofx6fUUAehzRwX8Ed1b485OHH9CK43xHp0tlMwT54mbeCRjAqzomqPbzbW5BGz8CevFbd4sepWxj3qVcZRvbNAGP4W1Z0lSBxhXPAXtisn4m6aiXcWqQKBHcHZJgfxgdfx5/KoruC4spy24DDkZAzjFdVpYtNe0eWzugWk24IIxk46j3zQB5DRWjrmkXOjXpt7pR6o69GH+e1Z1ABSjGeelJRQA5GZHDISrKcgjqDXoHgbxu0Df2Z4hmMumMG2O3WJscfUV57RQB7NLawajAbnSpUZSoRzE3yyYNKuiqGXzY1jEQxndtJYf8A1j1rh/hvcXy62tvasTA3zSAtgDg8/WvXRJFJbyI5jkVwFDEEFSKAOeSxh87fI52BcthuTg4496uhbOAB4FJRCc7h80mPWrkltH8rxrg8/cx0B5z+fWoVtowNqFwcEbgQfm7D/wCvQAySTPlm2JRl6b1wCM0iRrLcRMYRuBGJDyMkcZ/OrqxxQYPlFy65OctuBHXHbpU2k2c+tPIuni2jt7XD3N/cMRbWcf3iXbIycc7Ovrgc1lXr08PB1KrtFDSbdkYmsadeai9hpWlwG71K5fi0jHOBwWPYL6k8Cuy8PW0Hhp7ewtbiLUdbjl8ua9RN9ppbHhhCp4lnA4LHgdDjlTzur+Io7QnQvB7z2sN5hbzV5/lu77noOhij64Awfpzun0m6Fp4r0fSYZII47RlRgEIUjPPA615nsauY61040v5esv8AF2X93r9rsXdQ23PXJ/Cdjp2pJcWN1NNaXXzTXUr+ZLI2OTKT36+w4AAGBV1DCIFQSXCPnAcj7y9AVzVTxNcLaRXMlmoSXedxXkMpPUKetYTGZrZVHmSJKNzAORj0IHb6CvXjFRSjFWSMzXmuXS5n8tTJIHxNgbQ4PYj1qjduJLh5UilkQfN5e0sQwGOgqPUIpE0aK6kkaO5aX5ysnbHBK9c8d6hhhvUie4tpPnx5iSQ8F2J5DDsaYFPXLq3m0wwxW8TzvMJWMQKyQgDpjuParutXsF3BptrKiTTCwP7xUKn6Y9qxZrdn1NJFLrDIvzhTuZW7mtDxZaT2EejzneA8ZxICc47e9AHE6hYR6xZxiACGeJSrFcAg/jxz6V1v7N+mq/iidLqHElqHY8cMeMZHQcnOR6VyWjyLLqd1AshVXkJJz97PQ8/lXpPwt8zSfHEYk8hI7iNhuB2g8Z+YjjPFAHp+ozmW7uWBJTJYN0Kj7uR6jjmq7xxgKjEblGFZW2nPr7imzzSx5lj4iyenIOTzg0iXEThVkjwWbmRG43dh/wDWoAm2DKgMWDEHEuMHjpx1/GjbGySI5MPULkblLZ6ZHSmRxmLd80TBx9/k5wT19amkUbUw2EYbyE4BJ7igDxj4iQmPXJHyXDcAYBz+XH4V4t49tdPv1ufMllhvLJR5kxz5TE9EwerfSvVfjP4rh0G9aSUL57hkSANySB97Hp71816pf6jfKkmoSTOsjF1ZwQGPTI9aAM6ilJyScAZ7CkoAKKKKACuy+HPh86lqIvLn5bWA5TP8bjn8h1/L3rnNF0yfVr5ba3wDjczE8Kvr/wDWr1yULoOlx6dCp3hQq8dAee3U9aAMrxTfNd3CwQxmdSNobYQWI78GrFronlWqtIMkNggr29M1b0KzETG9mXyGztjVgRz9DUmtXgitvKjk2x8lyrcE+mKAMLxBeoZhbWzhEUDiN/T2Ncx4il+w6Ytl5jtcXJEsmf4UBOFPvkZ/CtBmjsbae/u0MnlHbFyQJJD0HPp1P0rjLq4lu7iSe4kaSVzlmbvQBDRRRQAUUUUAFFFFABV/Rr42F4GbJgcbJVHdT/UdaoUUAdhLA9nMHjl+VlEkbjPzr9fxro9L1NYgY5WBhPPzHlT6CuJ0PUohAbC+YrCx3RSj/lk3v/smtVFnt7hgY8dAc9H4zkUAdxfWEN6qKJApkUg5Uj6HIrm4459H1ILPhRuxuZvyrU0bV/kCzPiIEE4HMeP6VuX9jbalBhAshcfI2A3I9fagCO50m31mBxPCk0QAPTv6gjkVx+ofDwk77G7CK2SElUnb/wACH+FdHp9zdaTcmC8jwFbaCTgMtdPbTQXUBmtyVJ4JJ4AoA8iHgHVBLiWW2EfUurFuPyFbK/D21ERL3VySOM4VRnvXfyop2ZLbgcMQMAVHiOYkeYCN55AI49frigDirbwBYeWDJLdOWI6FRir6+CdGjQB7SWR3OOJSMfrXUrGqpGfN+QEnHcH3oZWaQqZU2LklgR17Y796AMrRNIstHDC0iEYcAgFstuPbmtaIEOEYBSAMlhnnt0oHlSrIFOB94BhgjH161HMWiQq+QFwMjoe/agCfzmMcgiKDJG7enHvj8RTnHnOqIjMpw+Qu0bh39MVGjARMZJVIDjK55GRwenSnKGaNwoSMLnA6DB5oASEae+pldX1Gaxskh839wha4uzux5MHYN0yT0ByBjLLY1PUDqEFtaiCCw0i0fNto8J3ImDkSSEf6yQ9cnIBORk/MYtvmPvLIIlAJ57njINV9QuYrW0ecoqsgI3RgfN26+tccsFCdf29RuTXwp7R80u77u76KxXNpZHL6myTa158bKIbfduGf1HrW54FgmvtUlvMuH3hfNwMMQcj6cVxMsn2u53NmYEEttIwOex713Xgm3ls2hjjlfdcONqqSNvPP412EnsGs2w1mCxNuzm827JVTnDDnp6GszxD5Wh28NvaENqDrucu2BFn+EV13g+2FnrtsHdSXZVLEgFxng/WuV+MtjNa+M3mmTzIplWWMDjjGPzBBoA4xJruS7dt0pnOeQdxZcdx3qzp+rTWkgjlf92CHkRvkPXse9OijeNUlUIvPXJyPrUVzhW+ZA4LZ6g4z3wevNAHqvh7weNUubW9Kg6dcKJEkUjdjHIJ9c1J8ZrC3i0ciPzJb8oFgjH3Y41457810nh65/wCEb8O+G7O4CsJIGeRsYKEjcBj6tj8Ky9a1S31ow39tDDOsa4b5iGjYDkMB2oA+aPDNhOl/Lcoo/wBHyXikY8e31r0Q3Kx26Om7EnONwGB35rqfFHw5g8R2kmqeEpfsmsKgFzaZ2pNx2PY/p64ryXTUu4LWTTdTjlt5IZGRo5UIZDnkEHHFAHsfhfW2+ypbTujOnH3zkj3B6V09tcR3IdI12Sj5lHRiw4yOzfzr5602/wBQ0i5ETxvPDyqyZyQM8dOa9f8AAnjrw9pVi/20SPLKc72AJwB0wcDHU8UAdgqzSKREmUkIIAUg7qm8S6naeEPBmo65rfyJBEf3RIbk8AAep9KaPib4Qjg3Jqa5xnykhfd+gxXiHxd8a6h43sLnSkhjg0hjmPaCXbIIDMemeelAHzh428S3XirxBcajds2xiVhjP/LNM8D/ABrBycY7Cp76znsbl4LqNo5F6g9/ceoprW8ywiVoZBEejlTj86AIaKKUAsQACSeABQAlS20Et1OkFvG0krnCooySa1tH8NajqU6oIWgjyA0kqkBfw6mvU/Dmh6Z4Vs5LoCWe9CYaQLkn2A/hoAb4V0WDwxooeYI17MAzsR/F6c9hV+x01Lu4N1cuqsHwgAJDHrnHao9P+0a1dNfXsDiELt2lSGH4dDV/VbmPS4A5UxyBf3W5MZb064oAq+JblLRCr4MvPO4Dg98Vx0zNqcqRW77gTzvGRjuaZreoySXJlnd/NcjaVGQBjoQaztammsfDsjpJk3bCEEgA7MEt784A/GgDC8S6oL64SC3J+x2w2Rj+8e7/AI/yxWLRRQAUUUUAFFFFABRRRQAUUUUAFbWla7JbRx215Gt1ZKeEYfMnuprFooA7h82ksc0BDWtyN6MW6qex966LQ9ZW0jHmENAxxkHlP/rVwugaihgGnXcgSPcXgkIzsc9j/sn9D9a1ovNsndHRQV6rnG4f1oA7zW5IryyhEIL4y6Sj1rI8NyXsN0sccTPIOSjmqGmX0tpNC4d2jZsMu7IXv0rrgtreyxXdm0kc8fLqOTj6elAHQ6ZbPqEBe0iJlL7WR8HBxziifS57aNvtVtMFOScrgCq3h+/uLG7L22YpI28xSRksT1zmvc/CGv6PrlmYrhrOHVmG1orhQYpT7Z7n/OaAPBSskqhsKygHCgcnjp7UMVSRUkRBvUH5iRjAr6Du/AGiX7Mt5pE+mTHjztOlLI/4YOPxUVzknwv0hmVbPxLGWUbVScKX+h+YH9KAPHiqlFHygAEgDj9e1LHCrR4BOTncoJbqcdTXqcnwa1QANDqFi6gEj5nUk/XFY918LfFNusgjs47lck5S4UE/99EZoA4IqSF2/K/ALKc5APamyN5QEmSFk6FgM8dsVral4U8U6eRJLoE6x7vmkdgOT16VyN14Z15lZ7sPCobiNm9+cY9qAJdT1aCxBdZSZQCNpPtjAFchqN5d3U6SsZEikODuYYyOgxW6+hzGLESzvMpwQydDn1PWsmW0ZRHFJwZGP7tmOQ470AXdDsIo5E/eEsCc4UZY/QV634N023sQNVviIY4VbyYX43tgYIz9a47wtpcdkZJ7rY12QNi44XGDzXTXAvtWnSKzHnSup2Bct/3z/hQBt2sl14guibZCUJwzNwYznsfXNd34ksLXx3paWEcvl+IbCMmJnGBMOhGT6kD6H8ah0a10nwV4csbjxa5/tFQXS1jbcxGc9OOe/JxWr4C+IvhvxFdXVtb239mXNt8yrchFMiH+IEH68UAeHT29xp1zJZ3geK9iOHWRNp+h9a674e+F1vP+JzripHo1oS7M/wB6VwfuDPUdK9a1PS/B3i8xz6hbWF7Iv3ZHyj/Qngn6GtG9uNC0DQ3jZbKGyt0O23XaB64C+poA8i8S+IL/AFLUbzVliU2UaAojdUXOPz7n3NVfDmovJcreWV01nfKu4PyI3Gejg+taNr8U9A1G/a01jw6sVo7YSSNd2E9WwBWlqXhyC4nfUdHu4JdOuirpGDgBffH8qAL8N5PrJe98PFbHxDaDdc2B+7MP76/3gf8APu7U9FsPiLpguBt03xLbptbaeM/7Xqv6ivNPEepS+GtStNRso2h1C2YhdvIZQfunPUGvS9Nm0Hx/bR6hoV9/Z+shMvbBghD9yVHJ/wB4fzoA8Z8QPqOhX32XX7P7DdxPgShcxyehDe9V5pIZm3DbIucmNzgDI6ggV7zftqzwG18T6CmpWn3QyoHwv94kZ5+uK4/UfBfh67HnaQ13p43kmFhlR6gCgDyraqMJIlZQARgtnae3P409oQVjxkhh93jnsSrZ9a7u88D+TAJLDU4Ji54BicMPYg9a5u60a+jjeK6towQchlQlR6n1GaAOevLCKXd5tuH2HnzFBZffaf5iqN1aWlxF9mvo08t+S3OMe4rWu/to4VAJI+gOeR3xWUdLvrv5bx1SHoQQQVH+GKAOTvNE8OwTtCto7uv9yRzn361raLo/7xTa2dtbQdCzINxHo2efxrYSw0fTCkiTxzTKhUq3P0xVYWWo6tIHSVRCp+Xb3HvQBrI1vZWzNJGgEY6ZODWdbM95IRex+SxIKgcAj0zWjbafM5Ed3IHt1wVBj+U+1Z2r6tDCxgsZIwyjDy8sE+goAva5qsenIqLNEZQuBHG5PP8AtCuLvL24v7ky3VyCmciN2IAP0rMu5Lhr3zTOHJ4DCP734Gq72V3crJNDHKfVtmVPsQKAG6hdD7WxD7DEMBgePpmqfjaXzbnTn3MxNop9h8zdPyq49qkJDajPaQRY3GM/MzfQdawNc1H+074yrGscSKI4kVcYQdM+/JP40AZ1FFFABRRRQAUUUUAFFFFABRRRQAUUUUAFdVo+prqEcNneFFu0G2GVh/rB2Rvf0Pf69eVooA7Au1vcOmwRTYw6sT09q3dP1BbaaKSA75AvzR5zn6VyNn4kuEhWC+jW7hHG5uJAPQN/jXQoLaeEXunStLa4ClSvzxHrhqAPQtKvUvtkiR7J4+HTkH8RW28iR26yxqjt1IVck815LbX0tvcGaOYn5xgf412Oj+KwlttulIbJyyn+lAHr2g/EXW9PhhQTC5hH3Yp03ED03ZB+nNb6/E2C93DWNDtbmNeFLLjnPowavHIdQgn2SW7gxpjaAw7+taAv2RSsyvuLHLKeW/KgD2Gz8XeEftIuG0u5tLgEBfs+QD+CsB+la1t498MS8R3+oIyHdtYSHcPTnORXiX29C0bPIBsAICqTj8aknuA5PlujA7gRgKRx1oA9g1LxJ4ZuEZLi5vZFkBJXYTz71yWoazpDuDbWb3yOmQJ127cccYrio74uSWViMYG6THH4dc0puURI2MZVA7bQG5GevWgC5qNzaXpYW0CW7sxOVyAOK4C60h9O1lbu7/fWUkmTIo3FMjuK7QSrwxYHLEZCgfpVC/lsLpJoGnHlMQWyxByB2NAF3w7p7XWphZVubiHI27IuDjjkivURqWk+AdPklk2yao+dsIGfKzxkmvLdE1e70+1Mem6g6RSHbgH7vocmmSl7q5uW1ASOkuP34fcQ3rg+9AFXxJ9u1e9u9VS7aWVyZXQnK9DnA9PauLhkjvGVJEnS4jf5Hj+U49DXbyOtpK9vDEbiMLkbuDg+351k6hbRXWn74LMQXijds3Y3gdgaAPSPB+h3Vxob3VxNL5cSnaVbHmL3P4VwOsXrfaiqvPdSpuMKliQBnuO9ey6JG9x4b0trfcscuktcbW6qwGGX3ryS0tA1xcSXkX+u+7hTkGgDOgF9LbyS6ikcak5X5iDz2rrvBPiOfSbJrO/+axJ2iNXyUyex7GsxGikTF5GPJA2mPPWkgaErLHCu2J14wOuO9AGl4utTqYa5t5Fksg2Y38wYHcBs8gjmvMXstTl1GdtOaOOLOAyS7Tyc7vpXe3du1zafeJR+C6EDJA5yKLW0McMaQ4QICoUjqD796ANDw34j8TaRBDBFrN5JIiE/vm81D3wQc/pXV2/xT1drYrfWVhcoTghkYFh+Bx+lcQJ1YshGxwudrEL+X400uwBVl+RiPlOMqe/Tr+FAHY3vjySSFd2mWsDEAboiSMDvj1rGvfEdzfyoiTxRyMmdpXAPt7Vi27hJXVWXC/MXxhW/wNQ3V64cksJCpxhcDg9x60AT3l3KxkMpjIGTgnIPsDVB4Hkt1SXygvGxmJO32PpUM17G7YvriGNecBeSx9xWZN4n+yIY9PVWLcbWAw350AbiWSxbTLFEnA2vjOPoaZqF1DZIzTtAAM5YJw31HY+9cVeatrDoFcxW0JY5ZsBR7MM9PcVgX0lmvz6hrkG/d92JzL/LOPxoA3PEnicNF5NsHA6FwxrN0/T47gC51ExWduPmMsrYVhn3rnm8U2lm7nS9OV5eiz3Lbs++0D+tcxdXdzdlWuriacqMAyOWx9M0Aeg6r4m8P6YjJolr9ruf4ZnyqoR39T/nmuSv/FGs30jNJfyxg8bYP3S49MLjP41iUUAKSWJLEknkk96SiigAooooAKKKKACiiigAop4CEn5iPTigJk4DL+PFADKKkEbEgDBJ9Dmm7WxnBx64oAbRSkEdRiigBKKKKACrNje3NhcCazmaKQd17/UdDVaigDprbxQXZRqdlBMOhkiXy5PrxwfyFbNpLpN45WDVYovNX7k6FCp9N3T9a4CigD0iW01C1nSMI4VgvzqxI9iK0hJrluEkZHJ46Z4A7n1rzKPVNQijWOK+ukjUYCrMwAHsM1Jba3qls4aDUbtCPSVsflmgD1J/FNzDtS4iBIG0cEk+9T/8JRLJIongiwy56fj/ACrzq38a63EwMlxHcAHOJoVb9cZq5b+O7nJS906xuIWGCqoUb8Dk/wAqAPQYfFVqhaJIikgBOR6fjWjJ4qt5Vb9yPuB9w9uorgbbxF4au1LXEd3p023GFHmKT7Ec/mKneTw9HZwTf28G3NyhiYsB3BXGaAOmuddR2CjC4PylF6f4Vb8O6tpjyvHeq2WIdWI4BrlbY+G7gqbbxBHEzcEToyAD8amNtp5lVbTxFYNPKwUKJR8x6YoA9KtLiyuY3it5o1cEswDA8flVe78PwXM6PFdXMbkHaynIJHIzXA3Wnazpkkge2L4IG6ME5H4Vdstc1i3lMaW0pjzkcnKn6mgDrL621JLZDY+RNJENu/BVj6ZrM0x7iS5toL6CdZkGUlXLc9wfxqrb+L7tTIDHIrglW3Kcj0xT11+4u/mkLKwXKkqQd2eRmgD6U8MXVnceDrR0mhEtnayW8yEYJDD7uPwFfP2r60mn3MdvbsZGI5DLnYfSt7RPHV9aac0SxMyMvzAx8t759azb2S31VnlewzOx+cMpUtx1yO9AHKpqeo3izRSQqgY5Vv7nritPQ/NRES4vYWdMnCrgjn3q0LG5RWCQoxUZwejA9qoX2kam8hks4WWYjdnjB9aAL2oiGW4eU6ouyMZKxkDj196x5tVkttqQ3SzRKTwGKgj61BLoGrh1a2iw5y4YYxtPUGqUvhzUIJy81xBDuJRlMgA56GgC8dZnikEjWxcKd6uXJBB7fSrMvi262MPJtgCRjDYYc9MfSsIaLLC7LcapZRLy3zXAAxj0NQ6fY6JFct9t8QacV4+7KGB/HNAGhqXiy/t5WiLwZLD5SNpFZtz4jvJM7lWSM8fKPT+RrG1fxwgvJF0nT7VrcHAkuULtIB3IyMVSXx3qQzm004hgAQYDggfjQBtRrczymVAxSP5zJIuFC9+awdZ8TvueDS1SGPo0wQbmP+yewrL1TXr7UVMcjrFAf+WMI2J+I7/jWVQBJNLJM5eZ3kc9WYkk1HRRQAUUUUAFFFFABRRRQAUUUUAFFFFABRRRQAUUUUAKPajJxjJxSUUAP3sTknJ6880okO7JVT7YqOigCUygjHloPpTvMRpFLJhccgCoKKALCi3P3i457DtUpitCp2StkDPJxn9KpUUAXTZoVBSdCTjg002MmTtZSOx9aqUoJByDg0ATtZzjP7s8c037NNtz5T4+lCXEyHKyuD9alXUboDiYn6gGgCAxSAZKNj6UzB9K3rOeSVCJCGGD/CKtrbxSRlnjUsOnHtQBytFaOtwxw3ESxIFBiBIHrk1nUAFFFFAHQW3jLxFbRxpFq10EjUKoZt2AOnWrI8f+JgSf7UYknJzDGc/+O1y1FAHZQfEfxFHu3XEEu4YPmQL+fAp6/EnXwAM2Zwc5NuK4qigDs0+JHiBGcrJajd2EAwPpRJ8SvEzjAvI05zlYVyf0rjKKAOsHxC8UD/mKN/36j/8Aiar3fjjxJd/67Vp/XKBUP/joFc3RQBoza3qsxzLqV65/2p2P9aoOzOxZyWY9STkmm0UAFFFFABRRRQAU9VBHLqPY5plFAEqRoT80qKPof8KXZFg/vcH3U1DRQBO0cQUkTqxH8O081BRRQAUUUUAFFFFABRRRQAUUUUAFFFFAH//Z);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Computed tomography of the lower chest of an elderly female with organoaxial volvulus shows accumulated food and fluid in a distended stomach with evidence of pneumatosis of the stomach wall (yellow arrow). A small gas bubble in the liver&nbsp;represents portal venous air&nbsp;(blue arrow). The patient was decompressed in the operating room and the hernia was repaired.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_803=[""].join("\n");
var outline_f0_50_803=null;
var title_f0_50_804="TM change not cholesteatoma";
var content_f0_50_804=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=ALLRG%2F62245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=ALLRG%2F62245&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Abnormalities of the tympanic membrane that are not cholesteatoma",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 360px; height: 363px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    White abnormalities of the tympanic membrane that are not cholesteatoma. There is a shallow retraction of the pars flaccida (asterisk).",
"    <div class=\"footnotes\">",
"     T: tympanosclerosis; B: bone (promontory below, stapes head above); F: foreign body (a white tympanostomy tube).",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Isaacson G. Diagnosis of pediatric cholesteatoma. Pediatrics 2007; 120:603. Copyright &copy; 2007 by the AAP.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_804=[""].join("\n");
var outline_f0_50_804=null;
var title_f0_50_805="Generalized lichen planus";
var content_f0_50_805=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=DERM%2F50632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=DERM%2F50632&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 470px\">",
"   <div class=\"ttl\">",
"    Generalized lichen planus",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 335px; height: 396px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Violaceous and hyperpigmented polygonal papules are present in a widespread distribution in this patient with generalized lichen planus.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Reproduced with permission from: Wolters Kluwer. Copyright &copy; 2008.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_805=[""].join("\n");
var outline_f0_50_805=null;
var title_f0_50_806="Rosiglitazone: Patient drug information";
var content_f0_50_806=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"disclaimer\">",
"   The content on the UpToDate website is not intended nor recommended as a substitute",
"for medical advice, diagnosis, or treatment.  Always seek the advice of your own physician or",
"other qualified health care professional regarding any medical questions or conditions.  The",
"use of this website is governed by the",
"   <a href=\"/home/terms-use\" target=\"_blank\">",
"    UpToDate Terms of Use",
"   </a>",
"   &copy;2013 UpToDate, Inc.",
"  </div>",
"  <div id=\"drugTitle\">",
"   Rosiglitazone: Patient drug information",
"  </div>",
"  <div id=\"lexiTitleImg\">",
"   <img height=\"17\" src=\"./../images/lexiComp/Lexicomp_2012_71x17.myextg\" width=\"71\"/>",
"  </div>",
"  <div class=\"clear\">",
"  </div>",
"  <div id=\"drugCopy\">",
"   Copyright 1978-2013 Lexicomp, Inc. All rights reserved.",
"  </div>",
"  <div id=\"topicText\">",
"   <p>",
"    (For additional information",
"    <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=see_link\">",
"     see \"Rosiglitazone: Drug information\"",
"    </a>",
"    and",
"    <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/35/13879?source=see_link\">",
"     see \"Rosiglitazone: Pediatric drug information\"",
"    </a>",
"    )",
"   </p>",
"   <div class=\"list ubnlist drugH1Div drugBrandNames\" id=\"F219381\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: U.S.",
"    </span>",
"    <ul>",
"     <li>",
"      Avandia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"list cbnlist drugH1Div drugBrandNames\" id=\"F219382\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Brand Names: Canada",
"    </span>",
"    <ul>",
"     <li>",
"      Avandia&reg;",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt war-os drugH1Div\" id=\"F10028206\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     Warning",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700337",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug may cause or make heart failure worse. It may raise the chance of chest pain or heart attack. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s3602102",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       You may only get this drug through the AVANDIA-Rosiglitazone Medicines Access Program.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2700454",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       This drug comes with an extra patient fact sheet called a Medication Guide. Read it with care. Read it again each time this drug is refilled.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yya-os drugH1Div\" id=\"F10028208\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What is this drug used for?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691404",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It is used to lower blood sugar in patients with high blood sugar (diabetes).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2691248",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       It may take 3 months to see the full effect.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt coi-os drugH1Div\" id=\"F10028207\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I need to tell my doctor before I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2702892",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have an allergy to rosiglitazone or any other part of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2705171",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are allergic to any drugs, foods, or other substances. Tell your doctor about the allergy and what signs you had, like rash; hives; itching; shortness of breath; wheezing; cough; swelling of face, lips, tongue, or throat; or any other signs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701381",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a very weak heart.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2701047",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are breast-feeding.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yye-os drugH1Div\" id=\"F10028212\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some things I need to know or do while I take this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697780",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Wear disease medical alert ID (identification).",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696820",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not run out of this drug.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697010",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you are 80 or older, use this drug with care. You could have more side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have heart disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697269",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have high cholesterol, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697290",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have liver disease, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697148",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have a weak heart, talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698463",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have your blood work checked often. Talk with your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698495",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Have an eye exam and visit the foot doctor every year.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696717",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Check all drugs you are taking with your doctor. This drug may not mix well with some other drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696750",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not drive if your blood sugar has been low. There is a greater chance of you having a crash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696618",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Avoid beer, wine, or mixed drinks.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697595",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       There is a chance of pregnancy in women of childbearing age who have not been ovulating.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2697641",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Tell your doctor if you are pregnant or plan on getting pregnant. You will need to talk about the benefits and risks of using this drug while you are pregnant.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696708",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Birth control pills and other hormone-based birth control may not work to stop pregnancy. Use 2 kinds of birth control while taking this drug.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyf-os drugH1Div\" id=\"F10028213\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects of this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698210",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Low blood sugar may occur. Signs may be dizziness, headache, feeling sleepy, feeling weak, shaking, a fast heartbeat, confusion, hunger, or sweating. Keep hard candies, glucose tablets, liquid glucose, or juice on hand for low blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698143",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       High cholesterol level.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698119",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Headache.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698258",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Nose irritation.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698392",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698364",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698391",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Weak bones.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698201",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Harm to the liver may rarely happen.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698129",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Heart failure may happen.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyh-os drugH1Div\" id=\"F10028215\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What are some side effects that I need to call my doctor about right away?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698721",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you think there has been an overdose, call 1-800-222-1222 (the American Association of Poison Control Centers), your local poison control center (file://www.aapcc.org), or emergency room (ER) right away.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699066",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of an allergic reaction, like rash; hives; itching; red, swollen, blistered, or peeling skin with or without fever; wheezing; tightness in the chest or throat; trouble breathing or talking; unusual hoarseness; or swelling of the mouth, face, lips, tongue, or throat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699077",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Signs of infection. These include a fever of 100.5&deg;F (38&deg;C) or higher, chills, very bad sore throat, ear or sinus pain, cough, more sputum or change in color of sputum, pain with passing urine, mouth sores, wound that will not heal, or anal itching or pain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699111",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very low blood sugar or very high blood sugar.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698640",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Trouble breathing.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698626",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Chest pain or pressure.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699094",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Swelling in your legs or belly.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699062",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       A big weight gain.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699042",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Very upset stomach or throwing up.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698981",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Not able to eat.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698634",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Dark urine or yellow skin or eyes.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698995",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Pain when passing urine or blood in urine.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699084",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Sudden change in eyesight or in the way you see color.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698658",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Feeling very tired or weak.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698603",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Any rash.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2698977",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Side effect or health problem is not better or you are feeling worse.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyc-os drugH1Div\" id=\"F10028210\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How is this drug best taken?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695786",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take as you have been told, even if you feel well.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695852",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take this drug at the same time of day.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2695914",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take with or without food. Take with food if it causes an upset stomach.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2694865",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Follow the diet and workout plan that your doctor told you about.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyd-os drugH1Div\" id=\"F10028211\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     What do I do if I miss a dose?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696562",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Take a missed dose as soon as you think about it, with a meal.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696496",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If it is close to the time for your next dose, skip the missed dose and go back to your normal time.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696475",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not take 2 doses at the same time or extra doses.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2696457",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not change the dose or stop this drug. Talk with the doctor.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyi-os drugH1Div\" id=\"F10028216\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     How do I store and/or throw out this drug?",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699336",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store at room temperature.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699264",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Protect from light.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b498:s2699266",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Store in a dry place. Do not store in a bathroom.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"   <div class=\"ord-stmt yyj-os drugH1Div\" id=\"F10028217\" xmlns=\"file://www.w3.org/1999/xhtml\">",
"    <span class=\"drugH1\">",
"     General drug facts",
"    </span>",
"    <ul class=\"statements\" style=\"list-style-type:none;\">",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699675",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If your symptoms or health problems do not get better or if they become worse, call your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699673",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Do not share your drugs with others and do not take anyone else's drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699678",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep all drugs out of the reach of children and pets.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699709",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       If you have any questions about this drug, please talk with your doctor, pharmacist, or other health care provider.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s3302581",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       In Canada, take any unused drugs to the pharmacy. Also, visit file://www.hc-sc.gc.ca/hl-vs/iyh-vsv/med/disposal-defaire-eng.php#th to learn about the right way to get rid of unused drugs.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699677",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Keep a list of all your drugs (prescription, natural products, vitamins, OTC) with you. Give this list to your doctor.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699671",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       These are not all of the side effects that may occur. If you have questions about side effects, call your doctor. Call your doctor for medical advice about side effects.",
"      </span>",
"     </li>",
"     <li class=\"statement\">",
"      <span class=\"attributes\" style=\"display:none;\">",
"       <span class=\"entity\">",
"        &bull;",
"       </span>",
"       <span class=\"link\">",
"        urn:lims:b259:s2699683",
"       </span>",
"      </span>",
"      <span class=\"content\">",
"       Talk with the doctor before starting any new drug, including prescription or OTC, natural products, or vitamins.",
"      </span>",
"     </li>",
"    </ul>",
"   </div>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 11035 Version 36.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1104-61.234.146.186-8641F3AC89-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_806=[""].join("\n");
var outline_f0_50_806=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219381\">",
"      Brand Names: U.S.",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F219382\">",
"      Brand Names: Canada",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028206\">",
"      Warning",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028208\">",
"      What is this drug used for?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028207\">",
"      What do I need to tell my doctor before I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028212\">",
"      What are some things I need to know or do while I take this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028213\">",
"      What are some side effects of this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028215\">",
"      What are some side effects that I need to call my doctor about right away?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028210\">",
"      How is this drug best taken?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028211\">",
"      What do I do if I miss a dose?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028216\">",
"      How do I store and/or throw out this drug?",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#F10028217\">",
"      General drug facts",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?2/26/2472?source=related_link\">",
"      Rosiglitazone: Drug information",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"drug drug_pediatric\" href=\"UTD.htm?13/35/13879?source=related_link\">",
"      Rosiglitazone: Pediatric drug information",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_50_807="Cervical epidural injection";
var content_f0_50_807=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=NEURO%2F65832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=NEURO%2F65832&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 564px\">",
"   <div class=\"ttl\">",
"    Cervical epidural injection",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 544px; height: 381px; background-image: url(data:image/jpeg;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    Illustration of an axial view of the cervical intervertebral foramen and adjacent structures at the level of C6 with a needle inserted parallel to the axis of the foramen along its posterior wall.",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     Adapted from Rathmell, JP, Aprill C, Bogduk, N. Cervical transforaminal injection of steroids. Anesthesiology 2004; 100:1595.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_807=[""].join("\n");
var outline_f0_50_807=null;
var title_f0_50_808="Prevention and treatment of dengue virus infection";
var content_f0_50_808=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"2\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Prevention and treatment of dengue virus infection",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/808/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/808/contributors\">",
"     Alan L Rothman, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/808/contributors\">",
"     Anon Srikiatkhachorn, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/808/contributors\">",
"     Siripen Kalayanarooj, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/808/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/808/contributors\">",
"     Martin S Hirsch, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/808/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/808/contributors\">",
"     Elinor L Baron, MD, DTMH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/50/808/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jan 16, 2013.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Dengue is a febrile illness that is caused by any one of four serotypes of this flavivirus (DENV-1, DENV-2, DENV-3, and DENV-4). It is endemic in more than 100 countries in tropical and subtropical regions of the world and causes an estimated 50 million infections annually worldwide [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/1-3\">",
"     1-3",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Although mild dengue disease and dengue fever (DF) contributes more than half of the total public health burden of dengue-associated illness [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/4\">",
"     4",
"    </a>",
"    ], the more serious manifestations of dengue hemorrhagic fever (DHF) and dengue shock syndrome (DSS) provide the major impetus for efforts to prevent infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/5\">",
"     5",
"    </a>",
"    ]. Epidemiologic studies have demonstrated that the greatest risk factor for the development of DHF or DSS is secondary infection with a different dengue serotype from the original infecting virus [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/6\">",
"     6",
"    </a>",
"    ]. Thus, severe disease occurs primarily in patients who reside in hyperendemic areas where multiple serotypes circulate simultaneously.",
"   </p>",
"   <p>",
"    Dengue virus infection is a risk for anyone living in or traveling in a dengue endemic region, especially in tropical Asia, Central and South America, and the Caribbean. In most of these regions, dengue virus transmission occurs year-round. However, the risk of infection tends to be seasonal and can be expected to be highest during a recognized outbreak of dengue infections. The objectives of programs to prevent dengue infections differ depending upon whether local residents or visitors are targeted. There is no direct therapy available against the dengue virus, which increases the importance of prevention.",
"   </p>",
"   <p>",
"    Measures to prevent dengue and supportive treatment for the different clinical features of dengue virus infection will be reviewed here. The epidemiology, pathogenesis, clinical manifestations, and diagnosis of infection are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=see_link\">",
"     \"Epidemiology of dengue virus infections\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=see_link\">",
"     \"Clinical presentation and diagnosis of dengue virus infections\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     PREVENTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;The greatest risk for dengue virus infection is in individuals residing in endemic areas and not in travelers.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h2\">",
"     Public health efforts in endemic areas",
"    </span>",
"    &nbsp;&mdash;&nbsp;Control of Aedes mosquitoes, which transmit dengue virus, and the development of vaccines are two potential approaches in preventing dengue virus infections.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h3\">",
"     Mosquito control",
"    </span>",
"    &nbsp;&mdash;&nbsp;Mosquito control is the most effective approach to the prevention of dengue transmission. Programs targeting the Aedes aegypti mosquito as a means to eliminate urban yellow fever in the Americas from the 1940s through 1970s were quite successful [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/7\">",
"     7",
"    </a>",
"    ]. These programs were also effective at reducing dengue transmission in the region. These programs were based on a \"top down\" approach involving aggressive mosquito surveillance and insecticide use. However, lack of attention and funding of these programs in the 1970s led to re-emergence of A. aegypti throughout its former region and the corresponding re-emergence of dengue.",
"   </p>",
"   <p>",
"    Insecticide spraying, in response to dengue outbreaks, is not highly effective against A. aegypti mosquitoes, which frequently breed inside houses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/7,8\">",
"     7,8",
"    </a>",
"    ]. Community-based approaches involving education of the population in efforts to reduce breeding sites, such as discarded tires and other containers that accumulate standing water, have shown some promise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/7\">",
"     7",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In one study, a comprehensive community and governmental control strategy, including the seeding of water vessels with copepods that feed on mosquito larvae, was successful in eliminating A. aegypti and dengue transmission in 32 communities in rural areas of Vietnam [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/9\">",
"     9",
"    </a>",
"    ]. However, this strategy will be more difficult to apply in cities where breeding sites are different and community participation may be harder to sustain [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/10\">",
"     10",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h3\">",
"     Vaccination",
"    </span>",
"    &nbsp;&mdash;&nbsp;Infection with dengue virus provides long-term protection against the particular serotype that caused the disease, supporting the feasibility of a dengue vaccine. However, it provides only short-lived immunity to the other three dengue virus serotypes. In view of the association of dengue hemorrhagic fever (DHF) with previous exposure to dengue viruses and the recognition that all four serotypes are capable of inducing DHF it is the general consensus in the scientific and public health communities that any candidate vaccine should produce protective immunity against DENV 1-4. Since waning immunity might also increase the risk for DHF in vaccinees, vaccine-induced protective immunity should also be long-lived [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/11\">",
"     11",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Animal studies indicate that protective immunity against dengue can be mediated by neutralizing antibodies, especially those directed against the envelope (E) glycoprotein. However, natural dengue infection induces low levels of cross-reactive antibodies that are detected in neutralization assays, but do not prevent infection with the other dengue serotypes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/12\">",
"     12",
"    </a>",
"    ]. Studies have shed light on the molecular basis for antibody neutralization of virus infection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/13,14\">",
"     13,14",
"    </a>",
"    ]; however, until improved assays are available, the cross-reactivity will continue to complicate the laboratory assessment of vaccine-induced immunity.",
"   </p>",
"   <p>",
"    No licensed vaccine is yet available for preventing dengue, although several are in development [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/15,16\">",
"     15,16",
"    </a>",
"    ]. In a phase 2 trial of CYD-TDV, a recombinant, live, attenuated tetravalent dengue vaccine based on the yellow fever 17D vaccine strain, the vaccine reduced the risk of dengue infection by only 30 percent among 4000 children in Thailand [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/17\">",
"     17",
"    </a>",
"    ]. For unclear reasons, the vaccine failed to protect against DENV-2, which was the prevalent serotype in the region at the time of the study. The results of phase 3 trials of this vaccine underway in larger cohorts in Asia and the Americas will be needed to provide clarification of the vaccine&rsquo;s efficacy in different populations and epidemiologic settings. The results cannot be extrapolated to the other dengue vaccines in development because the correlates of protective immunity are not known.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h2\">",
"     Recommendations for travelers",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most travelers from non-endemic countries are at exceedingly low risk for DHF because they lack previous exposure to dengue viruses (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    ). Possible exceptions include immigrants from endemic areas subsequently returning to their countries of origin and frequent international travelers. Regardless of the risk for DHF, most travelers will wish to avoid the morbidity of dengue fever.",
"   </p>",
"   <p>",
"    Avoidance of exposure to infected A. aegypti mosquitoes is the primary approach to prevention of dengue virus infections in travelers. These mosquitoes predominantly live in urban areas in and around houses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/8\">",
"     8",
"    </a>",
"    ]. Thus, travelers to major cities are at risk for exposure to A. aegypti. Bed netting is of little use since the mosquitoes are most active during the daytime. Remaining in well-screened or air-conditioned buildings during the day can reduce the risk of exposure but many travelers are unwilling or unable to comply. When outside during the day, travelers wishing to avoid dengue should wear clothing that reduces the amount of exposed skin and should use an effective mosquito repellent, such as N,N-diethyl-metatoluamide (DEET).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h1\">",
"     THERAPY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Since, as noted above, there is no specific therapy available for dengue virus infections, it is important to exclude other treatable diagnoses. Patients at risk for dengue can acquire other diseases with similar clinical features, such as malaria, typhoid fever, and leptospirosis. Symptoms in patients with dengue virus infections resolve in five to seven days.",
"   </p>",
"   <p>",
"    Supportive treatments are available for the specific disease manifestations of dengue virus infection.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h2\">",
"     Management of fever",
"    </span>",
"    &nbsp;&mdash;&nbsp;Patients with dengue fever should be cautioned to maintain intake of oral fluid to avoid dehydration. Fever and myalgias can be managed with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"     acetaminophen",
"    </a>",
"    (maximum 60",
"    <span class=\"nowrap\">",
"     mg/kg/day",
"    </span>",
"    in children or 4",
"    <span class=\"nowrap\">",
"     g/day",
"    </span>",
"    in adults).",
"    <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"     Aspirin",
"    </a>",
"    or nonsteroidal antiinflammatory agents should generally be avoided because of the risk of bleeding complications, and in children because of the potential risk of Reye's syndrome. The most important measure to assist the patient with suspected dengue fever is to carefully evaluate the patient for impending complications or early evidence of dengue hemorrhagic fever (DHF), as described below. (See",
"    <a class=\"local\" href=\"#H13\">",
"     'Outpatient management and early recognition of DHF/severe dengue'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h2\">",
"     Management of significant bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;Gastrointestinal bleeding, epistaxis, or menorrhagia in patients with DHF (and occasionally in patients with dengue fever) can be severe enough to require blood transfusion. Significant internal bleeding should be suspected in patients with signs of intravascular hypovolemia without elevation of hematocrit. In these circumstances, blood replacement should be performed with 5",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    of packed red blood cells (or 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    whole blood). The clinical response and post transfusion hematocrit should be monitored. Use of a histamine H2 receptor antagonist or proton pump inhibitor is reasonable in patients with gastrointestinal bleeding, although there is no evidence of benefit.",
"   </p>",
"   <p>",
"    Factors that contribute to bleeding include thrombocytopenia due to decreased platelet survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/18\">",
"     18",
"    </a>",
"    ] and, in severe cases, frank disseminated intravascular coagulation (see",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    ). Platelet transfusions have not been shown to be effective at preventing or controlling hemorrhage, but may be warranted in patients with severe thrombocytopenia",
"    <span class=\"nowrap\">",
"     (&lt;10,000/mm",
"     <sup>",
"      3",
"     </sup>",
"     )",
"    </span>",
"    and active bleeding. Prophylactic platelet transfusions in patients with severe thrombocytopenia but without active bleeding are generally not recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/19,20\">",
"     19,20",
"    </a>",
"    ]. Administration of intravenous vitamin K1 is recommended for patients with severe liver dysfunction or prolonged prothrombin time [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h2\">",
"     Management of plasma leakage",
"    </span>",
"    &nbsp;&mdash;&nbsp;Plasma leakage in DHF is important to manage with intravascular volume repletion to prevent or reverse hypovolemic shock [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/22\">",
"     22",
"    </a>",
"    ]. In mild cases, particularly when medical attention is received early, oral rehydration may be sufficient. However, in patients with established intravascular volume loss, intravenous fluid administration is recommended. Blood transfusion is appropriate in patients with significant bleeding or those who have low hematocrit and fail to improve despite fluid resuscitation. Subsequent hematocrit measurements must be interpreted with caution since it is critical to assess the adequacy of both blood and fluid repletion; in complex cases, it can be challenging to distinguish whether a decrease in hematocrit reflects volume repletion or blood loss.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h3\">",
"     Treatment of shock",
"    </span>",
"    &nbsp;&mdash;&nbsp;Protocols for intravenous fluid therapy have been developed by the World Health Organization (WHO) based upon clinical experience mainly in children from Southeast Asia (",
"    <a class=\"graphic graphic_algorithm graphicRef82833 \" href=\"UTD.htm?30/45/31440\">",
"     algorithm 1",
"    </a>",
"    ) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/19,21\">",
"     19,21",
"    </a>",
"    ]. For patients with shock, initial resuscitation with normal saline or Ringer's lactate (10 mL per kg of body weight for children or 500 mL for adults), preferably with 5 percent dextrose, is recommended, either as an infusion over the first hour or as a bolus (infused over 10 to 15 minutes) for patients in profound shock. A second infusion of an equal volume is recommended in patients who remain in shock.",
"   </p>",
"   <p>",
"    There has been debate as to whether crystalloids or colloids should be used for volume replacement in critically ill patients. Three randomized, blinded trials have investigated the effect of different fluid regimens on outcome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/23-25\">",
"     23-25",
"    </a>",
"    ]. The largest of these studies was a double-blind randomized comparison of three fluids for initial resuscitation of 512 Vietnamese children with dengue shock syndrome [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/25\">",
"     25",
"    </a>",
"    ]. Three hundred eighty-three patients with moderate shock were assigned to Ringer's lactate or one of two different colloid solutions: 6 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    70 or 6 percent hydroxyethyl starch. One hundred twenty-nine patients with severe shock were randomized to receive one of the two colloids. The treatment regimen closely followed the WHO protocol above, with 15",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    administered over the first hour and 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over the second hour. Only one patient died. This trial established that Ringer's lactate was a safe, effective, and inexpensive alternative in initial resuscitation of patients with moderate shock. In patients with severe shock, dextran and starch performed similarly, although dextran was associated with more hypersensitivity reactions.",
"   </p>",
"   <p>",
"    In patients who remain in shock despite the two initial boluses of crystalloid, we switch to a colloid solution (10",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    over the next hour); we favor 10 percent",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/5/21588?source=see_link\">",
"     dextran",
"    </a>",
"    40 in normal saline as the colloid of choice. Switching to a colloid solution is also appropriate in patients who have signs of fluid overload (eg, puffy eyelids, distended abdomen, tachypnea, or dyspnea). As noted above, patients who have persistent hypoperfusion with falling hematocrit require blood transfusion. Other possible complications, such as acidosis, hypoglycemia, or hypocalcemia, should also be investigated and corrected as needed.",
"   </p>",
"   <p>",
"    Once blood pressure has been restored, intravenous fluids should be continued but the infusion rate should be gradually reduced over the next 24 to 36 hours. The patient&rsquo;s clinical condition, including vital signs, urine output, and hematocrit, should be checked prior to each reduction in the infusion rate. There have been no controlled comparisons of infusion regimens; however, we typically use the following progression in the infusion rate: 10",
"    <span class=\"nowrap\">",
"     mL/kg",
"    </span>",
"    over the first hour, then 7",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    for one to two hours, 5",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    for four to six hours, and 3",
"    <span class=\"nowrap\">",
"     mL/kg/hour",
"    </span>",
"    for four to six hours. This gradual reduction is intended to minimize the risks of both recurrent shock and volume overload.",
"   </p>",
"   <p>",
"    The adequacy of fluid repletion should be assessed by serial physical examinations and measurements of hematocrit, blood pressure, pulse rate, and urine output. Patients with shock on presentation should initially have vital signs measured at least every 15 minutes until stable, and hematocrit measured every four to six hours. Narrowing of the pulse pressure is an indication of hypovolemia even with a normal systolic blood pressure. Normalization of the hematocrit is an important goal of early fluid repletion; however, a normal or low hematocrit may be misleading in patients with overt bleeding and severe hypovolemia. Suspected bleeding in the gastrointestinal tract should be treated with blood transfusions. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=see_link\">",
"     \"Treatment of severe hypovolemia or hypovolemic shock in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Close clinical observation is essential, even after normal blood volume is restored, because patients can develop recurrent shock over the 24 hours after the initial resuscitation, which represents the period of increased vascular permeability in DHF. Most patients who present for medical attention before profound shock develops and who receive appropriate fluid therapy will recover quickly.",
"   </p>",
"   <p>",
"    The fluids that are lost into potential spaces (eg, pleura, peritoneum) during the period of plasma leakage are rapidly reabsorbed. Thus, intravenous fluid supplementation should be discontinued once patients have passed the period of plasma leakage. Usually no more than 48 hours of intravenous fluid therapy are required. Excessive fluid administration after this point can precipitate hypervolemia and pulmonary edema.",
"   </p>",
"   <p>",
"    In the absence of complications from prolonged hypotension or from medical interventions, most patients with DHF recover within a few days of admission. Discharge from the hospital is appropriate when patients have been afebrile for at least 24 hours or have passed two days after an episode of shock, are clinically well, and have normal appetite, urine output, and hematocrit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24968065\">",
"    <span class=\"h3\">",
"     Adjunctive therapy for shock and/or bleeding",
"    </span>",
"    &nbsp;&mdash;&nbsp;The basis of DHF pathogenesis is hypothesized to be immunologic, which has led to interest in immunomodulatory drugs for therapy. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=see_link\">",
"     \"Pathogenesis of dengue virus infection\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Several trials have demonstrated that corticosteroids are no more effective than placebo in reducing death, need for blood transfusion, or serious complications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/26,27\">",
"     26,27",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other modalities, including intravenous immunoglobulins,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?13/28/13765?source=see_link\">",
"     pentoxifylline",
"    </a>",
"    , and activated factor VII, have also been proposed for use [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/28-30\">",
"     28-30",
"    </a>",
"    ]. Thus far data are limited and not shown convincing benefit.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h3\">",
"     Unusual complications",
"    </span>",
"    &nbsp;&mdash;&nbsp;Encephalopathy and liver failure are uncommon manifestations of DHF, and are associated with a high mortality rate [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/31\">",
"     31",
"    </a>",
"    ]. While seizures or jaundice should always be regarded as indicative of severe disease, no specific treatment is available.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Outpatient management and early recognition of DHF/severe dengue",
"    </span>",
"    &nbsp;&mdash;&nbsp;Because dramatic plasma leakage can develop suddenly, substantial attention has been placed upon the early identification of patients at higher risk for shock and other complications. The following clinical features are helpful in this determination:",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Duration of illness &ndash; The period of maximum risk for shock is between the third and seventh day of illness. This tends to coincide with resolution of fever. Plasma leakage generally first becomes evident between 24 hours before and 24 hours after defervescence.",
"     </li>",
"     <li>",
"      \"Alarm",
"      <span class=\"nowrap\">",
"       signs\"/&rdquo;Warning",
"      </span>",
"      signs&rdquo; &ndash; WHO guidelines recommend attention to clinical warning signs for severe dengue, including severe abdominal pain or tenderness, persistent vomiting, lethargy or restlessness, abrupt change from fever to hypothermia, bleeding, pallor,",
"      <span class=\"nowrap\">",
"       cold/clammy",
"      </span>",
"      extremities, liver enlargement on physical exam, or abnormal mental status [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/19,21\">",
"       19,21",
"      </a>",
"      ]. These recommendations were based on the judgment of expert clinicians, and have not been rigorously evaluated in prospective studies. In one study, these signs were noted in a minority of patients with severe dengue, and in most cases developed less than one day prior to hospitalization [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/32\">",
"       32",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Hematocrit &ndash; An elevation of the hematocrit is an indication that plasma leakage has already occurred and that fluid repletion is urgently required.",
"     </li>",
"     <li>",
"      Platelet count &ndash; Severe thrombocytopenia",
"      <span class=\"nowrap\">",
"       (100,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"      or lower) is one of the clinical criteria for DHF and usually precedes overt plasma leakage.",
"     </li>",
"     <li>",
"      Serum aspartate transaminase (AST) &ndash; Mild elevations in serum transaminases are common in both dengue fever and DHF. However, levels are significantly higher in patients with DHF, and elevated AST levels are noted earlier in illness than the other signs listed above. In one study conducted in Thailand, a normal AST level was a strong negative predictor of DHF (negative predictive value 0.96) even in the first three days of illness [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/1\">",
"       1",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Soluble dengue NS1 protein &ndash; Blood levels of soluble dengue NS1 protein (&gt;600",
"      <span class=\"nowrap\">",
"       mg/mL)",
"      </span>",
"      were predictive of DHF in one study of Thai children with secondary dengue 2 virus infections [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/33\">",
"       33",
"      </a>",
"      ]. Several assays for detection of soluble dengue NS1 in serum have become commercially available outside the United States; however, current assays do not provide a quantitative measurement of soluble dengue NS1 protein levels.",
"     </li>",
"     <li>",
"      Other considerations &ndash; Coexisting medical conditions, such as pregnancy, infancy, old age, obesity, diabetes mellitus, renal failure, and chronic hemolytic diseases, may increase the risk of severe dengue",
"      <span class=\"nowrap\">",
"       and/or",
"      </span>",
"      complicate management. Referral for hospitalization is recommended for such patients regardless of other findings [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/19\">",
"       19",
"      </a>",
"      ]. Additionally, hospitalization should be considered for patients who may have difficulties with outpatient follow-up or with timely self-referral should complications develop (eg, patients who live alone or who live far from a healthcare facility without a reliable means of transport).",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Patients with suspected dengue who do not have any of the above indicators probably can be safely managed as outpatients as long as close clinical observation is assured. Daily outpatient visits may be needed to permit serial assessment of blood pressure, hematocrit, and platelet count.",
"   </p>",
"   <p>",
"    Prospective validation of strategies for management and triage of suspected dengue cases is lacking. One study in Malaysia over a two month period tested a standard treatment protocol for patients with suspected dengue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/34\">",
"     34",
"    </a>",
"    ]. Daily outpatient visits were conducted and referral for hospitalization was made only for one of the following signs:",
"   </p>",
"   <p>",
"    <ul class=\"bulletCompact-block\">",
"     <li>",
"      Blood pressure",
"      <span class=\"nowrap\">",
"       &lt;90/60",
"      </span>",
"      mmHg",
"     </li>",
"     <li>",
"      Hematocrit &gt;50 percent",
"     </li>",
"     <li>",
"      Platelet count",
"      <span class=\"nowrap\">",
"       &lt;50,000/mm",
"       <sup>",
"        3",
"       </sup>",
"      </span>",
"     </li>",
"     <li>",
"      Evidence of bleeding other than petechiae",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    There were no deaths among 162 adults studied (average age 27 years), of whom 28 (17 percent) had DHF; the overall hospitalization rate was 44 percent. All of the subjects with DHF either were hospitalized or qualified for hospitalization according to the protocol, whereas 89 (66 percent) of the subjects without DHF were managed without hospitalization.",
"   </p>",
"   <p>",
"    For many resource-poor dengue endemic countries, routine laboratory testing is not readily available. One study of 1250 children aged 2 months to 10 years presenting to a pediatric hospital in southern Vietnam evaluated whether an assessment tool designed for first level healthcare workers, using only clinical signs, could appropriately classify and guide management of acute illnesses in an endemic area [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/35\">",
"     35",
"    </a>",
"    ]. The assessment tool was derived from the",
"    <span class=\"nowrap\">",
"     WHO/UNICEF",
"    </span>",
"    \"Integrated Management of Childhood Illness\" algorithm designed for use in Africa and was modified to include common signs and symptoms of DHF. Although the 20 children with established dengue shock syndrome were correctly identified as requiring urgent hospitalization, classification of less severe DHF was imperfect and reevaluation within one to two days was needed to detect children who developed shock.",
"   </p>",
"   <p>",
"    Several studies have applied decision tree analysis to develop algorithms for early management of patients with suspected dengue, although the study populations and conclusions have differed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/36-38\">",
"     36-38",
"    </a>",
"    ]. Until these findings can be externally validated in a prospective fashion, the use of any of these specific algorithms in clinical practice cannot be recommended.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h1\">",
"     FUTURE DIRECTIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;To develop an anti-dengue drug, animal model systems are needed for drug testing. A dengue mouse model has been validated and demonstrated to be a suitable test system for antiviral drugs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/39\">",
"     39",
"    </a>",
"    ]. In one study, administration of an antiviral agent targeting dengue RNA-dependent RNA polymerase significantly reduced viremia in a dose-dependent manner [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/808/abstract/40\">",
"     40",
"    </a>",
"    ]. Furthermore, reduced levels of viremia were associated with declining levels of proinflammatory cytokines.",
"   </p>",
"   <p>",
"    These results suggest that lowering viremia may ameliorate the severity of dengue fever symptoms and possibly reduce the risk of progression to dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS).",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, &ldquo;The Basics&rdquo; and &ldquo;Beyond the Basics.&rdquo; The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on &ldquo;patient info&rdquo; and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topic (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?16/27/16818?source=see_link\">",
"       \"Patient information: Dengue fever (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H846381\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Dengue is a febrile illness that is caused by any one of four serotypes of this flavivirus (DEN-1, DEN-2, DEN-3, and DEN-4). It is endemic in more than 100 countries in tropical and subtropical regions of the world and causes an estimated 50 million infections annually worldwide. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Epidemiologic studies have demonstrated that the greatest risk factor for the development of dengue hemorrhagic fever (DHF) or dengue shock syndrome (DSS) is secondary infection with a different dengue serotype from the original infecting virus. Thus, severe disease occurs primarily in patients who reside in hyperendemic areas where multiple serotypes circulate simultaneously. (See",
"      <a class=\"local\" href=\"#H1\">",
"       'Introduction'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      The greatest risk for dengue virus infection is among individuals residing in endemic areas. (See",
"      <a class=\"local\" href=\"#H2\">",
"       'Prevention'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Mosquito control is the most effective approach to the prevention of dengue transmission. (See",
"      <a class=\"local\" href=\"#H4\">",
"       'Mosquito control'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      To date, there is no licensed vaccine available for preventing dengue. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Vaccination'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Most travelers from non-endemic countries are at exceedingly low risk for DHF because they lack previous exposure to dengue viruses. Possible exceptions include immigrants from endemic areas subsequently returning to their countries of origin and frequent international travelers. (See",
"      <a class=\"local\" href=\"#H6\">",
"       'Recommendations for travelers'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Patients with dengue should be cautioned to maintain their fluid intake to avoid dehydration and to take",
"      <a class=\"drug drug_general\" href=\"UTD.htm?15/27/15802?source=see_link\">",
"       acetaminophen",
"      </a>",
"      as needed for fevers and myalgias.",
"      <a class=\"drug drug_general\" href=\"UTD.htm?24/7/24698?source=see_link\">",
"       Aspirin",
"      </a>",
"      or nonsteroidal antiinflammatory agents should generally be avoided. (See",
"      <a class=\"local\" href=\"#H8\">",
"       'Management of fever'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      It is important to manage plasma leakage in DHF with intravascular volume repletion to prevent or reverse hypovolemic shock. Blood transfusion is appropriate in patients with significant bleeding. The adequacy of fluid repletion should be assessed by serial determination of hematocrit, blood pressure, pulse, and urine output. (See",
"      <a class=\"local\" href=\"#H10\">",
"       'Management of plasma leakage'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Early identification of patients at higher risk for shock and other complications of dengue is important. Patients with suspected dengue who have none of the warning signs for more severe illness and can maintain their fluid intake can be managed as outpatients, but may need daily re-evaluation. (See",
"      <a class=\"local\" href=\"#H13\">",
"       'Outpatient management and early recognition of DHF/severe dengue'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/1\">",
"      Kalayanarooj S, Vaughn DW, Nimmannitya S, et al. Early clinical and laboratory indicators of acute dengue illness. J Infect Dis 1997; 176:313.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/2\">",
"      Gubler DJ. Dengue and dengue hemorrhagic fever. Clin Microbiol Rev 1998; 11:480.",
"     </a>",
"    </li>",
"    <li>",
"     World Health Organization. Geneva: WHO, 2002.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/4\">",
"      Anderson KB, Chunsuttiwat S, Nisalak A, et al. Burden of symptomatic dengue infection in children at primary school in Thailand: a prospective study. Lancet 2007; 369:1452.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/5\">",
"      Halstead SB. The XXth century dengue pandemic: need for surveillance and research. World Health Stat Q 1992; 45:292.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/6\">",
"      Burke DS, Nisalak A, Johnson DE, Scott RM. A prospective study of dengue infections in Bangkok. Am J Trop Med Hyg 1988; 38:172.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/7\">",
"      Gubler DJ. Aedes aegypti and Aedes aegypti-borne disease control in the 1990s: top down or bottom up. Charles Franklin Craig Lecture. Am J Trop Med Hyg 1989; 40:571.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/8\">",
"      Halstead SB. Selective primary health care: strategies for control of disease in the developing world. XI. Dengue. Rev Infect Dis 1984; 6:251.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/9\">",
"      Kay B, Vu SN. New strategy against Aedes aegypti in Vietnam. Lancet 2005; 365:613.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/10\">",
"      Hales S, van Panhuis W. A new strategy for dengue control. Lancet 2005; 365:551.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/11\">",
"      Monath TP. Dengue and yellow fever--challenges for the development and use of vaccines. N Engl J Med 2007; 357:2222.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/12\">",
"      Endy TP, Nisalak A, Chunsuttitwat S, et al. Relationship of preexisting dengue virus (DV) neutralizing antibody levels to viremia and severity of disease in a prospective cohort study of DV infection in Thailand. J Infect Dis 2004; 189:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/13\">",
"      Pierson TC, Diamond MS. Molecular mechanisms of antibody-mediated neutralisation of flavivirus infection. Expert Rev Mol Med 2008; 10:e12.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/14\">",
"      Sukupolvi-Petty S, Austin SK, Purtha WE, et al. Type- and subcomplex-specific neutralizing antibodies against domain III of dengue virus type 2 envelope protein recognize adjacent epitopes. J Virol 2007; 81:12816.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/15\">",
"      Durbin AP, Whitehead SS. Dengue vaccine candidates in development. Curr Top Microbiol Immunol 2010; 338:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/16\">",
"      Guirakhoo F, Pugachev K, Zhang Z, et al. Safety and efficacy of chimeric yellow Fever-dengue virus tetravalent vaccine formulations in nonhuman primates. J Virol 2004; 78:4761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/17\">",
"      Sabchareon A, Wallace D, Sirivichayakul C, et al. Protective efficacy of the recombinant, live-attenuated, CYD tetravalent dengue vaccine in Thai schoolchildren: a randomised, controlled phase 2b trial. Lancet 2012; 380:1559.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/18\">",
"      Mitrakul C, Poshyachinda M, Futrakul P, et al. Hemostatic and platelet kinetic studies in dengue hemorrhagic fever. Am J Trop Med Hyg 1977; 26:975.",
"     </a>",
"    </li>",
"    <li>",
"     Anonymous. Dengue: guidelines for diagnosis, treatment, prevention and control- new edition. World Health Organization, Geneva 2009, p. 1.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/20\">",
"      Thomas L, Kaidomar S, Kerob-Bauchet B, et al. Prospective observational study of low thresholds for platelet transfusion in adult dengue patients. Transfusion 2009; 49:1400.",
"     </a>",
"    </li>",
"    <li>",
"     WHO Regional Office for Southeast Asia. Comprehensive guidelines for prevention and control of dengue and dengue haemorrhagic fever. Revised and expanded version. SEARO Technical Publication Series, New Delhi 2011.",
"    </li>",
"    <li>",
"     Nimmannitya S. Dengue hemorrhagic fever: Diagnosis and management. In: Dengue and Dengue Hemorrhagic Fever, Gubler DJ, Kuno G (Eds), CAB International, Wallingford 1997. p.133.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/23\">",
"      Ngo NT, Cao XT, Kneen R, et al. Acute management of dengue shock syndrome: a randomized double-blind comparison of 4 intravenous fluid regimens in the first hour. Clin Infect Dis 2001; 32:204.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/24\">",
"      Dung NM, Day NP, Tam DT, et al. Fluid replacement in dengue shock syndrome: a randomized, double-blind comparison of four intravenous-fluid regimens. Clin Infect Dis 1999; 29:787.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/25\">",
"      Wills BA, Nguyen MD, Ha TL, et al. Comparison of three fluid solutions for resuscitation in dengue shock syndrome. N Engl J Med 2005; 353:877.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/26\">",
"      Panpanich R, Sornchai P, Kanjanaratanakorn K. Corticosteroids for treating dengue shock syndrome. Cochrane Database Syst Rev 2006; :CD003488.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/27\">",
"      Tam DT, Ngoc TV, Tien NT, et al. Effects of short-course oral corticosteroid therapy in early dengue infection in Vietnamese patients: a randomized, placebo-controlled trial. Clin Infect Dis 2012; 55:1216.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/28\">",
"      Dimaano EM, Saito M, Honda S, et al. Lack of efficacy of high-dose intravenous immunoglobulin treatment of severe thrombocytopenia in patients with secondary dengue virus infection. Am J Trop Med Hyg 2007; 77:1135.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/29\">",
"      Chuansumrit A, Wangruangsatid S, Lektrakul Y, et al. Control of bleeding in children with Dengue hemorrhagic fever using recombinant activated factor VII: a randomized, double-blind, placebo-controlled study. Blood Coagul Fibrinolysis 2005; 16:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/30\">",
"      Salgado D, Zabaleta TE, Hatch S, et al. Use of pentoxifylline in treatment of children with dengue hemorrhagic fever. Pediatr Infect Dis J 2012; 31:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/31\">",
"      Nimmannitya S, Thisyakorn U, Hemsrichart V. Dengue haemorrhagic fever with unusual manifestations. Southeast Asian J Trop Med Public Health 1987; 18:398.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/32\">",
"      Rigau-P&eacute;rez JG, Laufer MK. Dengue-related deaths in Puerto Rico, 1992-1996: diagnosis and clinical alarm signals. Clin Infect Dis 2006; 42:1241.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/33\">",
"      Libraty DH, Young PR, Pickering D, et al. High circulating levels of the dengue virus nonstructural protein NS1 early in dengue illness correlate with the development of dengue hemorrhagic fever. J Infect Dis 2002; 186:1165.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/34\">",
"      Chin CK, Kang BH, Liew BK, et al. Protocol for out-patient management of dengue illness in young adults. J Trop Med Hyg 1993; 96:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/35\">",
"      Cao XT, Ngo TN, Kneen R, et al. Evaluation of an algorithm for integrated management of childhood illness in an area of Vietnam with dengue transmission. Trop Med Int Health 2004; 9:573.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/36\">",
"      Tanner L, Schreiber M, Low JG, et al. Decision tree algorithms predict the diagnosis and outcome of dengue fever in the early phase of illness. PLoS Negl Trop Dis 2008; 2:e196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/37\">",
"      Lee VJ, Lye DC, Sun Y, Leo YS. Decision tree algorithm in deciding hospitalization for adult patients with dengue haemorrhagic fever in Singapore. Trop Med Int Health 2009; 14:1154.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/38\">",
"      Potts JA, Gibbons RV, Rothman AL, et al. Prediction of dengue disease severity among pediatric Thai patients using early clinical laboratory indicators. PLoS Negl Trop Dis 2010; 4:e769.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/39\">",
"      Johnson AJ, Roehrig JT. New mouse model for dengue virus vaccine testing. J Virol 1999; 73:783.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/808/abstract/40\">",
"      Schul W, Liu W, Xu HY, et al. A dengue fever viremia model in mice shows reduction in viral replication and suppression of the inflammatory response after treatment with antiviral drugs. J Infect Dis 2007; 195:665.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 3030 Version 11.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1004-183.166.191.243-84F2B57B49-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_808=[""].join("\n");
var outline_f0_50_808=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H846381\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      PREVENTION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      Public health efforts in endemic areas",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      - Mosquito control",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      - Vaccination",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      Recommendations for travelers",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      THERAPY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      Management of fever",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      Management of significant bleeding",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      Management of plasma leakage",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      - Treatment of shock",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H24968065\">",
"      - Adjunctive therapy for shock and/or bleeding",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      - Unusual complications",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Outpatient management and early recognition of DHF/severe dengue",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      FUTURE DIRECTIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H846381\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"ID/3030\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"ID/3030|ALG\">",
"      <a href=\"#\" title=\"ALGORITHMS\">",
"       ALGORITHMS",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_algorithm\" href=\"UTD.htm?30/45/31440\" title=\"algorithm 1\">",
"      Management algorithm for dengue fever with hypotensive shock",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/34/18985?source=related_link\">",
"      Clinical presentation and diagnosis of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/55/4984?source=related_link\">",
"      Epidemiology of dengue virus infections",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?36/5/36953?source=related_link\">",
"      Pathogenesis of dengue virus infection",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?16/27/16818?source=related_link\">",
"      Patient information: Dengue fever (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?13/20/13639?source=related_link\">",
"      Treatment of severe hypovolemia or hypovolemic shock in adults",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_50_809="Medical prophylaxis of postoperative Crohn's disease";
var content_f0_50_809=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"4\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Medical prophylaxis of postoperative Crohn's disease",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/809/contributors\">",
"     Authors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/809/contributors\">",
"     Puneeta Tandon, MD, FRCPC",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/809/contributors\">",
"     Robert M Penner, BSc, MD, FRCPC, MSc",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/809/contributors\">",
"     Richard N Fedorak, MD, FRCPC",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/809/contributors\">",
"     Section Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/809/contributors\">",
"     J Thomas LaMont, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/809/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/809/contributors\">",
"     Shilpa Grover, MD, MPH",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/50/809/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Dec 20, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H5501037\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Crohn's disease is a chronic inflammatory bowel disease that results in significant morbidity and economic burden [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/1,2\">",
"     1,2",
"    </a>",
"    ]. Surgical intervention rates are approximately 70 percent after ten years from diagnosis, although improvements in medical therapy may be decreasing the need for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/3,4\">",
"     3,4",
"    </a>",
"    ]. The most common indications for surgery are failure of medical therapy and intestinal obstruction. The high rate of postoperative recurrence has stimulated multiple studies of prophylactic therapy.",
"   </p>",
"   <p>",
"    This topic will discuss medical prophylaxis after surgery for patients with Crohn's disease. Other aspects of the medical and surgical management of Crohn's disease are discussed separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link\">",
"     \"Surgical management of ulcerative colitis\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=see_link\">",
"     \"Overview of the medical management of mild to moderate Crohn's disease in adults\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=see_link\">",
"     \"Overview of the management of Crohn's disease in children and adolescents\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=see_link\">",
"     \"Overview of the medical management of severe or refractory Crohn's disease in adults\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501044\">",
"    <span class=\"h1\">",
"     RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Postoperative recurrence can be defined by endoscopic findings or clinical symptoms.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501051\">",
"    <span class=\"h2\">",
"     Endoscopic",
"    </span>",
"    &nbsp;&mdash;&nbsp;Endoscopic recurrence precedes clinical recurrence. It occurs most commonly at the site of surgical anastomosis, and is characterized initially by aphthous and serpiginous ulceration [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/5\">",
"     5",
"    </a>",
"    ]. A meta-analysis of the placebo rates of severe endoscopic recurrence in postoperative Crohn's disease estimated that among patients treated with placebo, the clinical relapse rate was 24 percent and the severe endoscopic recurrence rate was 50 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/6\">",
"     6",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other studies have provided estimates of the time frame of endoscopic recurrence. In a cohort of 89 patients who had undergone ileal resection, endoscopic findings were present in 73 percent of patients within one year and 85 percent within three years of resection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/5,7\">",
"     5,7",
"    </a>",
"    ]. Similar findings were described in another report in which 72 percent of patients had endoscopic findings present after one year without a significant increase in recurrence in a 10-year period (77 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/8\">",
"     8",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The recurrence rate may be much lower in patients with Crohn's colitis who undergo a total colectomy and ileostomy as compared to ileal resection. Such patients have only a 10 percent recurrence rate in the small intestine at 10 years, usually in the bowel immediately above the stoma [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/4,9,10\">",
"     4,9,10",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The explanation for this difference in recurrence rate between those who have a resection and anastomosis versus colectomy and ileostomy may be related to contact with intestinal contents in the neoterminal ileum [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. In an illustrative report, three patients with Crohn's disease who had undergone a curative ileocolonic resection with ileocolonic anastomosis and temporary protective proximal loop ileostomy had no evidence of ileitis six months after resection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/11\">",
"     11",
"    </a>",
"    ]. However, infusion of the ileostomy contents into the bypassed ileal segment for seven days resulted in morphologic evidence of focal inflammation on ileal biopsy. Thus, intestinal contents including bile salts, digestive enzymes, bacteria, and dietary antigens may trigger the postoperative recurrence of Crohn's disease in the terminal ileum proximal to the ileocolonic anastomosis in the first days after surgery. These findings suggest that prophylactic therapy should begin soon after resection and anastomosis are performed, and continue indefinitely.",
"   </p>",
"   <p>",
"    Whether the severity of endoscopic findings correlates with the clinical course is uncertain. While some studies have found that severe radiologic or endoscopic findings (such as stricture, deep ulceration, cobblestoning, or fistulization) predicted symptomatic recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/5,13\">",
"     5,13",
"    </a>",
"    ], others have shown poor correlation between symptoms, endoscopy, and repeat surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/13-16\">",
"     13-16",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501058\">",
"    <span class=\"h2\">",
"     Clinical",
"    </span>",
"    &nbsp;&mdash;&nbsp;Clinical recurrence is based upon signs and symptoms of disease. The Crohn's disease activity index (CDAI) has often been used to provide a more objective measure of clinical activity (",
"    <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=see_link\">",
"     calculator 1",
"    </a>",
"    ). In one report, symptomatic recurrence based on elevation of the CDAI was observed in 20 and 34 percent of patients with endoscopic recurrence at one and three years, respectively [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/5\">",
"     5",
"    </a>",
"    ]. Clinical recurrence rates as high as 55 percent at 5 years and 76 percent at 15 years have been described in other reports [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/14\">",
"     14",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    A meta-analysis of the placebo rates of clinical relapse in postoperative Crohn's disease estimated that among patients treated with placebo, the pooled clinical relapse rate was 24 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/6\">",
"     6",
"    </a>",
"    ]. Follow-up duration among the included trials ranged from three to up to five years. However, there was significant variability among the studies in part due to differences in the length of follow-up.",
"   </p>",
"   <p>",
"    Repeat surgery is required in approximately 25 percent of patients within five years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/17-20\">",
"     17-20",
"    </a>",
"    ]. After ileocolonic resection and anastomosis, approximately 50 percent of patients presenting with clinical symptoms have repeat surgery within 10 years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/17-20\">",
"     17-20",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501065\">",
"    <span class=\"h1\">",
"     PREDICTORS OF RECURRENCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Disease patterns, surgical techniques, and clinical variables have been found to be risk factors for postoperative recurrence, although the quality and consistency of the data are variable [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Disease duration &ndash; Shorter preoperative disease duration is associated with an increased rate of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/22\">",
"       22",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Widespread disease &ndash; The presence of proximal gastrointestinal (duodenum or jejunum) and diffuse widespread disease that involves the colon has been associated with clinical and endoscopic recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/18,23-26\">",
"       18,23-26",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Stricturing versus penetrating disease &ndash; The data regarding this feature are conflicting. One series found that recurrence after conservative surgery was more likely in young patients with stricturing disease [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/27\">",
"       27",
"      </a>",
"      ]. In contrast, another series found no cases of recurrence within three years in 12 patients with stricturing disease compared with 12 of 22 patients (55 percent) who had penetrating disease [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/28\">",
"       28",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Fistulization &ndash; Conflicting data also exist regarding whether presentation with intestinal fistulas increases the risk of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/22,29-31\">",
"       22,29-31",
"      </a>",
"      ]. One report suggested that the risk of recurrence with another fistula was increased, although the overall risk of recurrence was not [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/32\">",
"       32",
"      </a>",
"      ]. A later study suggested a significantly increased risk of recurrence in patients with fistulizing disease (odds ratio 4.09) [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/33\">",
"       33",
"      </a>",
"      ]. In general, patients with a history of fistulas have a worse prognosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/10\">",
"       10",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Perianal disease &ndash; The presence of perianal fistulous disease is a risk factor for increased risk of recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/34\">",
"       34",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Surgical technique &ndash; Side to side anastomosis of an ileocolic resection is associated with lower recurrence rates than end to end anastomosis [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/35\">",
"       35",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Smoking &ndash; Several studies have suggested that smoking increases the risk of clinical, endoscopic, and surgical recurrence [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/36-40\">",
"       36-40",
"      </a>",
"      ], although a larger prospective population-based study did not support this conclusion [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/41\">",
"       41",
"      </a>",
"      ].",
"     </li>",
"     <li>",
"      Genetics &ndash; Whether genetic factors predict disease recurrence has not been well studied. One report found that patients with the",
"      <span class=\"nowrap\">",
"       Nod2/CARD15",
"      </span>",
"      mutation had a higher rate of postoperative recurrence and required surgery earlier compared with patients with Crohn's not carrying the mutation [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/42\">",
"       42",
"      </a>",
"      ]. (See",
"      <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=see_link\">",
"       \"Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease\"",
"      </a>",
"      .)",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501072\">",
"    <span class=\"h1\">",
"     POSTOPERATIVE SURVEILLANCE",
"    </span>",
"    &nbsp;&mdash;&nbsp;Colonoscopy is the best modality for assessing recurrence of mucosal Crohn's disease at anastomotic sites and the ileum. Since mucosal inflammation precedes clinical recurrence, we suggest performing a colonoscopy within the first year after surgery and then treatment should be modified based on patient's risk factors and endoscopic findings.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501079\">",
"    <span class=\"h1\">",
"     MEDICAL PROPHYLAXIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The high rate of postoperative recurrence has stimulated multiple studies of prophylactic therapy. However, optimal approaches have not yet been defined. A meta-analysis, including 23 studies, of the use of medical therapies for the prevention of postoperative recurrence of Crohn's disease concluded that nitroimidazole antibiotics,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    , and immunosuppressive therapies with",
"    <span class=\"nowrap\">",
"     <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"      azathioprine",
"     </a>",
"     /6-mercaptopurine",
"    </span>",
"    <span class=\"nowrap\">",
"     (AZA/6-MP),",
"    </span>",
"    all appear superior to placebo for the prevention of postoperative recurrence of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"     43",
"    </a>",
"    ]. There were insufficient randomized controlled trials of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    ,",
"    <a class=\"drug drug_general\" href=\"UTD.htm?32/7/32880?source=see_link\">",
"     budesonide",
"    </a>",
"    , tenovil, interleukin 10, and probiotics to draw conclusions regarding efficacy. Despite several randomized trials evaluating the efficacy of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?8/28/8647?source=see_link\">",
"     sulfasalazine",
"    </a>",
"    in the prevention of postoperative recurrence, the benefit of their use has not been established [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43-46\">",
"     43-46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The risks and benefits of individual treatments need to be weighed. As an example, the use of immunosuppressive therapy in the postoperative period may be considered problematic. However, a review of perioperative safety profiles of drugs commonly administered for Crohn's disease found compelling evidence of adverse effects on wound healing only for glucocorticoids, but not for immunomodulators or anti-tumor necrosis factor (anti-TNF) agents [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/47\">",
"     47",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501086\">",
"    <span class=\"h2\">",
"     Antibiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;The observation that recurrent disease develops only when the mucosa is re-exposed to luminal contents suggests that bacteria may have a role in promoting disease recurrence and provides a rationale for controlled trials of antibiotic prophylaxis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/11,12\">",
"     11,12",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In two studies, the use of nitroimidazole antibiotics appeared to reduce the risk of clinical and endoscopic recurrence relative to placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/48,49\">",
"     48,49",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      An initial trial included 60 patients who underwent curative ileal resection and primary anastomosis, who were randomly assigned to three months of therapy with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (20",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) or placebo one week after surgical resection [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/48\">",
"       48",
"      </a>",
"      ]. Compared with placebo, metronidazole therapy resulted in a lower rate of total (52 versus 75 percent) and severe (13 versus 43 percent) endoscopic recurrence in the neoterminal ileum at three months and a lower clinical recurrence rate at one year (4 versus 25 percent).",
"     </li>",
"     <li>",
"      A second study included 80 patients who had undergone ileal or ileocolonic resection who were randomly assigned to ornidazole (not available in the United States) or placebo for one year [",
"      <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/49\">",
"       49",
"      </a>",
"      ]. The clinical recurrence rate was significantly lower in the ornidazole group at 12 months (8 versus 38 percent). Adverse effects requiring discontinuation of medication were significantly more common in the treatment group (32 versus 13 percent). The majority of dropouts were due to a metallic taste and gastrointestinal upset. Paresthesias and peripheral neuropathy were self-limited after discontinuation of the drug and overall side effects were less common than have been reported with metronidazole.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    These data suggest a modest benefit from the short-term use of nitroimidazole antibiotics in preventing postoperative recurrence during the first year after resection in patients with ileal or ileocolonic disease. However, their role is uncertain, particularly considering the need for long-term therapy and the potential for adverse effects when these medications are prescribed for long periods.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501093\">",
"    <span class=\"h2\">",
"     Mesalamine",
"    </span>",
"    &nbsp;&mdash;&nbsp;Multiple randomized controlled trials have evaluated",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    agents for prevention of postoperative recurrence but have produced discordant results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/50-56\">",
"     50-56",
"    </a>",
"    ]. A 2011 meta-analysis of nine randomized controlled trials found that mesalamine agents were more effective than placebo for preventing relapse following surgery (odds ratio 0.7) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/57\">",
"     57",
"    </a>",
"    ]. The number needed to treat to prevent one recurrence was approximately 16 to 19.",
"   </p>",
"   <p>",
"    A 2009 meta-analysis included five studies that examined the effect of",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    compared with placebo. That analysis found that mesalamine therapy was associated with a significantly reduced risk of severe endoscopic recurrence (RR = 0.5) and clinical recurrence (RR = 0.76) compared with placebo [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"     43",
"    </a>",
"    ]. Patient withdrawal and serious adverse events were similar in both treatment groups.",
"   </p>",
"   <p>",
"    Another study of 256 patients compared the effect of high dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    (4 grams daily) versus low dose (2.4 grams daily) with placebo for one year following resection. The rate of any endoscopic recurrence at one year was greater in the low-dose group than in the high-dose group (62 versus 46 percent), yet there was no significant difference in the rate of severe endoscopic recurrence between the two doses [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/58\">",
"     58",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    These data suggest that",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    prophylaxis is associated with a modest benefit in preventing relapse. Although there remains uncertainty about its efficacy, mesalamine is generally safe and well tolerated and, thus, it is a reasonable option in some patients. Such patients include those who appear to benefit from mesalamine prior to resection, those without high-risk features for relapse, or those unwilling to consider agents with more side effects.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501100\">",
"    <span class=\"h2\">",
"     Azathioprine and 6-MP",
"    </span>",
"    &nbsp;&mdash;&nbsp;Most of the experience with AZA (2.0 to 2.5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    daily) or 6-MP (50 mg daily) following surgical resection has come from patients with Crohn's disease who have undergone intestinal resection, rather than colectomy. In patients requiring resection secondary to complications such as obstruction, fistula, perforation, or abscess, it is preferable not to resect other areas of the intestinal tract that are minimally involved, and in which complications have not occurred. In these circumstances, AZA or 6-MP may be effective for maintaining remission in the minimally involved areas, and delaying recurrence in the area of resection.",
"   </p>",
"   <p>",
"    The magnitude of benefit of AZA and 6-MP was best demonstrated in two meta-analyses of controlled trials involving patients who had undergone surgery for Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43,59\">",
"     43,59",
"    </a>",
"    ]. Compared with placebo, AZA or 6-MP was associated with a significantly decreased risk of clinical recurrence (RR = 0.59) and severe endoscopic recurrence (RR = 0.64) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"     43",
"    </a>",
"    ]. Both agents were significantly more effective than placebo with or without antibiotic induction and were also more effective than",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    in preventing clinical recurrence at one [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"     43",
"    </a>",
"    ] and two years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/59\">",
"     59",
"    </a>",
"    ], and preventing severe postoperative endoscopic recurrences at one year [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43,59\">",
"     43,59",
"    </a>",
"    ]. While drug withdrawal because of adverse effects was significantly higher in the patients treated with AZA or 6-MP (17 versus 10 percent) than in placebo, with or without antibiotic induction or mesalamine, serious adverse events were similar among treatments [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/59\">",
"     59",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In contrast to the findings in these meta-analyses, a study performed in a highly selected patient population of laparoscopically treated Crohn's disease patients with terminal ileal disease found that the use of immunosuppressive prophylaxis (mostly AZA and 6-MP) was not associated with a delay in recurrence [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/60\">",
"     60",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The benefit of AZA may be increased (by approximately 20 percent) by combining it with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"     metronidazole",
"    </a>",
"    (in the first three months only) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/59,61\">",
"     59,61",
"    </a>",
"    ]. Further studies are needed to clarify the magnitude of benefit and identify which subsets of patients may benefit most. In the meantime, many use this combination of drugs in selected patients who are considered to be at high risk for relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/62\">",
"     62",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5501065\">",
"     'Predictors of recurrence'",
"    </a>",
"    above and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=see_link&amp;anchor=H165136591#H165136591\">",
"     \"Surgical management of ulcerative colitis\", section on 'Immunosuppressive therapy'",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=see_link&amp;anchor=H3879301#H3879301\">",
"     \"Operative management of Crohn's disease of the small bowel and colon\", section on 'Immunosuppressive therapy'",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    The optimal duration of therapy with immunomodulators is unknown. In a study of 326 Crohn's disease patients after their first intestinal surgery, treatment with AZA or 6-MP for &gt;36 months decreased the risk of surgical recurrence by 41 percent compared with no treatment or treatment for less than 3 months [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/40\">",
"     40",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=see_link\">",
"     \"Immunomodulator therapy in Crohn's disease\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501107\">",
"    <span class=\"h2\">",
"     Other therapies",
"    </span>",
"    &nbsp;&mdash;&nbsp;Other therapies have been reported for the medical prophylaxis of postoperative Crohn's disease; however, there are insufficient randomized controlled trials to draw conclusions.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501114\">",
"    <span class=\"h3\">",
"     Probiotics",
"    </span>",
"    &nbsp;&mdash;&nbsp;Five studies were identified in the meta-analysis which evaluated the effect of probiotics for postoperative maintenance of Crohn's disease [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"     43",
"    </a>",
"    ]. None of these studies showed significant evidence to support the use of probiotics for postoperative maintenance of Crohn's disease. Three small controlled trials (not included in the meta-analysis) have had conflicting results [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/63-65\">",
"     63-65",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=see_link\">",
"     \"Probiotics for gastrointestinal diseases\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501121\">",
"    <span class=\"h3\">",
"     Infliximab",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is limited experience with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    for prevention of relapse. A nonrandomized study compared seven patients who received infliximab plus low dose",
"    <a class=\"drug drug_general\" href=\"UTD.htm?23/38/24170?source=see_link\">",
"     methotrexate",
"    </a>",
"    with 16 patients who received",
"    <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"     mesalamine",
"    </a>",
"    alone [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/66\">",
"     66",
"    </a>",
"    ]. None of the patients in the",
"    <span class=\"nowrap\">",
"     infliximab/methotrexate",
"    </span>",
"    group had endoscopic or clinical recurrence during two years of follow-up compared with 12 of 16 patients with recurrence in the mesalamine group.",
"   </p>",
"   <p>",
"    A randomized controlled trial in 24 patients who had undergone ileocolonic resection found a significantly lower endoscopic recurrence rate one year postoperatively with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    compared with placebo (9 versus 85 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/67\">",
"     67",
"    </a>",
"    ]. As a secondary outcome, the trial also showed a nonsignificant trend towards improved clinical remission rates.",
"   </p>",
"   <p>",
"    In a postoperative cohort study of 12 patients treated with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    (5",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    at two, six, and eight weeks following surgery and then every eight weeks for 24 months), 10 of 12 patients experienced endoscopic relapse within four months of discontinuing the medication [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/68\">",
"     68",
"    </a>",
"    ]. All patients without recurrence were then treated with a lower dose of infliximab (3",
"    <span class=\"nowrap\">",
"     mg/kg",
"    </span>",
"    every eight weeks) with resolution of endoscopic disease in all patients at one year.",
"   </p>",
"   <p>",
"    Adverse events such as infusion reactions, demyelinating disease, heart failure, and less common side effects have been described following treatment with",
"    <a class=\"drug drug_general\" href=\"UTD.htm?28/6/28776?source=see_link\">",
"     infliximab",
"    </a>",
"    . These risks must be weighed against the potential benefits when considering this agent for prevention of relapse. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=see_link\">",
"     \"Infliximab in Crohn's disease\"",
"    </a>",
"    and",
"    <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=see_link\">",
"     \"Tumor necrosis factor-alpha inhibitors: An overview of adverse effects\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501128\">",
"    <span class=\"h3\">",
"     Elemental enteral nutrition",
"    </span>",
"    &nbsp;&mdash;&nbsp;A single small nonrandomized trial in 40 patients evaluated long-term postoperative enteral nutrition for prevention of endoscopic and clinical relapse [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/809/abstract/69\">",
"     69",
"    </a>",
"    ]. Patients were given an unrestricted, unsupplemented postoperative diet or a low fat diet with nocturnal enteral supplementation with an elemental formulation. After 12 months, clinical recurrence rates were significantly lower in the supplemental group (5 versus 35 percent).",
"   </p>",
"   <p>",
"    Patients were selected for enteral nutrition if they had previously demonstrated compliance with such an approach. In a previous study, the authors noted low compliance with long-term enteral feeding. Thus, further studies are needed to clarify the efficacy and acceptability of this approach.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"PATIENT_INFORMATION\">",
"    <span class=\"h1\">",
"     INFORMATION FOR PATIENTS",
"    </span>",
"    &nbsp;&mdash;&nbsp;UpToDate offers two types of patient education materials, \"The Basics\" and \"Beyond the Basics.\" The Basics patient education pieces are written in plain language, at the 5",
"    <sup>",
"     th",
"    </sup>",
"    to 6",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level, and they answer the four or five key questions a patient might have about a given condition. These articles are best for patients who want a general overview and who prefer short, easy-to-read materials. Beyond the Basics patient education pieces are longer, more sophisticated, and more detailed. These articles are written at the 10",
"    <sup>",
"     th",
"    </sup>",
"    to 12",
"    <sup>",
"     th",
"    </sup>",
"    grade reading level and are best for patients who want in-depth information and are comfortable with some medical jargon.",
"   </p>",
"   <p>",
"    Here are the patient education articles that are relevant to this topic. We encourage you to print or e-mail these topics to your patients. (You can also locate patient education articles on a variety of subjects by searching on \"patient info\" and the keyword(s) of interest.)",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Basics topics (see",
"      <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=see_link\">",
"       \"Patient information: Crohn's disease in adults (The Basics)\"",
"      </a>",
"      )",
"     </li>",
"     <li>",
"      Beyond the Basics topics (see",
"      <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=see_link\">",
"       \"Patient information: Crohn's disease (Beyond the Basics)\"",
"      </a>",
"      )",
"     </li>",
"    </ul>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5501149\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Postoperative recurrence of Crohn's disease can be defined by endoscopic findings or clinical symptoms. Consensus has not been achieved on optimal strategies for prevention of recurrent Crohn's disease after surgery. (See",
"      <a class=\"local\" href=\"#H5501044\">",
"       'Recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Disease patterns, surgical techniques, and clinical variables appear to be risk factors for postoperative recurrence. We recommend identifying those patients at high risk and considering the risk versus benefit of treating these patients more aggressively. (See",
"      <a class=\"local\" href=\"#H5501065\">",
"       'Predictors of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Smoking cessation should be strongly encouraged for all patients who smoke based on the benefits of smoking cessation in general and the benefits for Crohn's disease recurrence. (See",
"      <a class=\"local\" href=\"#H5501065\">",
"       'Predictors of recurrence'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We suggest extended (often lifelong) prophylactic medical therapy for all patients with Crohn's disease after surgery (",
"      <a class=\"grade\" href=\"._grade_5?title=Grade 2B\">",
"       Grade 2B",
"      </a>",
"      ).",
"      <br/>",
"      <br/>",
"      Treatment options with demonstrated efficacy include",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      , imidazole antibiotics,",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      , and 6-MP. (See",
"      <a class=\"local\" href=\"#H5501079\">",
"       'Medical prophylaxis'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      (3 to 4 g daily) in patients who appeared to benefit from mesalamine prior to resection and who do not have high-risk predictive factors for recurrence as listed above, or those unwilling to consider agents with potential for more side effects. (See",
"      <a class=\"local\" href=\"#H5501065\">",
"       'Predictors of recurrence'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H5501093\">",
"       'Mesalamine'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Imidazole antibiotics have more consistent clinical effects than",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      in the short-term, but their long-term use (beyond three months) is greatly limited by side effects. We recommend three months of imidazole antibiotic maintenance therapy in all patients starting immunosuppressive therapy and patients unwilling to consider other long-term therapies or in those with contraindications to immunosuppressive therapy. (See",
"      <a class=\"local\" href=\"#H5501086\">",
"       'Antibiotics'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      We use long-term",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      (2.0 to 2.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) or 6-MP (1.5",
"      <span class=\"nowrap\">",
"       mg/kg",
"      </span>",
"      daily) with",
"      <a class=\"drug drug_general\" href=\"UTD.htm?19/38/20065?source=see_link\">",
"       metronidazole",
"      </a>",
"      (250 mg three times daily for the first three months) in patients who have high-risk predictive factors for recurrence or poor outcomes following recurrence. (See",
"      <a class=\"local\" href=\"#H5501100\">",
"       'Azathioprine and 6-MP'",
"      </a>",
"      above.)",
"      <br/>",
"      <br/>",
"      Factors that put patients at increased risk include:",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"hyphen-block\">",
"     <li>",
"      Jejunal or extensive ileal-colonic disease",
"     </li>",
"     <li>",
"      Initial presentation requiring surgery",
"     </li>",
"     <li>",
"      Age less than 30 years",
"     </li>",
"     <li>",
"      Fistulizing disease",
"     </li>",
"     <li>",
"      Patients undergoing a second resection",
"     </li>",
"     <li>",
"      Failure of medical management",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      In patients with active disease who require resection despite taking adequate doses of",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-MP, we consider anti-tumor necrosis factor (anti-TNF) maintenance therapy postoperatively. However, the risk benefit ratio of this approach must be discussed with the patient, since this therapy has not been evaluated in large randomized controlled trials. (See",
"      <a class=\"local\" href=\"#H5501121\">",
"       'Infliximab'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Whatever the chosen method of postoperative medical maintenance, consideration should be given to endoscopic reassessment of the bowel 9 to 12 months postoperatively. Endoscopically active disease in patients maintained with antibiotics or",
"      <a class=\"drug drug_general\" href=\"UTD.htm?21/44/22215?source=see_link\">",
"       mesalamine",
"      </a>",
"      should prompt consideration of immunomodulator therapy, while active disease on",
"      <a class=\"drug drug_general\" href=\"UTD.htm?38/3/38967?source=see_link\">",
"       azathioprine",
"      </a>",
"      or 6-MP should prompt consideration of substituting or adding anti-TNF therapy. (See",
"      <a class=\"local\" href=\"#H5501072\">",
"       'Postoperative surveillance'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/1\">",
"      Longobardi T, Jacobs P, Bernstein CN. Work losses related to inflammatory bowel disease in the United States: results from the National Health Interview Survey. Am J Gastroenterol 2003; 98:1064.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/2\">",
"      Wolters FL, Russel MG, Stockbr&uuml;gger RW. Systematic review: has disease outcome in Crohn's disease changed during the last four decades? Aliment Pharmacol Ther 2004; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/3\">",
"      Vind I, Riis L, Jess T, et al. Increasing incidences of inflammatory bowel disease and decreasing surgery rates in Copenhagen City and County, 2003-2005: a population-based study from the Danish Crohn colitis database. Am J Gastroenterol 2006; 101:1274.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/4\">",
"      Bernell O, Lapidus A, Hellers G. Recurrence after colectomy in Crohn's colitis. Dis Colon Rectum 2001; 44:647.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/5\">",
"      Rutgeerts P, Geboes K, Vantrappen G, et al. Predictability of the postoperative course of Crohn's disease. Gastroenterology 1990; 99:956.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/6\">",
"      Renna S, Camm&agrave; C, Modesto I, et al. Meta-analysis of the placebo rates of clinical relapse and severe endoscopic recurrence in postoperative Crohn's disease. Gastroenterology 2008; 135:1500.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/7\">",
"      Olaison G, Smedh K, Sj&ouml;dahl R. Natural course of Crohn's disease after ileocolic resection: endoscopically visualised ileal ulcers preceding symptoms. Gut 1992; 33:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/8\">",
"      Rutgeerts P, Geboes K, Vantrappen G, et al. Natural history of recurrent Crohn's disease at the ileocolonic anastomosis after curative surgery. Gut 1984; 25:665.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/9\">",
"      Goligher JC. The long-term results of excisional surgery for primary and recurrent Crohn's disease of the large intestine. Dis Colon Rectum 1985; 28:51.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/10\">",
"      Borley NR, Mortensen NJ, Chaudry MA, et al. Recurrence after abdominal surgery for Crohn's disease: relationship to disease site and surgical procedure. Dis Colon Rectum 2002; 45:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/11\">",
"      D'Haens GR, Geboes K, Peeters M, et al. Early lesions of recurrent Crohn's disease caused by infusion of intestinal contents in excluded ileum. Gastroenterology 1998; 114:262.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/12\">",
"      Rutgeerts P, Goboes K, Peeters M, et al. Effect of faecal stream diversion on recurrence of Crohn's disease in the neoterminal ileum. Lancet 1991; 338:771.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/13\">",
"      McLeod RS, Wolff BG, Steinhart AH, et al. Risk and significance of endoscopic/radiological evidence of recurrent Crohn's disease. Gastroenterology 1997; 113:1823.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/14\">",
"      Achkar JP, Shen B. Medical management of postoperative complications of inflammatory bowel disease: pouchitis and Crohn's disease recurrence. Curr Gastroenterol Rep 2001; 3:484.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/15\">",
"      Kotanagi H, Kramer K, Fazio VW, Petras RE. Do microscopic abnormalities at resection margins correlate with increased anastomotic recurrence in Crohn's disease? Retrospective analysis of 100 cases. Dis Colon Rectum 1991; 34:909.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/16\">",
"      de Jong E, van Dullemen HM, Slors JF, et al. Correlation between early recurrence and reoperation after ileocolonic resection in Crohn's disease: a prospective study. J Am Coll Surg 1996; 182:503.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/17\">",
"      Kim NK, Senagore AJ, Luchtefeld MA, et al. Long-term outcome after ileocecal resection for Crohn's disease. Am Surg 1997; 63:627.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/18\">",
"      Michelassi F, Balestracci T, Chappell R, Block GE. Primary and recurrent Crohn's disease. Experience with 1379 patients. Ann Surg 1991; 214:230.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/19\">",
"      Andrews HA, Lewis P, Allan RN. Prognosis after surgery for colonic Crohn's disease. Br J Surg 1989; 76:1184.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/20\">",
"      Larson DW, Pemberton JH. Current concepts and controversies in surgery for IBD. Gastroenterology 2004; 126:1611.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/21\">",
"      Cho SM, Cho SW, Regueiro M. Postoperative management of Crohn disease. Med Clin North Am 2010; 94:179.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/22\">",
"      Sachar DB, Wolfson DM, Greenstein AJ, et al. Risk factors for postoperative recurrence of Crohn's disease. Gastroenterology 1983; 85:917.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/23\">",
"      Raab Y, Bergstr&ouml;m R, Ejerblad S, et al. Factors influencing recurrence in Crohn's disease. An analysis of a consecutive series of 353 patients treated with primary surgery. Dis Colon Rectum 1996; 39:918.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/24\">",
"      D'Haens GR, Gasparaitis AE, Hanauer SB. Duration of recurrent ileitis after ileocolonic resection correlates with presurgical extent of Crohn's disease. Gut 1995; 36:715.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/25\">",
"      Heimann TM, Greenstein AJ, Lewis B, et al. Prediction of early symptomatic recurrence after intestinal resection in Crohn's disease. Ann Surg 1993; 218:294.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/26\">",
"      Bernell O, Lapidus A, Hellers G. Risk factors for surgery and postoperative recurrence in Crohn's disease. Ann Surg 2000; 231:38.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/27\">",
"      Sampietro GM, Corsi F, Maconi G, et al. Prospective study of long-term results and prognostic factors after conservative surgery for small bowel Crohn's disease. Clin Gastroenterol Hepatol 2009; 7:183.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/28\">",
"      Sachar DB, Lemmer E, Ibrahim C, et al. Recurrence patterns after first resection for stricturing or penetrating Crohn's disease. Inflamm Bowel Dis 2009; 15:1071.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/29\">",
"      Holzheimer RG, Molloy RG, Wittmann DH. Postoperative complications predict recurrence of Crohn's disease. Eur J Surg 1995; 161:129.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/30\">",
"      Aeberhard P, Berchtold W, Riedtmann HJ, Stadelmann G. Surgical recurrence of perforating and nonperforating Crohn's disease. A study of 101 surgically treated Patients. Dis Colon Rectum 1996; 39:80.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/31\">",
"      Lautenbach E, Berlin JA, Lichtenstein GR. Risk factors for early postoperative recurrence of Crohn's disease. Gastroenterology 1998; 115:259.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/32\">",
"      Yamamoto T, Allan RN, Keighley MR. Perforating ileocecal Crohn's disease does not carry a high risk of recurrence but usually re-presents as perforating disease. Dis Colon Rectum 1999; 42:519.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/33\">",
"      Avidan B, Sakhnini E, Lahat A, et al. Risk factors regarding the need for a second operation in patients with Crohn's disease. Digestion 2005; 72:248.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/34\">",
"      Sandborn WJ, Fazio VW, Feagan BG, et al. AGA technical review on perianal Crohn's disease. Gastroenterology 2003; 125:1508.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/35\">",
"      Scarpa M, Ruffolo C, Bertin E, et al. Surgical predictors of recurrence of Crohn's disease after ileocolonic resection. Int J Colorectal Dis 2007; 22:1061.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/36\">",
"      Ryan WR, Allan RN, Yamamoto T, Keighley MR. Crohn's disease patients who quit smoking have a reduced risk of reoperation for recurrence. Am J Surg 2004; 187:219.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/37\">",
"      Moskovitz D, McLeod RS, Greenberg GR, Cohen Z. Operative and environmental risk factors for recurrence of Crohn's disease. Int J Colorectal Dis 1999; 14:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/38\">",
"      Yamamoto T. Factors affecting recurrence after surgery for Crohn's disease. World J Gastroenterol 2005; 11:3971.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/39\">",
"      Cottone M, Orlando A, Modesto I. Postoperative maintenance therapy for inflammatory bowel disease. Curr Opin Gastroenterol 2006; 22:377.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/40\">",
"      Papay P, Reinisch W, Ho E, et al. The impact of thiopurines on the risk of surgical recurrence in patients with Crohn's disease after first intestinal surgery. Am J Gastroenterol 2010; 105:1158.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/41\">",
"      Moum B, Ekbom A, Vatn MH, et al. Clinical course during the 1st year after diagnosis in ulcerative colitis and Crohn's disease. Results of a large, prospective population-based study in southeastern Norway, 1990-93. Scand J Gastroenterol 1997; 32:1005.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/42\">",
"      Alvarez-Lobos M, Arostegui JI, Sans M, et al. Crohn's disease patients carrying Nod2/CARD15 gene variants have an increased and early need for first surgery due to stricturing disease and higher rate of surgical recurrence. Ann Surg 2005; 242:693.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/43\">",
"      Doherty G, Bennett G, Patil S, et al. Interventions for prevention of post-operative recurrence of Crohn's disease. Cochrane Database Syst Rev 2009; :CD006873.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/44\">",
"      Summers RW, Switz DM, Sessions JT Jr, et al. National Cooperative Crohn's Disease Study: results of drug treatment. Gastroenterology 1979; 77:847.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/45\">",
"      Wenckert A, Kristensen M, Eklund AE, et al. The long-term prophylactic effect of salazosulphapyridine (Salazopyrin) in primarily resected patients with Crohn's disease. A controlled double-blind trial. Scand J Gastroenterol 1978; 13:161.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/46\">",
"      Ewe K, Herfarth C, Malchow H, Jesdinsky HJ. Postoperative recurrence of Crohn's disease in relation to radicality of operation and sulfasalazine prophylaxis: a multicenter trial. Digestion 1989; 42:224.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/47\">",
"      Busti AJ, Hooper JS, Amaya CJ, Kazi S. Effects of perioperative antiinflammatory and immunomodulating therapy on surgical wound healing. Pharmacotherapy 2005; 25:1566.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/48\">",
"      Rutgeerts P, Hiele M, Geboes K, et al. Controlled trial of metronidazole treatment for prevention of Crohn's recurrence after ileal resection. Gastroenterology 1995; 108:1617.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/49\">",
"      Rutgeerts P, Van Assche G, Vermeire S, et al. Ornidazole for prophylaxis of postoperative Crohn's disease recurrence: a randomized, double-blind, placebo-controlled trial. Gastroenterology 2005; 128:856.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/50\">",
"      Lochs H, Mayer M, Fleig WE, et al. Prophylaxis of postoperative relapse in Crohn's disease with mesalamine: European Cooperative Crohn's Disease Study VI. Gastroenterology 2000; 118:264.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/51\">",
"      McLeod RS, Wolff BG, Steinhart AH, et al. Prophylactic mesalamine treatment decreases postoperative recurrence of Crohn's disease. Gastroenterology 1995; 109:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/52\">",
"      Caprilli R, Andreoli A, Capurso L, et al. Oral mesalazine (5-aminosalicylic acid; Asacol) for the prevention of post-operative recurrence of Crohn's disease. Gruppo Italiano per lo Studio del Colon e del Retto (GISC). Aliment Pharmacol Ther 1994; 8:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/53\">",
"      Fiasse R, Fontaine F, Vanheuverzwyn R. Prevention of Crohn's disease recurrences after intestinal resection with Eudragid-L-coated 5-aminosalicylic acid. Preliminary results of a one year double-blind placebo controlled study. Gastroenterology 1991; 100:A208.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/54\">",
"      Sutherland LR, Martin F, Bailey RJ, et al. A randomized, placebo-controlled, double-blind trial of mesalamine in the maintenance of remission of Crohn's disease. The Canadian Mesalamine for Remission of Crohn's Disease Study Group. Gastroenterology 1997; 112:1069.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/55\">",
"      Brignola C, Cottone M, Pera A, et al. Mesalamine in the prevention of endoscopic recurrence after intestinal resection for Crohn's disease. Italian Cooperative Study Group. Gastroenterology 1995; 108:345.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/56\">",
"      Florent C, Cortot A, Quandale P, et al. Placebo-controlled clinical trial of mesalazine in the prevention of early endoscopic recurrences after resection for Crohn's disease. Groupe d'Etudes Th&eacute;rapeutiques des Affections Inflammatoires Digestives (GETAID). Eur J Gastroenterol Hepatol 1996; 8:229.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/57\">",
"      Gordon M, Naidoo K, Thomas AG, Akobeng AK. Oral 5-aminosalicylic acid for maintenance of surgically-induced remission in Crohn's disease. Cochrane Database Syst Rev 2011; :CD008414.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/58\">",
"      Caprilli R, Cottone M, Tonelli F, et al. Two mesalazine regimens in the prevention of the post-operative recurrence of Crohn's disease: a pragmatic, double-blind, randomized controlled trial. Aliment Pharmacol Ther 2003; 17:517.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/59\">",
"      Peyrin-Biroulet L, Deltenre P, Ardizzone S, et al. Azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in Crohn's disease: a meta-analysis. Am J Gastroenterol 2009; 104:2089.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/60\">",
"      Malireddy K, Larson DW, Sandborn WJ, et al. Recurrence and impact of postoperative prophylaxis in laparoscopically treated primary ileocolic Crohn disease. Arch Surg 2010; 145:42.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/61\">",
"      D'Haens GR, Vermeire S, Van Assche G, et al. Therapy of metronidazole with azathioprine to prevent postoperative recurrence of Crohn's disease: a controlled randomized trial. Gastroenterology 2008; 135:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/62\">",
"      Sandborn WJ, Feagan BG. The efficacy of azathioprine and 6-mercaptopurine for the prevention of postoperative recurrence in patients with Crohn's disease remains uncertain. Gastroenterology 2004; 127:990.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/63\">",
"      Campieri M, Rizzello F, Venturi A, et al. Combination of antibiotic and probiotic treatment is efficacious in prophylaxis of post-operative recurrence of Crohn's disease: a randomized controlled study vs mesalamine (abstract). Gastroenterology 2000; 118:A781.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/64\">",
"      Madsen K, Backer JL, Leddin D, et al. A randomized controlled trial of VSL#3 for the prevention of endoscopic recurrence following surgery for Crohn's disease (abstract). Gastroenterology 2008; 134 (Suppl):A361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/65\">",
"      Prantera C, Scribano ML, Falasco G, et al. Ineffectiveness of probiotics in preventing recurrence after curative resection for Crohn's disease: a randomised controlled trial with Lactobacillus GG. Gut 2002; 51:405.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/66\">",
"      Sorrentino D, Terrosu G, Avellini C, Maiero S. Infliximab with low-dose methotrexate for prevention of postsurgical recurrence of ileocolonic Crohn disease. Arch Intern Med 2007; 167:1804.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/67\">",
"      Regueiro M, Schraut W, Baidoo L, et al. Infliximab prevents Crohn's disease recurrence after ileal resection. Gastroenterology 2009; 136:441.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/68\">",
"      Sorrentino D, Paviotti A, Terrosu G, et al. Low-dose maintenance therapy with infliximab prevents postsurgical recurrence of Crohn's disease. Clin Gastroenterol Hepatol 2010; 8:591.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/809/abstract/69\">",
"      Yamamoto T, Nakahigashi M, Umegae S, et al. Impact of long-term enteral nutrition on clinical and endoscopic recurrence after resection for Crohn's disease: A prospective, non-randomized, parallel, controlled study. Aliment Pharmacol Ther 2007; 25:67.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 4084 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1003-190.111.122.2-0C8C6D5D65-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_809=[""].join("\n");
var outline_f0_50_809=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H5501149\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501037\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501044\">",
"      RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501051\">",
"      Endoscopic",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501058\">",
"      Clinical",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501065\">",
"      PREDICTORS OF RECURRENCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501072\">",
"      POSTOPERATIVE SURVEILLANCE",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501079\">",
"      MEDICAL PROPHYLAXIS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501086\">",
"      Antibiotics",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501093\">",
"      Mesalamine",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501100\">",
"      Azathioprine and 6-MP",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5501107\">",
"      Other therapies",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5501114\">",
"      - Probiotics",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5501121\">",
"      - Infliximab",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H5501128\">",
"      - Elemental enteral nutrition",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#PATIENT_INFORMATION\">",
"      INFORMATION FOR PATIENTS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H5501149\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   CALCULATORS",
"  </h1>",
"  <div id=\"relatedCalculators\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"calc calc_professional\" href=\"UTD.htm?5/61/6098?source=related_link\" title=\"calculator 1\">",
"      Calculator: Crohn's disease activity index (CDAI)",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?26/48/27401?source=related_link\">",
"      Immune and microbial mechanisms in the pathogenesis of inflammatory bowel disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?7/31/7673?source=related_link\">",
"      Immunomodulator therapy in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/4/44105?source=related_link\">",
"      Infliximab in Crohn's disease",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?37/29/38361?source=related_link\">",
"      Operative management of Crohn's disease of the small bowel and colon",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?40/47/41722?source=related_link\">",
"      Overview of the management of Crohn's disease in children and adolescents",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?18/54/19305?source=related_link\">",
"      Overview of the medical management of mild to moderate Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?6/11/6329?source=related_link\">",
"      Overview of the medical management of severe or refractory Crohn's disease in adults",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_patient\" href=\"UTD.htm?23/40/24196?source=related_link\">",
"      Patient information: Crohn's disease (Beyond the Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_basics\" href=\"UTD.htm?9/56/10115?source=related_link\">",
"      Patient information: Crohn's disease in adults (The Basics)",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?16/10/16554?source=related_link\">",
"      Probiotics for gastrointestinal diseases",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?4/50/4906?source=related_link\">",
"      Surgical management of ulcerative colitis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?39/55/40825?source=related_link\">",
"      Tumor necrosis factor-alpha inhibitors: An overview of adverse effects",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_50_810="Congenital pulmonary airway (cystic adenomatoid) malformation";
var content_f0_50_810=[" <noscript>",
"  <div id=\"javascriptDisabled\">",
"   It seems to us that you have your JavaScript turned off on your browser. JavaScript is required in order for our site to behave correctly.  Please enable your JavaScript to continue use our site.",
"  </div>",
" </noscript>",
" <div id=\"printHeader\">",
"  <div id=\"printHeaderLogo\">",
"   <img alt=\"UpToDate\" src=\"./../images/UTD2_masthead.myextg\">",
"    <img align=\"right\" alt=\"Wolters Kluwer Health\" height=\"40\" src=\"./../images/logoWKH.myextg\" width=\"175\">",
"     <br>",
"      <div id=\"printHeaderText\">",
"       Official reprint from  UpToDate",
"       <sup>",
"        &reg;",
"       </sup>",
"       <br>",
"        <a href=\"file://www.uptodate.com\">",
"         www.uptodate.com",
"        </a>",
"        &copy;2013 UpToDate",
"        <sup>",
"         &reg;",
"        </sup>",
"       </br>",
"      </div>",
"     </br>",
"    </img>",
"   </img>",
"  </div>",
"  <div id=\"printHeaderLinks\">",
"   <a class=\"TOPIC\" href=\"#\" id=\"printHeaderPrint\" rel=\"5\" title=\"Click here to print\">",
"    Print",
"   </a>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a href=\"#\" id=\"printHeaderBack\" title=\"Back to normal view\">",
"    Back",
"   </a>",
"  </div>",
" </div>",
" <!-- TC:TOPIC_PAGE -->",
" <div id=\"topicContent\">",
"  <div id=\"topicTitle\">",
"   Congenital pulmonary airway (cystic adenomatoid) malformation",
"  </div>",
"  <div id=\"topicContributors\">",
"   <div>",
"    <a id=\"authors\">",
"    </a>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/810/contributors\">",
"     Author",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/810/contributors\">",
"     Christopher M Oermann, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/810/contributors\">",
"     Section Editors",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/810/contributors\">",
"     Joseph A Garcia-Prats, MD",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/810/contributors\">",
"     Gregory Redding, MD",
"    </a>",
"    <br/>",
"   </div>",
"   <div>",
"    <a class=\"contributor contributor_credentials contributorType\" href=\"UTD.htm?0/50/810/contributors\">",
"     Deputy Editor",
"    </a>",
"    <br/>",
"    <a class=\"contributor contributor_credentials\" href=\"UTD.htm?0/50/810/contributors\">",
"     Alison G Hoppin, MD",
"    </a>",
"    <br/>",
"   </div>",
"  </div>",
"  <div id=\"disclosures\">",
"   <a href=\"UTD.htm?0/50/810/contributor-disclosure\" target=\"_blank\">",
"    Disclosures",
"   </a>",
"  </div>",
"  <div id=\"reviewProcess\">",
"   <span>",
"    All topics are updated as new evidence becomes available and our",
"   </span>",
"   <a href=\"/home/editorial-policy\" target=\"_blank\">",
"    peer review process",
"   </a>",
"   <span>",
"    is complete.",
"   </span>",
"  </div>",
"  <div id=\"literatureReviewDate\">",
"   <span class=\"emphasis\">",
"    Literature review current through:",
"   </span>",
"   Oct 2013.",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <span class=\"emphasis\">",
"    This topic last updated:",
"   </span>",
"   Jul 12, 2012.",
"  </div>",
"  <div id=\"topicText\">",
"   <p class=\"headingAnchor\" id=\"H1\">",
"    <span class=\"h1\">",
"     INTRODUCTION",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital pulmonary airway malformation (CPAM), previously known as congenital cystic adenomatoid malformation (CCAM), is a rare developmental anomaly of the lower respiratory tract [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/1-5\">",
"     1-5",
"    </a>",
"    ]. Affected patients may present with respiratory distress in the newborn period or may remain asymptomatic until later in life. Many cases are now detected by routine prenatal ultrasound examination. Surgical resection is the definitive treatment.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H2\">",
"    <span class=\"h1\">",
"     EPIDEMIOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital pulmonary airway malformation (CPAM) is a rare developmental malformation of the lower respiratory tract, but they are still the most common congenital lung lesion. The widespread use of antenatal ultrasound examination has resulted in an increase in the prenatal diagnosis of CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/6,7\">",
"     6,7",
"    </a>",
"    ]. Data from large population registries suggest an incidence of congenital lung cysts in the range of 1 per 8300 to 35,000 live births [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/5\">",
"     5",
"    </a>",
"    ]. Large-cyst subtypes account for about 70 percent of CPAMs, or 2 to 8 per 100,000 live births.",
"   </p>",
"   <p>",
"    CPAMs occur sporadically. Their formation is not related to maternal factors such as race, age, or exposures. In some series, lesions that present in infancy have a slight male preponderance [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/7-10\">",
"     7-10",
"    </a>",
"    ], although others found no gender predilection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/11,12\">",
"     11,12",
"    </a>",
"    ]. There is no known genetic predisposition, with the exception of type 4 malformations, which have been associated with a familial pleuropulmonary blastoma syndrome. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pleuropulmonary blastoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H3\">",
"    <span class=\"h1\">",
"     PATHOGENESIS",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital pulmonary airway malformations (CPAMs) result from abnormalities of branching morphogenesis of the lung. The different types of CPAMs are thought to originate at different levels of the tracheobronchial tree and at different stages of lung development, possibly influenced by in utero airway obstruction",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    atresia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13-15\">",
"     13-15",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H5\">",
"     'Types'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The molecular mechanisms resulting in CPAM formation are unknown but may include an imbalance between cell proliferation and apoptosis during organogenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/16-19\">",
"     16-19",
"    </a>",
"    ]. Disorders of the HOXB5 gene have been implicated in this process [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/20\">",
"     20",
"    </a>",
"    ]. One study found that CPAMs resected from fetuses and newborns had twice as much cell proliferation and five times the number of apoptotic bodies as did normal fetal and neonatal lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/16\">",
"     16",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    This process may be mediated in part by glial cell-derived neurotrophic factor (GDNF), a growth factor that is widely expressed in organs with development characterized by epithelial-mesenchymal interaction. In one report, GDNF was detected in epithelial and endothelial cells from normal fetal lung and in epithelial cells from CPAMs, while none was found in normal lung tissue obtained from older infants and children (four months to three years of age) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/17\">",
"     17",
"    </a>",
"    ]. Vascularity was also reduced in CPAMs compared to normal lung tissue [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/18\">",
"     18",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H4\">",
"    <span class=\"h1\">",
"     PATHOLOGY",
"    </span>",
"    &nbsp;&mdash;&nbsp;Congenital pulmonary airway malformations (CPAMs) are hamartomatous lesions that are comprised of cystic and adenomatous elements arising from tracheal, bronchial, bronchiolar, or alveolar tissue. Large lesions can compromise alveolar growth and development by compressing adjacent normal tissue.",
"   </p>",
"   <p>",
"    CPAMs have connections with the tracheobronchial tree, although the connecting bronchi are usually not normal. The arterial supply and venous drainage from the lesion are from the pulmonary circulation, though vascular connections to the systemic circulation have been reported.",
"   </p>",
"   <p>",
"    CPAMs are equally distributed between the right and left lungs and can arise in all lobes. Lesions are usually limited to one lobe, but infrequently they can involve multiple lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/7,9,10\">",
"     7,9,10",
"    </a>",
"    ]. The CPAMs that present during adulthood tend to be in the lower lobes [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/21\">",
"     21",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H5\">",
"    <span class=\"h2\">",
"     Types",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAMs were previously known as congenital cystic adenomatoid malformations (CCAMs) which were divided into three major types based upon the size of the cysts and their cellular characteristics (predominantly bronchial, bronchiolar, or",
"    <span class=\"nowrap\">",
"     bronchiolar/alveolar",
"    </span>",
"    duct cells) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/1,2,22\">",
"     1,2,22",
"    </a>",
"    ]. Under this classification scheme, more than 65 percent of CPAMs were type 1, type 2 comprised 20 to 25 percent, and type 3 comprised 8 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/1,2\">",
"     1,2",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    In the present classification scheme these congenital cystic lung lesions are now called congenital pulmonary airway malformations (CPAM), and two additional types (0 and 4) were added. Type 0 arises from the trachea, and type 4 lesions have",
"    <span class=\"nowrap\">",
"     alveolar/distal",
"    </span>",
"    acinar origins [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/23-25\">",
"     23-25",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Each type of CPAM has distinct pathologic characteristics [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/22-25\">",
"     22-25",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H6\">",
"    <span class=\"h3\">",
"     Type 0",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 0 is the rarest form, comprising only 1 to 3 percent of cases, and originates from tracheal or bronchial tissue. The cysts are small, with a maximum diameter of 0.5 cm, and are lined with ciliated pseudostratified epithelium [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/25\">",
"     25",
"    </a>",
"    ]. Mucus cells and cartilage are present, but skeletal muscle is absent. This is a diffuse malformation that involves the entire lung. Gas exchange is severely impaired, and affected infants die at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H7\">",
"    <span class=\"h3\">",
"     Type 1",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 1 is the most common form of CPAM, comprising 60 to 70 percent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. This type is thought to originate from the distal bronchi or proximal bronchioles. Because there is well-differentiated tissue within the lesions, the embryologic insult likely occurs relatively late in gestation (7 to 10 weeks).",
"   </p>",
"   <p>",
"    Type 1 lesions are comprised of distinct thin-walled distinct cysts 2 to 10 cm in diameter (",
"    <a class=\"graphic graphic_picture graphicRef69459 \" href=\"UTD.htm?36/12/37059\">",
"     picture 1",
"    </a>",
"    ). The cysts are usually single but may be multiloculated. They are lined with ciliated pseudostratified columnar epithelium (",
"    <a class=\"graphic graphic_picture graphicRef82204 \" href=\"UTD.htm?8/2/8230\">",
"     picture 2",
"    </a>",
"    ) and the walls contain smooth muscle and elastic tissue. Mucus-producing cells are present in approximately one-third of cases, and a thin fibromuscular layer may be present under the epithelium. Small islands of abnormal cartilage are found in 5 to 10 percent of lesions. The adjacent alveoli are relatively normal, and in 95 percent of cases, only one lobe of the lung is involved [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The clinical presentation of type 1 of CPAMs depends primarily on the size of the cysts. Large cysts may be detected on prenatal ultrasound. If they compress adjacent normal lung they can cause respiratory distress in the neonate, mediastinal shift to the contralateral side and flattening of the ipsilateral diaphragm. Smaller cysts may present months or years after birth as incidental lesions or a focus of infection. This type of CPAM has malignant potential, but the magnitude of the risk is not well delineated. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Association with malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H8\">",
"    <span class=\"h3\">",
"     Type 2",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 2 lesions comprise 15 to 20 percent of CPAMs. They consist of multiple cysts 0.5 to 2 cm in diameter and solid areas that blend into adjacent normal tissue (",
"    <a class=\"graphic graphic_picture graphicRef54211 \" href=\"UTD.htm?7/50/7969\">",
"     picture 3",
"    </a>",
"    ). The cysts resemble dilated terminal bronchioles and are lined with ciliated cuboidal or columnar epithelium (",
"    <a class=\"graphic graphic_picture graphicRef66962 \" href=\"UTD.htm?7/53/8025\">",
"     picture 4",
"    </a>",
"    ). Type 2 lesions may also have a thin fibromuscular layer with an increase in elastic tissue. Mucus-secreting cells and cartilage are absent. There is usually little mass effect on the adjacent lung. Extralobar pulmonary sequestrations may have a similar appearance, but unlike type 2 CPAM, these have a systemic blood supply. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Other congenital anomalies are observed in patients with type 2 CPAM in up to 60 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/1,13\">",
"     1,13",
"    </a>",
"    ]. These malformations include esophageal atresia with tracheoesophageal fistula [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/26\">",
"     26",
"    </a>",
"    ], bilateral renal agenesis or dysgenesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/27\">",
"     27",
"    </a>",
"    ], intestinal atresia, other pulmonary malformations, and diaphragmatic, cardiac, central nervous system, and bony anomalies. This association with other congenital malformations suggests that insults resulting in type 2 CPAMs occur during the third week of gestation. In many cases, the associated anomalies are the presenting feature, and the CPAM is detected as a secondary finding. Type 2 CPAMs are not at risk for development of malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H9\">",
"    <span class=\"h3\">",
"     Type 3",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 3 CPAMs comprise 5 to 10 percent of CPAMs. They are often very large, and can involve an entire lobe or several lobes. They have an acinar origin and consist of adenomatoid proliferation of distal airways or airspaces. They can be a mixture of cystic and solid tissue or be entirely solid. Because of their large size and lack of differentiation, type 3 CPAMs are thought to result from an insult early in gestation (26 to 28 days).",
"   </p>",
"   <p>",
"    The numerous small cysts are less than 0.5 cm in diameter and are lined with nonciliated cuboidal epithelium. They have a thin fibromuscular layer and increased elastic tissue, similar to type 2 lesions. Mucus-secreting cells and cartilage are absent.",
"   </p>",
"   <p>",
"    Affected infants present in utero or at birth, with severe respiratory distress or death in the neonatal period [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. This type of CPAM has not been associated with malignancy.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H10\">",
"    <span class=\"h3\">",
"     Type 4",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 4 lesions comprise 10 to 15 percent of CPAMs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13,25\">",
"     13,25",
"    </a>",
"    ]. The cysts have a maximum diameter of 7 cm and consist of nonciliated, flattened, alveolar lining cells, with no mucus cells or skeletal muscle.",
"   </p>",
"   <p>",
"    Type 4 CPAMs may present at birth or in childhood, often with tension pneumothorax or infection, but they may also be identified as incidental findings in asymptomatic patients. Importantly, this type of CPAM is strongly associated with malignancy, especially with pleuropulmonary blastoma (PPB). (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Association with malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H11\">",
"    <span class=\"h1\">",
"     CLINICAL FEATURES",
"    </span>",
"    &nbsp;&mdash;&nbsp;The presentation of congenital pulmonary airway malformation (CPAM) is variable. Many are identified by routine prenatal ultrasound examination. Affected newborns can present with signs and symptoms of respiratory distress or be asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H12\">",
"    <span class=\"h2\">",
"     Prenatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;The appearance of CPAMs on prenatal ultrasound ranges from incidental findings of cystic-appearing lesions to massive pulmonary involvement [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/6,7,28-30\">",
"     6,7,28-30",
"    </a>",
"    ]. Fetal hydrops develops in as many as 40 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/31\">",
"     31",
"    </a>",
"    ]. Lesions regress during the course of gestation in as many as 59 percent of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/28,32-34\">",
"     28,32-34",
"    </a>",
"    ]. Complete spontaneous resolution in the postnatal period has been reported in a small number of cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33,35\">",
"     33,35",
"    </a>",
"    ]. A five-year retrospective review suggested that peak CPAM size occurred at approximately 25 weeks gestational age and that regression in size led to favorable outcomes unless severe hydrops was present [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/36\">",
"     36",
"    </a>",
"    ]. Prenatal diagnosis, course, and management of CPAM are discussed in a separate topic review. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=see_link\">",
"     \"Prenatal diagnosis and management of congenital pulmonary airway malformation\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H13\">",
"    <span class=\"h3\">",
"     Development of hydrops",
"    </span>",
"    &nbsp;&mdash;&nbsp;CPAMs that are large enough to cause mediastinal shift can lead to obstruction of the inferior vena cava and cardiac compression, resulting in the development of hydrops from increased central venous pressure [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/31\">",
"     31",
"    </a>",
"    ]. One study evaluated 41 fetuses with CPAMs with echocardiography. As compared to fetuses without hydrops, those with hydrops had a lower cardiac to thoracic ratio, increased early ventricular filling, and greater reversal of flow in the inferior vena cava with atrial contraction [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/37\">",
"     37",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Because of the variable natural history of CPAMs, it is difficult to predict at the time of the initial ultrasound whether lesions will regress or continue to grow and lead to significant problems, including hydrops. However, the appearance and volume of the CPAM may be predictive. In one report, microcystic lesions were usually associated with hydrops and a poor prognosis, while fetuses with macrocystic lesions usually did not have hydrops and were more likely to survive [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/38\">",
"     38",
"    </a>",
"    ]. Another study found that the combination of polyhydramnios, fetal hydrops, and a lung to thorax transverse area ratio of less than 0.25 was predictive of increased mortality and severe respiratory compromise [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/39\">",
"     39",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The volume of the CPAM adjusted for gestational age may predict an increased risk of hydrops (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55315 graphicRef63885 \" href=\"UTD.htm?13/1/13335\">",
"     image 1A-B",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/31,33\">",
"     31,33",
"    </a>",
"    ]. Fetuses with hydrops have a higher CPAM volume referenced to the fetal head (known as the CPAM volume ratio, CVR), as compared with nonhydropic fetuses. As an example, one study found that hydrops developed in 12 of 16 patients (75 percent) with CVR &gt;1.6, as compared to seven of 42 (16.7 percent) with CVR &le;1.6 [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/31\">",
"     31",
"    </a>",
"    ]. Because all except one fetus in the latter group had a dominant cyst, the authors concluded that the risk of hydrops is &lt;3 percent if CVR is &le;1.6 and no dominant cyst is present.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H14\">",
"    <span class=\"h2\">",
"     Neonatal presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Among CPAMs that are diagnosed after birth, approximately two-thirds present in the newborn period with respiratory symptoms. The likelihood of respiratory distress and its severity increases with the size of the lesion.",
"   </p>",
"   <p>",
"    The majority of CPAMs that present in newborns are type 1. Typical signs include tachypnea, increased respiratory effort with grunting and retractions, and cyanosis. Depending upon the extent of air trapping, large cysts may expand, which leads to respiratory distress.",
"   </p>",
"   <p>",
"    Type 2 CPAMs are often diagnosed soon after birth because of their association with other congenital anomalies, which are present in up to 60 percent of affected patients. Presenting respiratory signs and symptoms are similar to those noted with type 1 CPAMs.",
"   </p>",
"   <p>",
"    Type 3 CPAM is the most severe form (other than type 0, which is uniformly lethal at birth). Type 3 lesions are large and can involve the entire lung, and fetal hydrops and pulmonary hypoplasia are typical. Infants may be stillborn or present immediately after birth with severe, progressive respiratory distress, cyanosis, and respiratory failure. Nearly all affected infants are male [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/1\">",
"     1",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Type 4 CPAMs can present in the neonatal period with pneumothorax, and may be difficult to distinguish from type 1 lesions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/40\">",
"     40",
"    </a>",
"    ]. Because many type 4 lesions are probably due to pleuropulmonary blastoma, there should be a strong suspicion for malignancy in any infant presenting with pneumothorax and CPAM. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Association with malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H15\">",
"    <span class=\"h2\">",
"     Childhood presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately one-third of CPAMs are diagnosed after the neonatal period. These lesions typically are smaller and are CPAM types 1 or 4. A common presentation in older children is recurrent pneumonia [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/41,42\">",
"     41,42",
"    </a>",
"    ]. Other presenting complaints include cough, dyspnea,",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    cyanosis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/42\">",
"     42",
"    </a>",
"    ]. Findings on physical examination include decreased breath sounds over the lesion, hyperresonance, and chest wall asymmetry with a bulge on the affected side. CPAMs can also present with spontaneous pneumothorax. Because pneumothorax is most often associated with type 4 CPAMs, and type 4 CPAM is associated with malignancy, there should be a strong suspicion for malignancy in any child presenting with pneumothorax and CPAM. (See",
"    <a class=\"local\" href=\"#H31\">",
"     'Association with malignancy'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    The spectrum of CPAM presentation during childhood is illustrated in a report of 12 patients who were diagnosed with CPAM at 6 months to 23 years of age (mean 6.7 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/43\">",
"     43",
"    </a>",
"    ]. Of these, nine presented with recurrent pulmonary infections, one presented with pneumothorax, and two were discovered as incidental findings. Among the 11 patients who underwent surgical resection of CPAM, type 1 CPAMs were identified in seven patients, and type 2 CPAMs were identified in four patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H16\">",
"    <span class=\"h2\">",
"     Asymptomatic presentation",
"    </span>",
"    &nbsp;&mdash;&nbsp;Approximately half of patients with a prenatal diagnosis of CPAM are asymptomatic at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/18,33,44\">",
"     18,33,44",
"    </a>",
"    ]. In a large series of prenatally diagnosed CPAM, 55 percent were asymptomatic at birth [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33\">",
"     33",
"    </a>",
"    ]. Compared to symptomatic patients, fewer asymptomatic patients had mediastinal shift (27.5 versus 65 percent), polyhydramnios (7 versus 45 percent), or hydrops (0 versus 15 percent). Clinical signs developed in three patients within the first few weeks after birth. The symptoms consisted of tachypnea, cough during sleep, and lethargy. In another series of 48 children with perinatally detected CPAM, 35 were asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/45\">",
"     45",
"    </a>",
"    ]. Among the patients who were initially asymptomatic, three infants developed CPAM infections between 7 and 11 months of age.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H17\">",
"    <span class=\"h1\">",
"     EVALUATION",
"    </span>",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H18\">",
"    <span class=\"h2\">",
"     History",
"    </span>",
"    &nbsp;&mdash;&nbsp;Regardless of the patient's age and presenting signs and symptoms, the family history should be explored in detail for cancers and cystic lesions that might suggest familial pleuropulmonary blastoma syndrome. These include renal cystic disease, small bowel polyps, childhood cancers or dysplasias, and a history of spontaneous pneumothorax. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pleuropulmonary blastoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H19\">",
"    <span class=\"h2\">",
"     Imaging",
"    </span>",
"    &nbsp;&mdash;&nbsp;The diagnosis of congenital pulmonary airway malformation (CPAM) is made by radiographic imaging. The radiographic appearance of CPAM and other developmental anomalies of the lung is discussed in detail separately. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=see_link\">",
"     \"Radiographic appearance of developmental anomalies of the lung\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H20\">",
"    <span class=\"h3\">",
"     Prenatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;Prenatal diagnosis is typically made by ultrasonography (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef55315 graphicRef63885 \" href=\"UTD.htm?13/1/13335\">",
"     image 1A-B",
"    </a>",
"    and",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81883 \" href=\"UTD.htm?39/32/40451\">",
"     image 2",
"    </a>",
"    ). CPAMs presenting prenatally are classified by their ultrasound findings and gross anatomy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/38,46\">",
"     38,46",
"    </a>",
"    ]. Microcystic lesions consist of cysts &lt;5 mm in diameter and appear echogenic and solid, while macrocystic lesions contain one or more cysts &gt;5 mm in diameter.",
"   </p>",
"   <p>",
"    Prenatal magnetic resonance imaging (MRI) may help distinguish CPAM from congenital diaphragmatic hernia (CDH) or other less common lesions. In one series, 16 of 18 patients with fetal lung masses were diagnosed as CPAM by ultrasound [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/47\">",
"     47",
"    </a>",
"    ]. However, MRI imaging confirmed nine of the lesions to be CPAM, three were CDH, two were bronchopulmonary sequestrations (BPS), and one each was a foregut cyst, lung atresia, tracheal atresia, and bronchial stenosis. MRI results were confirmed at surgery or autopsy in 17 cases. One lesion that was diagnosed prenatally as CPAM by both ultrasound and MRI was determined to be a BPS on autopsy. Another study that evaluated the use of second-trimester ultrasound to diagnose congenital lung malformations also demonstrated poor correlation between the diagnosis by prenatal ultrasound and tissue diagnosis at autopsy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/48\">",
"     48",
"    </a>",
"    ]. Hence, a prenatal ultrasound diagnosis of CPAM should not be considered definitive.",
"   </p>",
"   <p>",
"    Poor prognostic signs include large CPAM size, bilateral lung involvement, polyhydramnios, and mediastinal shift (",
"    <a class=\"graphic graphic_diagnosticimage graphicRef81883 \" href=\"UTD.htm?39/32/40451\">",
"     image 2",
"    </a>",
"    )&nbsp;[",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/28\">",
"     28",
"    </a>",
"    ]. However, there are no reliable criteria for determining which lesions will grow and result in hydrops versus those that will stabilize or regress. This was illustrated in one series of 40 cases in which 56 percent of the lesions regressed spontaneously, although one-third of these had initially progressed [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/32\">",
"     32",
"    </a>",
"    ]. In 17 cases (42 percent), the mediastinal shift resolved, usually due to a decrease in the size of the CPAM, but also by simple growth of the fetus.",
"   </p>",
"   <p>",
"    Approximately 25 percent of infants with CPAM detected prenatally also have other structural anomalies; most of these cases are associated with type 2 CPAM [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/49\">",
"     49",
"    </a>",
"    ]. In patients with such anomalies, a fetal karyotype should be obtained, although CPAMs typically are not associated with chromosomal abnormalities.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H21\">",
"    <span class=\"h3\">",
"     Asymptomatic neonates",
"    </span>",
"    &nbsp;&mdash;&nbsp;The natural history of prenatally diagnosed CPAM is variable. Some lesions identified on prenatal ultrasound regress or disappear, and many infants are asymptomatic [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33,50,51\">",
"     33,50,51",
"    </a>",
"    ]. Among asymptomatic congenital cystic lesions which were confirmed by CT scan in the neonatal period, about 20 percent resolved spontaneously within the first year of life [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33,51\">",
"     33,51",
"    </a>",
"    ]. However, the lesions persist in most cases.",
"   </p>",
"   <p>",
"    We recommend that all infants with a prenatal diagnosis of CPAM have a chest radiograph in the neonatal period, even if they are asymptomatic. All of these infants should then have a CT scan of the chest at four to six weeks of age to confirm the diagnosis and further evaluate the lesion.",
"   </p>",
"   <p>",
"    The CT scan should be performed even in infants with normal chest radiographs because plain radiographs often fail to detect CPAM in asymptomatic neonates. As an example, in one case series of asymptomatic infants with prenatally diagnosed CPAM, the chest radiograph appeared normal at birth in 12 of 29 patients (42 percent) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33\">",
"     33",
"    </a>",
"    ]. However, when CT scan was performed at 45 days of age, cystic lung abnormalities were seen on CT scan in all but one infant.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H22\">",
"    <span class=\"h3\">",
"     Postnatal diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;In the newborn or child, the diagnosis of CPAM can usually be made on a plain radiograph, though CT scan of the chest is still recommended [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/7,47,52,53\">",
"     7,47,52,53",
"    </a>",
"    ]. Each of the major types has a characteristic appearance.",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Type 0 CPAM is lethal at birth, and the diagnosis is made at autopsy.",
"     </li>",
"     <li>",
"      Type 1 CPAM appears as a single lesion with one or a few large cysts that may be entirely air-filled or have air-fluid levels (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef76692 \" href=\"UTD.htm?16/11/16560\">",
"       image 3",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef56702 \" href=\"UTD.htm?35/0/35841\">",
"       image 4",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type 2 CPAMs have a radiographic appearance similar to that of type 1. However, the more numerous small cysts in type 2 lesions appear more homogeneous, with a \"bubbly\" appearance (",
"      <a class=\"graphic graphic_diagnosticimage graphicRef62424 \" href=\"UTD.htm?29/61/30673\">",
"       image 5",
"      </a>",
"      and",
"      <a class=\"graphic graphic_diagnosticimage graphicRef75275 \" href=\"UTD.htm?26/3/26673\">",
"       image 6",
"      </a>",
"      ).",
"     </li>",
"     <li>",
"      Type 3 CPAM often appears as a large, solid, homogeneous mass. There is usually a marked shift of the mediastinal contents to the contralateral side with hypoplasia of the ipsilateral lung due to mass effect.",
"     </li>",
"     <li>",
"      Type 4 CPAM may present at birth or in childhood, with tension pneumothorax, infection, or as an incidental finding.",
"     </li>",
"    </ul>",
"   </p>",
"   <p>",
"    Computerized tomography (CT) scans of the chest correlate with pathologic findings, and may be helpful in cases in which the chest radiograph is not diagnostic. In one report, preoperative CT findings were compared to pathologic findings [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/53\">",
"     53",
"    </a>",
"    ]. CT accurately identified both small (&lt;2 cm in diameter) and large cysts, and whether they were filled with air",
"    <span class=\"nowrap\">",
"     and/or",
"    </span>",
"    fluid. Areas of consolidation corresponded to glandular or bronchiolar structures; this was observed 43 percent of the scans. The area around cystic lesions where attenuation was lower than normal lung represented microcysts blending into normal lung parenchyma; this feature was seen in 29 percent of the CT scans.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H23\">",
"    <span class=\"h2\">",
"     Differential diagnosis",
"    </span>",
"    &nbsp;&mdash;&nbsp;The differential diagnosis of CPAM includes bronchopulmonary sequestration (BPS). On prenatal ultrasound, BPS appear as a well-defined, homogeneous, echodense mass [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46\">",
"     46",
"    </a>",
"    ]. In contrast to CPAM, BPS usually has no connection to the tracheobronchial tree and is supplied by an anomalous systemic artery, rather than the pulmonary circulation. The systemic arterial supply can be demonstrated by color flow Doppler. However, hybrid lesions with histologic characteristics of CPAM and a systemic arterial supply have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/54\">",
"     54",
"    </a>",
"    ]. In a series of 50 patients with BPS, 50 percent of the cases were associated with CPAMs [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/55\">",
"     55",
"    </a>",
"    ]. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=see_link\">",
"     \"Bronchopulmonary sequestration\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    In addition to BPS, the differential diagnosis of CPAM includes congenital diaphragmatic hernia, bronchogenic cyst, congenital lobar emphysema and localized pulmonary interstitial emphysema that may arise in patients receiving mechanical ventilation, and pneumatocoeles (which can be sequelae of bacterial pneumonia, especially due to staphylococcal infection). (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=see_link\">",
"     \"Congenital lobar emphysema\"",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H24\">",
"    <span class=\"h1\">",
"     MANAGEMENT",
"    </span>",
"    &nbsp;&mdash;&nbsp;The management of congenital pulmonary airway malformation (CPAM) depends on whether the patient has respiratory distress or is asymptomatic.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H25\">",
"    <span class=\"h2\">",
"     Symptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In symptomatic patients, CPAM is treated by surgical resection [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/12,56-60\">",
"     12,56-60",
"    </a>",
"    ]. Resection is frequently required in newborns with significant respiratory distress, but is often done electively in older children who present with less acute symptoms. In older children, resection is usually performed to prevent recurrent infection and to eliminate concerns regarding malignancy. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pleuropulmonary blastoma'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Lobectomy is preferred to wedge resection because of the technical difficulty in identifying planes of dissection with some lesions and the increased morbidity associated with partial resections [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/61\">",
"     61",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H26\">",
"    <span class=\"h2\">",
"     Asymptomatic patients",
"    </span>",
"    &nbsp;&mdash;&nbsp;In asymptomatic patients, we recommend surgical resection for all patients with bilateral or multifocal cysts or a family history of pleuropulmonary blastoma (PPB)-associated conditions. We also suggest surgical resection of lung cysts in infants or children without these features, but surveillance with serial CT scans is a reasonable alternative.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H27\">",
"    <span class=\"h3\">",
"     Surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Surgical resection is usually recommended for asymptomatic patients with CPAMs that have been identified by prenatal ultrasound or as an incidental radiographic finding. However, the timing of the surgical procedure is controversial. A report of a patient cohort seen over a 10-year period suggested that three to six months was an optimal age for surgery [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/51,62\">",
"     51,62",
"    </a>",
"    ]. This time frame was also recommended by another review of asymptomatic congenital lung malformations [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/63\">",
"     63",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Excision of the CPAM prevents complications (primarily infection but also the possibility of malignancy) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/64-66\">",
"     64-66",
"    </a>",
"    ]. The risk of malignancy is extremely low except in type 4 CPAMs, although type 1 lesions may also have some malignant potential. However, in a study in which patients were followed for 1.5 to 20 years after diagnosis, surgical resection later in childhood was associated with greater weight and height compared to intervention in infancy [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/9\">",
"     9",
"    </a>",
"    ]. (See",
"    <a class=\"local\" href=\"#H30\">",
"     'Complications'",
"    </a>",
"    below.)",
"   </p>",
"   <p>",
"    Minimally invasive surgery for asymptomatic patients with CPAM during infancy has been reported to be successful and without significant postoperative complications [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/67-70\">",
"     67-70",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H28\">",
"    <span class=\"h3\">",
"     Surveillance",
"    </span>",
"    &nbsp;&mdash;&nbsp;An alternative approach to surgical resection in asymptomatic patients is observation with serial chest CT scans for surveillance of malignancy. The drawbacks of this strategy are the low but present risk of malignant transformation, the risk of infection within the cysts, and radiation exposure. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=see_link\">",
"     \"Radiation-related risks of imaging studies\"",
"    </a>",
"    .)",
"   </p>",
"   <p>",
"    Because type 4 lesions may develop rapidly into solid pleuropulmonary blastomas, imaging must be performed frequently. Performing chest CT scans as frequently as every four months might not even be sufficient, and chest radiography is not an appropriate alternative [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/5\">",
"     5",
"    </a>",
"    ]. Thus, in patients in whom type 4 lesions are suspected or cannot be ruled out, surveillance is not an option. In one study of asymptomatic infants with perinatally diagnosed CPAMs, 15 percent developed infection and required surgical resection, and the remainder remained asymptomatic for a median of three years [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/45\">",
"     45",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The possibility of using serial Magnetic Resonance Imaging (MRI) for surveillance of asymptomatic CPAM lesions has not been evaluated, but MRI is generally less useful than CT for evaluating cystic lesions. MRI has been used for prenatal evaluation of CPAM lesions detected on fetal ultrasound. (See",
"    <a class=\"local\" href=\"#H12\">",
"     'Prenatal presentation'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H29\">",
"    <span class=\"h2\">",
"     Fetal surgery",
"    </span>",
"    &nbsp;&mdash;&nbsp;Without surgical intervention, most fetuses with large CPAMs resulting in hydrops die in utero or in the early neonatal period. Thus, fetal surgery should be considered in these cases [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46,71,72\">",
"     46,71,72",
"    </a>",
"    ]. In one series, surgical resection of the CPAM was performed in 13 fetuses at 21 to 29 weeks' gestation [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46\">",
"     46",
"    </a>",
"    ]. In the eight survivors, the hydrops resolved in one to two weeks and lung growth improved. There were four perioperative deaths, and one infant died in the early neonatal period from pulmonary hypoplasia. Maternal morbidity included wound infection, seroma, blood loss requiring transfusion, and pulmonary edema. Another series reported a 50 percent fetal survival, as compared to 3 percent survival in a similar group of patients without intervention [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/73\">",
"     73",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    When hydrops develops before 32 weeks gestation, then fetal intervention to resect the CPAM should be considered. The mother should be referred to a center experienced in fetal surgery. If the gestational age is greater than 32 weeks, some centers recommend early delivery so that surgical resection can be performed in the newborn. However, the outcome of these infants is poor [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46\">",
"     46",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    Other techniques for fetal intervention include thoracentesis [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/74\">",
"     74",
"    </a>",
"    ] and placement of a thoracoamniotic shunt [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46,75,76\">",
"     46,75,76",
"    </a>",
"    ]. However, their use is limited to large cysts that accumulate fluid [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/46\">",
"     46",
"    </a>",
"    ]. In addition, shunt placement has technical limitations, such as obstruction or dislodgement. In fetuses with associated life-threatening anomalies or in mothers with severe preeclampsia, termination of the pregnancy is an option. (See",
"    <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=see_link&amp;anchor=H26#H26\">",
"     \"Nonimmune hydrops fetalis\", section on 'Prognosis and management'",
"    </a>",
"    .)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H30\">",
"    <span class=\"h1\">",
"     COMPLICATIONS",
"    </span>",
"    &nbsp;&mdash;&nbsp;The most common complication of congenital pulmonary airway malformation (CPAM) is recurrent pulmonary infection. In some cases, this may be the presenting sign. A rare complication is spontaneous hemopneumothorax [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/77\">",
"     77",
"    </a>",
"    ]. The development of malignancy in some patients with previously unrecognized CPAM, while rare, is another reason for the recommendation to resect the lesions, even in asymptomatic patients.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H31\">",
"    <span class=\"h2\">",
"     Association with malignancy",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a substantial risk of malignancy for a child presenting with a large air-filled CPAM. This is because type 4 CPAMs often have this appearance and carry a malignancy risk [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. Type 1 and 2 lesions can also be large and air-filled; type 1 lesions are rarely associated with malignancy and type 2 lesions have no malignancy risk.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H32\">",
"    <span class=\"h3\">",
"     Pleuropulmonary blastoma",
"    </span>",
"    &nbsp;&mdash;&nbsp;Type 4 CPAM should be considered malignant lesions because approximately 30 percent of pleuropulmonary blastoma (PPB) present in a purely cystic form that is indistinguishable from nonmalignant cysts [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13,78-80\">",
"     13,78-80",
"    </a>",
"    ]. Indeed, there is increasing evidence that all type 4 CPAMs are actually cystic PPB [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. Because it is difficult to distinguish between CPAM types 1 and 4, some cases classified as CPAM type 1 are actually cystic PPB. Rhabdomyosarcomas originating in a CPAM have been reported [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/81,82\">",
"     81,82",
"    </a>",
"    ], but these are now thought to have been cases of PPB [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/83\">",
"     83",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    About 25 percent of PPBs are associated with a familial predisposition to dysplasia and metaplasia, presenting in other family members as PPB or a variety of other malignancies or cystic lesions, including renal cystic disease, small bowel polyps, and childhood cancers or dysplasias [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/84\">",
"     84",
"    </a>",
"    ]. Also, pneumothorax is a unique feature of type 4 CPAM, occurring in about 40 percent of cases later diagnosed as PPB [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, there should be a strong suspicion of malignancy in infants and children presenting with lung cysts and pneumothorax, with bilateral or multifocal lung cysts, or with a family history of PPB-associated conditions [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ].",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H33\">",
"    <span class=\"h3\">",
"     Other",
"    </span>",
"    &nbsp;&mdash;&nbsp;There is a weak association of CPAM type 1 with bronchoalveolar carcinoma (BAC) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/33,81,85,86\">",
"     33,81,85,86",
"    </a>",
"    ]. In patients with CPAM, BAC is usually discovered incidentally in cysts resected during adolescence or adulthood (range 6 months to 75 years) [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"     13",
"    </a>",
"    ]. Thus, the true rate of this malignancy and its clinical significance remains unclear.",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H34\">",
"    <span class=\"h1\">",
"     OUTCOME",
"    </span>",
"    &nbsp;&mdash;&nbsp;The prognosis for CPAM largely depends upon the type of malformation.",
"   </p>",
"   <p>",
"    Type 0 is a severe derangement of fetal development and is associated with other anomalies. It is not compatible with survival [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/23,24\">",
"     23,24",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    For the majority of type 1 lesions, surgical excision in the neonatal period is curative and the prognosis excellent [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/87,88\">",
"     87,88",
"    </a>",
"    ]. The remaining lung parenchyma undergoes compensatory growth and development [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/89\">",
"     89",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The prognosis for type 2 and 3 CPAMs is not as favorable, although recovery is possible [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/7,9,10,32,44,90\">",
"     7,9,10,32,44,90",
"    </a>",
"    ]. Outcomes in infants with type 2 lesions may be influenced by the severity of the accompanying congenital anomalies. Infants with type 3 lesions frequently have severe hypoplasia of the contralateral lung and are at risk for developing pulmonary hypertension [",
"    <a class=\"abstract\" href=\"UTD.htm?0/50/810/abstract/91,92\">",
"     91,92",
"    </a>",
"    ].",
"   </p>",
"   <p>",
"    The outcome of type 4 CPAM is also quite good with surgical resection. However, because this lesion probably represents cystic pleuropulmonary blastoma, oncologic consultation and complete surgical resection is essential. (See",
"    <a class=\"local\" href=\"#H32\">",
"     'Pleuropulmonary blastoma'",
"    </a>",
"    above.)",
"   </p>",
"   <p class=\"headingAnchor\" id=\"H35\">",
"    <span class=\"h1\">",
"     SUMMARY AND RECOMMENDATIONS",
"    </span>",
"   </p>",
"   <p>",
"    <ul class=\"bullet-block\">",
"     <li>",
"      Congenital pulmonary airway malformation (CPAM), previously known as congenital cystic adenomatoid malformation (CCAM), is a developmental anomaly of the respiratory tract. The appearance and clinical presentation of the lesion depends on the gestational age at which the anomaly developed as well its location within the tracheobronchial tree. CPAM are categorized as types 0 through 4. (See",
"      <a class=\"local\" href=\"#H5\">",
"       'Types'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type 1 CPAMs comprise approximately 70 percent of all CPAMs. Large cysts may be detected on prenatal ultrasound and may cause respiratory distress in the neonate. Smaller cysts may present months or years later as incidental findings on imaging studies or as a focus of recurrent pulmonary infection. Type 1 CPAMs are associated with a slight risk of malignancy. Care must be taken not to misclassify type 4 lesions as type 1, because type 4 lesions have a high malignant potential. (See",
"      <a class=\"local\" href=\"#H7\">",
"       'Type 1'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Type 4 CPAMs comprise 10 to 15 percent of all CPAMs. Many of these lesions are cystic forms of pleuropulmonary blastoma (PPB), so identification and resection of these lesions is essential. Important clues that suggest this type of CPAM are presentation with pneumothorax, the presence of bilateral or multifocal lung cysts, or a family history of lung cysts or PPB-associated conditions (see",
"      <a class=\"local\" href=\"#H10\">",
"       'Type 4'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Pleuropulmonary blastoma'",
"      </a>",
"      above).",
"     </li>",
"     <li>",
"      In symptomatic patients, CPAM is best managed by surgical resection. All resected cysts should be carefully examined for evidence of malignancy. Fetuses with large CPAMs resulting in hydrops may be candidates for fetal surgery. (See",
"      <a class=\"local\" href=\"#H24\">",
"       'Management'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic infants with a prenatal diagnosis of CPAM should be evaluated with a chest radiograph in the neonatal period. This should be followed by a CT scan at four to six weeks of age to confirm the diagnosis and further evaluate the lesion. A CT scan should be performed even in infants with normal chest radiographs. In a minority of infants the lesion will regress within the first few months of life. (See",
"      <a class=\"local\" href=\"#H21\">",
"       'Asymptomatic neonates'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      Asymptomatic patients with bilateral or multifocal cysts or a family history of PPB-associated conditions are at risk for malignancy and surgical resection is indicated. We also suggest surgical resection of lung cysts in asymptomatic infants and children without these features (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). Observation with serial CT scans is a reasonable alternative in this latter group. (See",
"      <a class=\"local\" href=\"#H26\">",
"       'Asymptomatic patients'",
"      </a>",
"      above.)",
"     </li>",
"     <li>",
"      In asymptomatic patients who undergo surgical resection of CPAM, we suggest performing the procedure between three and six months of age, or soon after the diagnosis is established in older patients (",
"      <a class=\"grade\" href=\"._grade_6?title=Grade 2C\">",
"       Grade 2C",
"      </a>",
"      ). (See",
"      <a class=\"local\" href=\"#H27\">",
"       'Surgery'",
"      </a>",
"      above and",
"      <a class=\"local\" href=\"#H32\">",
"       'Pleuropulmonary blastoma'",
"      </a>",
"      above.)",
"     </li>",
"    </ul>",
"   </p>",
"  </div>",
"  <div id=\"topicAgreement\">",
"   Use of UpToDate is subject to the",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_in_page\" target=\"_blank\">",
"    Subscription and License Agreement",
"   </a>",
"   .",
"  </div>",
"  <div class=\"headingAnchor\" id=\"references\">",
"   <h1>",
"    REFERENCES",
"   </h1>",
"   <ol id=\"reference\">",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/1\">",
"      Stocker JT, Drake RM, Madewell JE. Cystic and congenital lung disease in the newborn. Perspect Pediatr Pathol 1978; 4:93.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/2\">",
"      Landing BH, Dixon LG. Congenital malformations and genetic disorders of the respiratory tract (larynx, trachea, bronchi, and lungs). Am Rev Respir Dis 1979; 120:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/3\">",
"      Kravitz RM. Congenital malformations of the lung. Pediatr Clin North Am 1994; 41:453.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/4\">",
"      Albers GM, Wood RE. Update in the diagnosis and management of congenital malformations of the airway and lung. Clin Pulm Med 1995; 2:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/5\">",
"      Shanti CM, Klein MD. Cystic lung disease. Semin Pediatr Surg 2008; 17:2.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/6\">",
"      Taguchi T, Suita S, Yamanouchi T, et al. Antenatal diagnosis and surgical management of congenital cystic adenomatoid malformation of the lung. Fetal Diagn Ther 1995; 10:400.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/7\">",
"      De Santis M, Masini L, Noia G, et al. Congenital cystic adenomatoid malformation of the lung: antenatal ultrasound findings and fetal-neonatal outcome. Fifteen years of experience. Fetal Diagn Ther 2000; 15:246.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/8\">",
"      Takeda S, Miyoshi S, Inoue M, et al. Clinical spectrum of congenital cystic disease of the lung in children. Eur J Cardiothorac Surg 1999; 15:11.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/9\">",
"      Pinter A, Kalman A, Karsza L, et al. Long-term outcome of congenital cystic adenomatoid malformation. Pediatr Surg Int 1999; 15:332.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/10\">",
"      Evrard V, Ceulemans J, Coosemans W, et al. Congenital parenchymatous malformations of the lung. World J Surg 1999; 23:1123.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/11\">",
"      Nishibayashi SW, Andrassy RJ, Woolley MM. Congenital cystic adenomatoid malformation: 1 30-year experience. J Pediatr Surg 1981; 16:704.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/12\">",
"      Nuchtern JG, Harberg FJ. Congenital lung cysts. Semin Pediatr Surg 1994; 3:233.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/13\">",
"      Priest JR, Williams GM, Hill DA, et al. Pulmonary cysts in early childhood and the risk of malignancy. Pediatr Pulmonol 2009; 44:14.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/14\">",
"      Kunisaki SM, Fauza DO, Nemes LP, et al. Bronchial atresia: the hidden pathology within a spectrum of prenatally diagnosed lung masses. J Pediatr Surg 2006; 41:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/15\">",
"      Riedlinger WF, Vargas SO, Jennings RW, et al. Bronchial atresia is common to extralobar sequestration, intralobar sequestration, congenital cystic adenomatoid malformation, and lobar emphysema. Pediatr Dev Pathol 2006; 9:361.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/16\">",
"      Cass DL, Quinn TM, Yang EY, et al. Increased cell proliferation and decreased apoptosis characterize congenital cystic adenomatoid malformation of the lung. J Pediatr Surg 1998; 33:1043.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/17\">",
"      Fromont-Hankard G, Philippe-Chomette P, Delezoide AL, et al. Glial cell-derived neurotrophic factor expression in normal human lung and congenital cystic adenomatoid malformation. Arch Pathol Lab Med 2002; 126:432.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/18\">",
"      Cangiarella J, Greco MA, Askin F, et al. Congenital cystic adenomatoid malformation of the lung: insights into the pathogenesis utilizing quantitative analysis of vascular marker CD34 (QBEND-10) and cell proliferation marker MIB-1. Mod Pathol 1995; 8:913.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/19\">",
"      Berrocal T, Madrid C, Novo S, et al. Congenital anomalies of the tracheobronchial tree, lung, and mediastinum: embryology, radiology, and pathology. Radiographics 2004; 24:e17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/20\">",
"      Wilson RD, Hedrick HL, Liechty KW, et al. Cystic adenomatoid malformation of the lung: review of genetics, prenatal diagnosis, and in utero treatment. Am J Med Genet A 2006; 140:151.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/21\">",
"      Zylak CJ, Eyler WR, Spizarny DL, Stone CH. Developmental lung anomalies in the adult: radiologic-pathologic correlation. Radiographics 2002; 22 Spec No:S25.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/22\">",
"      Stocker JT, Madewell JE, Drake RM. Congenital cystic adenomatoid malformation of the lung. Classification and morphologic spectrum. Hum Pathol 1977; 8:155.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/23\">",
"      Stocker JT. Congenital pulmonary airway malformation - a new name for and an expanded classification of congenital cystic adenomatoid malformation of the lung. Histopathology 2002; 41:424.",
"     </a>",
"    </li>",
"    <li>",
"     Stocker JT. Congenital and developmental diseases. In: Pulmonary Pathology, Dail DH, Hammer SP (Eds), Springer, New York 1994. p.174.",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/25\">",
"      van Koningsbruggen S, Ahrens F, Brockmann M, et al. Congenital cystic adenomatoid malformation type 4. Pediatr Pulmonol 2001; 32:471.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/26\">",
"      De Felice C, Di Maggio G, Messina M, et al. Congenital cystic adenomatoid malformation of the lung associated with esophageal atresia and tracheoesophageal fistula. Pediatr Surg Int 1999; 15:260.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/27\">",
"      Krous HF, Harper PE, Perlman M. Congenital cystic adenomatoid malformation in bilateral renal agenesis. Its mitigation of Potter's syndrome. Arch Pathol Lab Med 1980; 104:368.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/28\">",
"      Duncombe GJ, Dickinson JE, Kikiros CS. Prenatal diagnosis and management of congenital cystic adenomatoid malformation of the lung. Am J Obstet Gynecol 2002; 187:950.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/29\">",
"      Miller JA, Corteville JE, Langer JC. Congenital cystic adenomatoid malformation in the fetus: natural history and predictors of outcome. J Pediatr Surg 1996; 31:805.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/30\">",
"      Bush A, Hogg J, Chitty LS. Cystic lung lesions - prenatal diagnosis and management. Prenat Diagn 2008; 28:604.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/31\">",
"      Crombleholme TM, Coleman B, Hedrick H, et al. Cystic adenomatoid malformation volume ratio predicts outcome in prenatally diagnosed cystic adenomatoid malformation of the lung. J Pediatr Surg 2002; 37:331.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/32\">",
"      Laberge JM, Flageole H, Pugash D, et al. Outcome of the prenatally diagnosed congenital cystic adenomatoid lung malformation: a Canadian experience. Fetal Diagn Ther 2001; 16:178.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/33\">",
"      Sauvat F, Michel JL, Benachi A, et al. Management of asymptomatic neonatal cystic adenomatoid malformations. J Pediatr Surg 2003; 38:548.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/34\">",
"      Revillon Y, Jan D, Plattner V, et al. Congenital cystic adenomatoid malformation of the lung: prenatal management and prognosis. J Pediatr Surg 1993; 28:1009.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/35\">",
"      Butterworth SA, Blair GK. Postnatal spontaneous resolution of congenital cystic adenomatoid malformations. J Pediatr Surg 2005; 40:832.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/36\">",
"      Kunisaki SM, Barnewolt CE, Estroff JA, et al. Large fetal congenital cystic adenomatoid malformations: growth trends and patient survival. J Pediatr Surg 2007; 42:404.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/37\">",
"      Mahle WT, Rychik J, Tian ZY, et al. Echocardiographic evaluation of the fetus with congenital cystic adenomatoid malformation. Ultrasound Obstet Gynecol 2000; 16:620.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/38\">",
"      Adzick NS, Harrison MR, Glick PL, et al. Fetal cystic adenomatoid malformation: prenatal diagnosis and natural history. J Pediatr Surg 1985; 20:483.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/39\">",
"      Usui N, Kamata S, Sawai T, et al. Outcome predictors for infants with cystic lung disease. J Pediatr Surg 2004; 39:603.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/40\">",
"      Gardikis S, Didilis V, Polychronidis A, et al. Spontaneous pneumothorax resulting from congenital cystic adenomatoid malformation in a pre-term infant: case report and literature review. Eur J Pediatr Surg 2002; 12:195.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/41\">",
"      Hulnick DH, Naidich DP, McCauley DI, et al. Late presentation of congenital cystic adenomatoid malformation of the lung. Radiology 1984; 151:569.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/42\">",
"      Parikh D, Samuel M. Congenital cystic lung lesions: is surgical resection essential? Pediatr Pulmonol 2005; 40:533.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/43\">",
"      Luj&aacute;n M, Bosque M, Mirapeix RM, et al. Late-onset congenital cystic adenomatoid malformation of the lung. Embryology, clinical symptomatology, diagnostic procedures, therapeutic approach and clinical follow-up. Respiration 2002; 69:148.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/44\">",
"      Waszak P, Claris O, Lapillonne A, et al. Cystic adenomatoid malformation of the lung: neonatal management of 21 cases. Pediatr Surg Int 1999; 15:326.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/45\">",
"      Aziz D, Langer JC, Tuuha SE, et al. Perinatally diagnosed asymptomatic congenital cystic adenomatoid malformation: to resect or not? J Pediatr Surg 2004; 39:329.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/46\">",
"      Adzick NS, Harrison MR, Crombleholme TM, et al. Fetal lung lesions: management and outcome. Am J Obstet Gynecol 1998; 179:884.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/47\">",
"      Hubbard AM, Adzick NS, Crombleholme TM, et al. Congenital chest lesions: diagnosis and characterization with prenatal MR imaging. Radiology 1999; 212:43.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/48\">",
"      Harmath A, Csaba A, Hauzman E, et al. Congenital lung malformations in the second trimester: prenatal ultrasound diagnosis and pathologic findings. J Clin Ultrasound 2007; 35:250.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/49\">",
"      Miller RK, Sieber WK, Yunis EJ. Congenital adenomatoid malformation of the lung. A report of 17 cases and review of the literature. Pathol Annu 1980; 15:387.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/50\">",
"      Winters WD, Effmann EL, Nghiem HV, Nyberg DA. Disappearing fetal lung masses: importance of postnatal imaging studies. Pediatr Radiol 1997; 27:535.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/51\">",
"      Calvert JK, Boyd PA, Chamberlain PC, et al. Outcome of antenatally suspected congenital cystic adenomatoid malformation of the lung: 10 years' experience 1991-2001. Arch Dis Child Fetal Neonatal Ed 2006; 91:F26.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/52\">",
"      Hernanz-Schulman M. Cysts and cystlike lesions of the lung. Radiol Clin North Am 1993; 31:631.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/53\">",
"      Kim WS, Lee KS, Kim IO, et al. Congenital cystic adenomatoid malformation of the lung: CT-pathologic correlation. AJR Am J Roentgenol 1997; 168:47.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/54\">",
"      Cass DL, Crombleholme TM, Howell LJ, et al. Cystic lung lesions with systemic arterial blood supply: a hybrid of congenital cystic adenomatoid malformation and bronchopulmonary sequestration. J Pediatr Surg 1997; 32:986.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/55\">",
"      Conran RM, Stocker JT. Extralobar sequestration with frequently associated congenital cystic adenomatoid malformation, type 2: report of 50 cases. Pediatr Dev Pathol 1999; 2:454.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/56\">",
"      Schwartz MZ, Ramachandran P. Congenital malformations of the lung and mediastinum--a quarter century of experience from a single institution. J Pediatr Surg 1997; 32:44.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/57\">",
"      Al-Bassam A, Al-Rabeeah A, Al-Nassar S, et al. Congenital cystic disease of the lung in infants and children (experience with 57 cases). Eur J Pediatr Surg 1999; 9:364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/58\">",
"      Shanmugam G, MacArthur K, Pollock JC. Congenital lung malformations--antenatal and postnatal evaluation and management. Eur J Cardiothorac Surg 2005; 27:45.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/59\">",
"      Duan M, Wang L, Cao Y, et al. Results of surgical treatment of congenital cystic lung disease. Thorac Cardiovasc Surg 2005; 53:61.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/60\">",
"      Stanton M, Davenport M. Management of congenital lung lesions. Early Hum Dev 2006; 82:289.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/61\">",
"      Muller CO, Berrebi D, Kheniche A, Bonnard A. Is radical lobectomy required in congenital cystic adenomatoid malformation? J Pediatr Surg 2012; 47:642.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/62\">",
"      Calvert JK, Lakhoo K. Antenatally suspected congenital cystic adenomatoid malformation of the lung: postnatal investigation and timing of surgery. J Pediatr Surg 2007; 42:411.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/63\">",
"      Laberge JM, Puligandla P, Flageole H. Asymptomatic congenital lung malformations. Semin Pediatr Surg 2005; 14:16.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/64\">",
"      d'Agostino S, Bonoldi E, Dante S, et al. Embryonal rhabdomyosarcoma of the lung arising in cystic adenomatoid malformation: case report and review of the literature. J Pediatr Surg 1997; 32:1381.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/65\">",
"      Murphy JJ, Blair GK, Fraser GC, et al. Rhabdomyosarcoma arising within congenital pulmonary cysts: report of three cases. J Pediatr Surg 1992; 27:1364.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/66\">",
"      Domizio P, Liesner RJ, Dicks-Mireaux C, Risdon RA. Malignant mesenchymoma associated with a congenital lung cyst in a child: case report and review of the literature. Pediatr Pathol 1990; 10:785.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/67\">",
"      Truitt AK, Carr SR, Cassese J, et al. Perinatal management of congenital cystic lung lesions in the age of minimally invasive surgery. J Pediatr Surg 2006; 41:893.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/68\">",
"      Albanese CT, Sydorak RM, Tsao K, Lee H. Thoracoscopic lobectomy for prenatally diagnosed lung lesions. J Pediatr Surg 2003; 38:553.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/69\">",
"      Vu LT, Farmer DL, Nobuhara KK, et al. Thoracoscopic versus open resection for congenital cystic adenomatoid malformations of the lung. J Pediatr Surg 2008; 43:35.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/70\">",
"      Nasr A, Bass J. Thoracoscopic vs open resection of congenital lung lesions: a meta-analysis. J Pediatr Surg 2012; 47:857.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/71\">",
"      Harrison MR, Adzick NS, Jennings RW, et al. Antenatal intervention for congenital cystic adenomatoid malformation. Lancet 1990; 336:965.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/72\">",
"      Adzick NS, Harrison MR, Flake AW, et al. Fetal surgery for cystic adenomatoid malformation of the lung. J Pediatr Surg 1993; 28:806.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/73\">",
"      Grethel EJ, Wagner AJ, Clifton MS, et al. Fetal intervention for mass lesions and hydrops improves outcome: a 15-year experience. J Pediatr Surg 2007; 42:117.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/74\">",
"      Brown MF, Lewis D, Brouillette RM, et al. Successful prenatal management of hydrops, caused by congenital cystic adenomatoid malformation, using serial aspirations. J Pediatr Surg 1995; 30:1098.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/75\">",
"      Sugiyama M, Honna T, Kamii Y, et al. Management of prenatally diagnosed congenital cystic adenomatoid malformation of the lung. Eur J Pediatr Surg 1999; 9:53.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/76\">",
"      Bernaschek G, Deutinger J, Hansmann M, et al. Feto-amniotic shunting--report of the experience of four European centres. Prenat Diagn 1994; 14:821.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/77\">",
"      Lee SC, Cheng YL, Yu CP. Haemopneumothorax from congenital cystic adenomatoid malformation in a cryptorchidism patient. Eur Respir J 2000; 15:430.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/78\">",
"      MacSweeney F, Papagiannopoulos K, Goldstraw P, et al. An assessment of the expanded classification of congenital cystic adenomatoid malformations and their relationship to malignant transformation. Am J Surg Pathol 2003; 27:1139.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/79\">",
"      Federici S, Domenichelli V, Tani G, et al. Pleuropulmonary blastoma in congenital cystic adenomatoid malformation: report of a case. Eur J Pediatr Surg 2001; 11:196.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/80\">",
"      Langston C. New concepts in the pathology of congenital lung malformations. Semin Pediatr Surg 2003; 12:17.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/81\">",
"      Granata C, Gambini C, Balducci T, et al. Bronchioloalveolar carcinoma arising in congenital cystic adenomatoid malformation in a child: a case report and review on malignancies originating in congenital cystic adenomatoid malformation. Pediatr Pulmonol 1998; 25:62.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/82\">",
"      Ozcan C, Celik A, Ural Z, et al. Primary pulmonary rhabdomyosarcoma arising within cystic adenomatoid malformation: a case report and review of the literature. J Pediatr Surg 2001; 36:1062.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/83\">",
"      Pai S, Eng HL, Lee SY, et al. Correction: Pleuropulmonary blastoma, not rhabdomyosarcoma in a congenital lung cyst. Pediatr Blood Cancer 2007; 48:370.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/84\">",
"      Priest JR, Watterson J, Strong L, et al. Pleuropulmonary blastoma: a marker for familial disease. J Pediatr 1996; 128:220.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/85\">",
"      Lantuejoul S, Nicholson AG, Sartori G, et al. Mucinous cells in type 1 pulmonary congenital cystic adenomatoid malformation as mucinous bronchioloalveolar carcinoma precursors. Am J Surg Pathol 2007; 31:961.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/86\">",
"      West D, Nicholson AG, Colquhoun I, Pollock J. Bronchioloalveolar carcinoma in congenital cystic adenomatoid malformation of lung. Ann Thorac Surg 2007; 83:687.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/87\">",
"      Davenport M, Warne SA, Cacciaguerra S, et al. Current outcome of antenally diagnosed cystic lung disease. J Pediatr Surg 2004; 39:549.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/88\">",
"      Laje P, Liechty KW. Postnatal management and outcome of prenatally diagnosed lung lesions. Prenat Diagn 2008; 28:612.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/89\">",
"      Zach MS, Eber E. Adult outcome of congenital lower respiratory tract malformations. Thorax 2001; 56:65.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/90\">",
"      Cloutier MM, Schaeffer DA, Hight D. Congenital cystic adenomatoid malformation. Chest 1993; 103:761.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/91\">",
"      Atkinson JB, Ford EG, Kitagawa H, et al. Persistent pulmonary hypertension complicating cystic adenomatoid malformation in neonates. J Pediatr Surg 1992; 27:54.",
"     </a>",
"    </li>",
"    <li>",
"     <a class=\"nounderline abstract\" href=\"UTD.htm?0/50/810/abstract/92\">",
"      Rossi R, Tjan TD, Hentschel R, et al. Successful perioperative management of congenital cystic adenomatoid malformation of the lung by high frequency oscillatory ventilation--report of two cases. Klin Padiatr 1998; 210:94.",
"     </a>",
"    </li>",
"   </ol>",
"  </div>",
"  <div id=\"topicVersionRevision\">",
"   Topic 6346 Version 10.0",
"  </div>",
" </div>",
" <div id=\"footer\">",
"  <div id=\"supportFooter\">",
"   <span class=\"sfInfo\">",
"    &copy; 2013 UpToDate, Inc. All rights reserved.",
"   </span>",
"   <span class=\"pipeSpace\">",
"    |",
"   </span>",
"   <a class=\"licenseLink\" href=\"./license\" id=\"sla_footer\">",
"    Subscription and License Agreement",
"   </a>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Release: 21.6- C21.56",
"   </span>",
"   <br/>",
"   <span class=\"sfInfo\">",
"    Licensed to:",
"    <span class=\"emphasis\">",
"     AsanBook Dig. Med. Lib.",
"    </span>",
"   </span>",
"   <span class=\"sfInfo\">",
"    <span class=\"pipeSpace\">",
"     |",
"    </span>",
"    Support Tag: [1002-221.179.173.170-4115C7D097-S244013.14]",
"    <br/>",
"   </span>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_810=[""].join("\n");
var outline_f0_50_810=[" <div id=\"toggleOutline\">",
"  <a href=\"#\" title=\"Collapse Topic Outline\">",
"   <img alt=\"\" src=\"./../images/orange_arrow_left.myextg\"/>",
"  </a>",
" </div>",
" <div id=\"innerOutline\">",
"  <h1>",
"   TOPIC OUTLINE",
"  </h1>",
"  <div id=\"outline\">",
"   <ul>",
"    <li>",
"     <a class=\"sr_button\" href=\"#H35\" id=\"summRecButton\">",
"      <span>",
"       SUMMARY &amp; RECOMMENDATIONS",
"      </span>",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H1\">",
"      INTRODUCTION",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H2\">",
"      EPIDEMIOLOGY",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H3\">",
"      PATHOGENESIS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H4\">",
"      PATHOLOGY",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H5\">",
"      Types",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H6\">",
"      - Type 0",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H7\">",
"      - Type 1",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H8\">",
"      - Type 2",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H9\">",
"      - Type 3",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H10\">",
"      - Type 4",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H11\">",
"      CLINICAL FEATURES",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H12\">",
"      Prenatal presentation",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H13\">",
"      - Development of hydrops",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H14\">",
"      Neonatal presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H15\">",
"      Childhood presentation",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H16\">",
"      Asymptomatic presentation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H17\">",
"      EVALUATION",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H18\">",
"      History",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H19\">",
"      Imaging",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H20\">",
"      - Prenatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H21\">",
"      - Asymptomatic neonates",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H22\">",
"      - Postnatal diagnosis",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H23\">",
"      Differential diagnosis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H24\">",
"      MANAGEMENT",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H25\">",
"      Symptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H26\">",
"      Asymptomatic patients",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H27\">",
"      - Surgery",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H28\">",
"      - Surveillance",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H29\">",
"      Fetal surgery",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H30\">",
"      COMPLICATIONS",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"outlineLink\" href=\"#H31\">",
"      Association with malignancy",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H32\">",
"      - Pleuropulmonary blastoma",
"     </a>",
"    </li>",
"    <li class=\"dashItem\">",
"     <a class=\"outlineLink\" href=\"#H33\">",
"      - Other",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H34\">",
"      OUTCOME",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"outlineLink\" href=\"#H35\">",
"      SUMMARY AND RECOMMENDATIONS",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a href=\"#references\">",
"      REFERENCES",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   <div class=\"openRelatedGraphics\" id=\"PEDS/6346\" rel=\"outline_link\">",
"    GRAPHICS",
"    <a class=\"graphics_icon\" href=\"#\" title=\"View All Related Graphics\">",
"     View All",
"    </a>",
"   </div>",
"  </h1>",
"  <div id=\"relatedGraphics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6346|DiagnosticImage\">",
"      <a href=\"#\" title=\"DIAGNOSTIC IMAGES\">",
"       DIAGNOSTIC IMAGES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?17/55/18290\" title=\"diagnostic image 1A\">",
"      CPAM prenatal ultrasound_length",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/12/26817\" title=\"diagnostic image 1B\">",
"      CPAM prenatal ultrasound_width x height",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?39/32/40451\" title=\"diagnostic image 2\">",
"      CPAM prenatal ultrasound_axial",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?16/11/16560\" title=\"diagnostic image 3\">",
"      CPAM type 1 chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?35/0/35841\" title=\"diagnostic image 4\">",
"      CPAM type 1 CT scan",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?29/61/30673\" title=\"diagnostic image 5\">",
"      CPAM newborn chest x-ray",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_diagnosticimage\" href=\"UTD.htm?26/3/26673\" title=\"diagnostic image 6\">",
"      CPAM newborn CT scan",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <div class=\"openRelatedGraphics\" id=\"PEDS/6346|PIC\">",
"      <a href=\"#\" title=\"PICTURES\">",
"       PICTURES",
"      </a>",
"     </div>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?36/12/37059\" title=\"picture 1\">",
"      CPAM type 1 gross pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?8/2/8230\" title=\"picture 2\">",
"      CPAM type 1 histology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/50/7969\" title=\"picture 3\">",
"      CPAM type 2 gross pathology",
"     </a>",
"    </li>",
"    <li class=\"bulletItem\">",
"     <a class=\"graphic graphic_picture\" href=\"UTD.htm?7/53/8025\" title=\"picture 4\">",
"      CPAM type 2 histology",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
"  <h1>",
"   RELATED TOPICS",
"  </h1>",
"  <div id=\"relatedTopics\">",
"   <ul>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?28/29/29144?source=related_link\">",
"      Bronchopulmonary sequestration",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?43/11/44214?source=related_link\">",
"      Congenital lobar emphysema",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?33/37/34393?source=related_link\">",
"      Nonimmune hydrops fetalis",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?11/18/11561?source=related_link\">",
"      Prenatal diagnosis and management of congenital pulmonary airway malformation",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?21/17/21785?source=related_link\">",
"      Radiation-related risks of imaging studies",
"     </a>",
"    </li>",
"    <li class=\"plainItem\">",
"     <a class=\"medical medical_review\" href=\"UTD.htm?29/49/30487?source=related_link\">",
"      Radiographic appearance of developmental anomalies of the lung",
"     </a>",
"    </li>",
"   </ul>",
"  </div>",
" </div>"].join("\n");
var title_f0_50_811="Binet staging system CLL";
var content_f0_50_811=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=HEME%2F80421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=HEME%2F80421&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Binet Staging System For Chronic Lymphocytic Leukemia",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tr>",
"      <td class=\"subtitle1\">",
"       Stage",
"      </td>",
"      <td class=\"subtitle1\">",
"       Description",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       A",
"      </td>",
"      <td>",
"       Two or less lymphoid bearing areas enlarged*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       B",
"      </td>",
"      <td>",
"       Three or more lymphoid bearing areas enlarged*",
"      </td>",
"     </tr>",
"     <tr>",
"      <td>",
"       C",
"      </td>",
"      <td>",
"       Presence of anemia (Hgb &lt;10.0 g/dL) or thrombocytopenia (platelet count &lt;100,000/microL)",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Five lymphoid bearing areas are possible: cervical, axillary, inguino-femoral, spleen, and liver.",
"    </div>",
"    <div class=\"reference\">",
"     Revised from Binet, JL, Auquier, A, Dighiero, G, et al. Cancer 1981; 48:198.",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_811=[""].join("\n");
var outline_f0_50_811=null;
var title_f0_50_812="Endothelial dysfunction factors";
var content_f0_50_812=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F56643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F56643&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Factors that cause and interventions that improve endothelial dysfunction",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\" class=\"container\">",
"     <tr>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Factors associated with endothelial dysfunction",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased age",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Male sex",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Family history of CHD",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Smoking",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased serum cholesterol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Low serum HDL-cholesterol",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Hypertension",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Increased serum homocysteine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Diabetes mellitus",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Obesity",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          High-fat meal",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"      <td class=\"container\">",
"       <table cellspacing=\"0\">",
"        <tr>",
"         <td class=\"subtitle1_single\">",
"          Interventions that improve endothelial function",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          L-arginine",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Estrogen",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Antioxidants",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Smoking cessation",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Cholesterol lowering",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          ACE inhibitors",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Exercise",
"         </td>",
"        </tr>",
"        <tr>",
"         <td>",
"          Homocysteine lowering",
"         </td>",
"        </tr>",
"       </table>",
"      </td>",
"     </tr>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_812=[""].join("\n");
var outline_f0_50_812=null;
var title_f0_50_813="Encopresis treatment plan";
var content_f0_50_813=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=PEDS%2F54749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=PEDS%2F54749&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=4\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    Example of treatment plan for a 4-year-old with encopresis",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        &nbsp;",
"       </td>",
"       <td class=\"subtitle1\">",
"        A. Mildly impacted",
"       </td>",
"       <td class=\"subtitle1\">",
"        B. Large impaction",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 1",
"       </td>",
"       <td>",
"        <p>",
"         1. Educate family and caregiver about fecal impaction and overflow incontinence and the need for long term laxative therapy.",
"        </p>",
"        <p>",
"         2. Start&nbsp;PEG (eg, Miralax&reg;) 4 teaspoons each morning. (3.5 tsp = approximately 17 gm)",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1. Educate family as in column A.",
"        </p>",
"        <p>",
"         2. Give Mineral oil 2-4 tablespoons mixed in beverage, eg, orange juice, over the top of Popsicle or freezer pop.",
"        </p>",
"        <p>",
"         3. Start&nbsp;PEG 17g (1 capful) twice a day.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 2",
"       </td>",
"       <td>",
"        1. Continue&nbsp;PEG 4 teaspoons each morning.",
"       </td>",
"       <td>",
"        <p>",
"         1. Repeat the Mineral oil and PEG.",
"        </p>",
"        <p>",
"         2. Give 1/2 to 1 full adult Fleets enema, depending on the size of the impaction.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 3",
"       </td>",
"       <td>",
"        <p>",
"         1. If beginning to pass 1-2 soft to loose stools daily, continue above dose of PEG.",
"        </p>",
"        <p>",
"         2. If not passing soft to loose stools, increase dose by 1/2 to 1 teaspoon each morning. Increase every two days until passing soft to loose stools. Soiling should gradually decrease and stop.",
"        </p>",
"       </td>",
"       <td>",
"        1. If has not passed a large amount of stool, repeat the Mineral oil,&nbsp;PEG and enema.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 4",
"       </td>",
"       <td>",
"        <p>",
"         1. Once the child is stooling daily with soft stools, continue the same dose.",
"        </p>",
"        <p>",
"         2. Have the patient sit on the toilet for 5 minutes 2-3 times daily after meals to help establish normal bowel movements.",
"        </p>",
"       </td>",
"       <td>",
"        <p>",
"         1. Start&nbsp;PEG 4 teaspoons each morning and titrate as in Day 3 for children who are mildly impacted.",
"        </p>",
"        <p>",
"         2. Continue as in column A.",
"        </p>",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Day 5-30",
"       </td>",
"       <td>",
"        Be sure parent calls if not making progress, so further adjustments in dose can be made. It ocasionally is necessary to give both a morning and an evening dose.",
"       </td>",
"       <td>",
"        Same as column A.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1 month",
"       </td>",
"       <td>",
"        <p>",
"         1. See patient back to evaluate progress and to reinforce need for regular laxative therapy.",
"        </p>",
"        <p>",
"         2. Give handout or good references for high fiber diet and have parents begin to modify diet to help long term.",
"        </p>",
"       </td>",
"       <td>",
"        Same as column A.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        1- 6 months",
"       </td>",
"       <td>",
"        See patient every 1-2 months to reinforce therapy - adjust dose of laxative if necessary",
"       </td>",
"       <td>",
"        Same as column A.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        6-12 months (or longer)",
"       </td>",
"       <td>",
"        Once maintaining normal bowel movements without soiling for several months, consider gradually tapering laxative over 2 months. Be sure patient is on a high fiber diet. Some children require ongoing laxative treatment for one or more years.",
"       </td>",
"       <td>",
"        Same as column A.",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        Beyond 12 months",
"       </td>",
"       <td>",
"        Follow as long as it takes for resolution. Can be months to several years before complete resolution.",
"       </td>",
"       <td>",
"        Same as column A.",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     PEG: polyethylene glycol without electrolytes (eg, Miralax&reg;)",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_813=[""].join("\n");
var outline_f0_50_813=null;
var title_f0_50_814="Prevalence of gallstones";
var content_f0_50_814=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=GAST%2F57092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=GAST%2F57092&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=2\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\">",
"   <div class=\"ttl\">",
"    The prevalence of gallstone disease (GSD) in selected populations",
"   </div>",
"   <div class=\"cntnt\">",
"    <table cellspacing=\"0\">",
"     <tbody>",
"      <tr>",
"       <td class=\"subtitle1\">",
"        Population",
"       </td>",
"       <td class=\"subtitle1\">",
"        Test",
"       </td>",
"       <td class=\"subtitle1\">",
"        Age",
"       </td>",
"       <td class=\"subtitle1\">",
"        Female percent GSD",
"       </td>",
"       <td class=\"subtitle1\">",
"        Male percent GSD",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        <p>",
"         Mexican-American",
"        </p>",
"        <p>",
"         1982-1984",
"        </p>",
"        <p>",
"         (n = 1388)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        20-39",
"       </td>",
"       <td>",
"        13.8",
"       </td>",
"       <td>",
"        2.6",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-59",
"       </td>",
"       <td>",
"        26.4",
"       </td>",
"       <td>",
"        9.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-74",
"       </td>",
"       <td>",
"        44.4",
"       </td>",
"       <td>",
"        15.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        <p>",
"         Puerto Ricans",
"        </p>",
"        <p>",
"         1982-1984",
"        </p>",
"        <p>",
"         (n = 582)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"3\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        20-39",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-49",
"       </td>",
"       <td>",
"        21.2",
"       </td>",
"       <td>",
"        3.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-74",
"       </td>",
"       <td>",
"        12.1",
"       </td>",
"       <td>",
"        11.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        <p>",
"         Rome, Italy",
"        </p>",
"        <p>",
"         1981-1982",
"        </p>",
"        <p>",
"         (n = 2320)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"       <td>",
"        2.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-39",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-49",
"       </td>",
"       <td>",
"        10.9",
"       </td>",
"       <td>",
"        6.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-59",
"       </td>",
"       <td>",
"        17.8",
"       </td>",
"       <td>",
"        14.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;65",
"       </td>",
"       <td>",
"        25",
"       </td>",
"       <td>",
"        14.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        <p>",
"         Bristol, England*",
"        </p>",
"        <p>",
"         1987-1989",
"        </p>",
"        <p>",
"         (n = 1896)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        3.9",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-39",
"       </td>",
"       <td>",
"        6.4",
"       </td>",
"       <td>",
"        -",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-49",
"       </td>",
"       <td>",
"        6.5",
"       </td>",
"       <td>",
"        4.7",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-59",
"       </td>",
"       <td>",
"        14.2",
"       </td>",
"       <td>",
"        22.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-69",
"       </td>",
"       <td>",
"        22.4",
"       </td>",
"       <td>",
"        11.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        <p>",
"         Pima Indians",
"        </p>",
"        <p>",
"         1967-1968",
"        </p>",
"        <p>",
"         (n = 596)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"6\">",
"        Oral cholecystogram",
"       </td>",
"       <td>",
"        15-25",
"       </td>",
"       <td>",
"        12.7",
"       </td>",
"       <td>",
"        0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        25-34",
"       </td>",
"       <td>",
"        73.2",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        35-44",
"       </td>",
"       <td>",
"        70.8",
"       </td>",
"       <td>",
"        11.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        45-54",
"       </td>",
"       <td>",
"        75.8",
"       </td>",
"       <td>",
"        31.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        55-64",
"       </td>",
"       <td>",
"        62.0",
"       </td>",
"       <td>",
"        66.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;65",
"       </td>",
"       <td>",
"        89.5",
"       </td>",
"       <td>",
"        67.8",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        <p>",
"         Okinawa, Japan&bull;",
"        </p>",
"        <p>",
"         1984",
"        </p>",
"        <p>",
"         (n = 2727)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"7\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        0-19",
"       </td>",
"       <td>",
"        0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        1.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-39",
"       </td>",
"       <td>",
"        3.5",
"       </td>",
"       <td>",
"        2.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-49",
"       </td>",
"       <td>",
"        3.0",
"       </td>",
"       <td>",
"        2.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-59",
"       </td>",
"       <td>",
"        4.0",
"       </td>",
"       <td>",
"        1.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-69",
"       </td>",
"       <td>",
"        9.0",
"       </td>",
"       <td>",
"        4.5",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        &gt;70",
"       </td>",
"       <td>",
"        9.5",
"       </td>",
"       <td>",
"        15.0",
"       </td>",
"      </tr>",
"      <tr>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        <p>",
"         United States&Delta;",
"        </p>",
"        <p>",
"         1988-1991",
"        </p>",
"        <p>",
"         (n = 14,000)",
"        </p>",
"       </td>",
"       <td colspan=\"1\" rowspan=\"5\">",
"        Ultrasonography",
"       </td>",
"       <td>",
"        20-29",
"       </td>",
"       <td>",
"        4.4",
"       </td>",
"       <td>",
"        1.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        30-39",
"       </td>",
"       <td>",
"        5.2",
"       </td>",
"       <td>",
"        1.1",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        40-49",
"       </td>",
"       <td>",
"        8.2",
"       </td>",
"       <td>",
"        5.9",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        50-59",
"       </td>",
"       <td>",
"        11.9",
"       </td>",
"       <td>",
"        7.3",
"       </td>",
"      </tr>",
"      <tr>",
"       <td>",
"        60-74",
"       </td>",
"       <td>",
"        16.4",
"       </td>",
"       <td>",
"        17.2",
"       </td>",
"      </tr>",
"     </tbody>",
"    </table>",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"    </div>",
"    <div class=\"reference\">",
"     * Adapted from: Heaton IW, Braddon FEM, Mountford RA, et al. Gut 1991; 32:316.",
"     <br>",
"      &bull; Adapted from: Nomura H, Kashiwagi S, Hayashi J, et al. Am J Epidemiol 1992; 136:787.",
"      <br>",
"       &Delta; Adapted from: Everhart JE, Khare M, Hill M, Maurer KR. Gastroenterology 1999; 117:632.",
"      </br>",
"     </br>",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_814=[""].join("\n");
var outline_f0_50_814=null;
var title_f0_50_815="Algorithm for management of new onset AF";
var content_f0_50_815=[" <div id=\"graphicsToolbar\">",
"  <div id=\"graphicsCopy\">",
"   &copy;2013 UpToDate",
"   <sup>",
"    &reg;",
"   </sup>",
"  </div>",
"  <div id=\"graphicsLinks\">",
"   <a href=\"?imageKey=CARD%2F52051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\">",
"    <img alt=\"Print this page\" src=\"./../images/icn_print.myextg\" title=\"Print this page\"/>",
"   </a>",
"   <a class=\"icontxt textLink\" href=\"?imageKey=CARD%2F52051&amp;source=image_view&amp;view=print&amp;elapsedTimeMs=1\" onclick=\"\" title=\"Print this page\">",
"    Print",
"   </a>",
"   <a class=\"etacLink\" href=\"#\">",
"    <img alt=\"Email graphic(s)\" src=\"./../images/icn_email.myextg\" title=\"Email graphic(s)\"/>",
"   </a>",
"   <a class=\"icontxt textLink etacLink\" href=\"#\" title=\"Email graphic(s)\">",
"    Email",
"   </a>",
"  </div>",
" </div>",
" <div class=\"graphic\">",
"  <div class=\"figure\" style=\"width: 500px\">",
"   <div class=\"ttl\">",
"    Management of new onset (hemodynamically stable) atrial fibrillation",
"   </div>",
"   <div class=\"cntnt\" style=\"width: 480px; height: 522px; background-image: url(data:image/gif;base64,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);\">",
"   </div>",
"   <div class=\"lgnd\">",
"    <div class=\"footnotes\">",
"     * Consider systemic anticoagulation with heparin or dabigatran depending on the patient's stroke risk factors and AF duration.",
"     <br>",
"      <span class=\"bullet\">",
"       &bull;",
"      </span>",
"      This strategy includes the need for short-term anticoagulation with heparin or warfarin.",
"      <br>",
"       &Delta; Oral anticoagulation is either dabigatran or warfarin.",
"       <br>",
"        <span class=\"lozenge\">",
"         &loz;",
"        </span>",
"        At least 4 weeks of oral anticoagulation after cardioversion in those whose AF was &gt;48h.",
"       </br>",
"      </br>",
"     </br>",
"    </div>",
"    <div class=\"reference\">",
"    </div>",
"   </div>",
"  </div>",
" </div>",
"</div>"].join("\n");
var script_f0_50_815=[""].join("\n");
var outline_f0_50_815=null;
